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ABSTRACT 
 
The interaction of carbohydrates with carbohydrate-binding proteins is key to a multitude 
of important biological events, such as cell-cell interactions and signal transduction. 
Carbohydrates are also essential for energy storage and transfer. Binding to the three-
dimensional display of carbohydrates at the cell surface (the glycocalyx) is known to play a 
role in many disease states, such as carbohydrate binding by viruses. Furthermore, changes 
in the distribution and type of oligosaccharides is known to occur at tumour cell surfaces.  
 
The importance of these natural events at the cell membrane surface provided the 
motivation for their study in a biomimetic environment. Inspired by previous work in the 
field of carbohydrate-lectin binding and work in the Webb group into mimicry of cellular 
processes using supramolecular chemistry, vesicular structures of synthetic glycolipids in 
natural phospholipids were created. Several synthetic glycolipids were synthesised and 
found to be capable of lateral phase separation in ordered-phase phospholipid bilayers, 
forming artificial lipid rafts in the bilayer.  
 
The glycolipid vesicle systems were used to study the effects of the lateral clustering of 
glycolipids on two different biochemical events at the membrane surface: Binding of 
mannosyl-lipids by concanavalin A (ConA) and the enzymatic galactosylation of N-
acetylglucosamine (GlcNAc)-lipids by bovine β-(1,4)-galactosyltransferase (β4GalT1). 
Fluorescence quenching titrations revealed that clustering of mannosyl-lipids had little 
effect on the strength of ConA binding. However, HPLC measurements showed that lateral 
clustering of GlcNAc-lipids could enhance their enzymatic galactosylation by β4GalT1. 
The work presented in this thesis represents the formulation of these vesicle systems and 
their study with ConA and β4GalT1. Further investigation with other phase-separating 
glycolipid-lectin/enzyme pairs is necessary to establish whether the effects of clustering 
observed herein are exclusive to ConA and β4GalT1, or are general phenomena observed at 
the membrane surface. 
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1. Introduction 
 
Carbohydrates are arguably the most important of the small molecule classes associated 
with normal biological function in the body. Although they fulfil a variety of roles, 
including energy transfer, energy storage and maintaining cellular structure, their 
interactions with carbohydrate-binding proteins are key to a multitude of important 
biological events, such as cell-cell interactions and signal transduction. Carbohydrates 
possess a great degree of inherent structural complexity; hexoses have four chiral centres 
with 16 possible stereoisomers, resulting in an estimated 1,056 to 27,648 different 
glycosidic linkages for a trisaccharide.
1
 As complexity increases further with each 
additional saccharide, a „glycocode‟ is created. Cell-surface oligosaccharides - which 
contain many glycosidic bonds and can be linear or branched - create a 3-dimensional 
display of various saccharide sequences, known as the glycocalyx.  
 
Research into the glycocalyx is a burgeoning area, as carbohydrates in the glycocalyx are 
known to play a role in many disease states, such as carbohydrate binding by viruses and 
changes in the distribution and type of oligosaccharide at tumour cell surfaces. 
Furthermore, subtle changes in the specificity of virus proteins via mutation can result in 
interspecies infection, for instance an antigenic switch in the preference of virus 
hemagglutinin proteins results in human susceptibility.
2
 
 
Understanding the glycocode extends beyond interest into disease states; it is essential for 
the comprehension of everyday cellular functions. Carbohydrate binding proteins, known as 
lectins (from the Latin – „to select‟), are ubiquitous in nature and display highly specific 
carbohydrate binding preferences.
1
 The advancement of analytical tools such as surface 
plasmon resonance (SPR) and mass spectrometry have aided the study of these proteins; in 
particular, array and surface technologies have allowed the profiling of carbohydrate 
binding preference of lectins obtained from naturally occurring sources.  
 
Inspired by previous work in the field of carbohydrate-lectin binding and work in the Webb 
group into mimicry of cellular processes using supramolecular chemistry, the goal of this 
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project was to create vesicular structures of natural phospholipids that also presented an 
artificial glycocalyx. This artificial glycocalyx was designed to be tuneable by the induction 
of the lateral phase separation of glycolipids in the bilayer, allowing the effect of domain 
formation on lectin binding to be investigated. The artificial glycocalyx was elaborated by 
the addition of extra carbohydrate residues using transferase enzymes, as investigated 
previously in the Flitsch group.
3, 4
 This „rebranding‟ of vesicles with different carbohydrate 
residues overall created a tuneable and functional surface responsive to external stimuli. 
 
1.1 The cell membrane 
 
A universal feature essential to all cells is a selectively permeable lipid bilayer, or cell 
membrane.
5
 The bilayer is a sheet-like assembly of non-covalently linked lipids, which 
physically separates the intracellular components of the cell from the extracellular 
environment, thus defining the cell boundary. The major constituents of cell membranes are 
phospholipids. Amphiphilic in nature they are driven to self-assemble tail-to-tail in water 
by the hydrophobic effect, so that their polar headgroups either face the aqueous 
surroundings or the cell interior. The fatty acid-based tails are made of carbon chains that 
differ in length from typically 12 to 20; the number of carbon atoms in the chains is always 
even as fatty acid chains are constructed from two-carbon building blocks. Though there 
are many classes of biological lipids, the three major types that constitute the membrane are 
phospholipids, glycolipids and sterols, and examples of these lipids are shown in Figure 
1.1. Phospholipids such as 1,2-dimyristoyl-sn-glycero-3-phosphocholine  (DMPC) are 
composed of hydrophilic choline, phosphate and glycerol linked to 2 hydrophobic 
hydrocarbon tails. Phospholipids are named according to their hydrocarbon tails; the fatty 
acid component of DMPC is myristic acid with a saturated 14 carbon chain. Other natural 
lipids such as sphingomyelin and the gangliosides – often complex, branched 
oligosaccharide lipids - are based upon a ceramide lipid backbone. The membrane also 
contains many integral proteins that fulfil numerous roles, including directing the flow of 
molecules or ions, detection of extracellular signals and the facilitation of cell-cell 
interactions. The thickness of the phospholipid bilayer is dependent on its constituent lipids 
and proteins, but is approximately six to ten nanometres thick.
5
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Figure 1.1 Examples of lipids found in cell membranes. 
 
The majority of cells have a saccharide-enriched coat (or polysaccharide matrix) on the 
external face of the plasma membrane, which as described previously, is termed the 
glycocalyx. The layer is composed of lipid-linked oligosaccharides (gangliosides) and 
membrane-bound glycoproteins that form a protective coat around the cell that acts as a 
physical barrier to extracellular species. Thickness of the glycocalyx layer differs between 
cell type and can depend upon the function of the tissue it belongs to, for instance the 
glycocalyx of human endothelial cells is several hundred nanometres thick. The glycocalyx 
oligosaccharide identity of each cell type differs, displaying a particular sequence which 
allows the differentiation of cell type through specific binding to the oligosaccharide 
moieties. Immune response to foreign bodies, such as bacteria and invasive organisms, also 
occurs through the identification of the terminal carbohydrate residues in their 
glycocalyces.  
 
1.1.1 Movement and membrane fluidity 
 
Lipid or protein movement in the bilayer comes in two forms, along the plane of the 
membrane (lateral diffusion, Figure 1.2.a) or transfer from one face of the membrane to the 
other (transverse diffusion or „flip-flop‟, Figure 1.2.b). As membranes are dynamic 
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structures, lipids and proteins are able to diffuse laterally unless constrained by binding 
events or other effects such as phase separation. In contrast, transverse diffusion is 
generally very slow or not possible at all unless catalysed by flippase enzymes.
6
 
 
 
 
Figure 1.2 Movement within the membrane; lateral (a) and transverse (b) diffusion. 
 
The ability of lipids and proteins to diffuse laterally is determined by the fluidity of the 
membrane.
5
 The membrane can exist as a rigid, organized state known as the solid ordered 
or gel phase (so), or a more fluid state, the liquid disordered phase (ld). Transition from the 
gel phase to the liquid disordered phase occurs at the phase transition temperature (Tm), 
which is dependent upon the length of the hydrophobic chain; increasing the length of the 
hydrophobic carbon chain increases the amount of favourable hydrophobic interactions, 
stabilising the membrane and increasing Tm. Techniques such as differential scanning 
calorimetry (DSC)
7
 and fluorescence spectroscopy (with a suitable membrane-embedded 
probe) are often used to measure phase transitions. Furthermore, with unsaturated lipids the 
C=C double bond is always cis, resulting in a more fluid membrane, as the kink in the lipid 
tail prevents any adjacent lipids from packing as tightly as in saturated lipid systems.
5
 
 
 
 
Figure 1.3 Phase transition diagram. 
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A third state, the liquid ordered state (lo) retains the fluidity of the ld phase but with 
increased molecular interactions between the membrane components, can arise in mixtures 
of lipids and cholesterol. Increasing the amount of cholesterol in phospholipid bilayers has 
a dramatic effect on its fluidity and diffusivity, and results in more complex phase 
behaviour. For example, in dimyristoyl phosphatidycholine (DMPC)/cholesterol mixtures 
at 37 °C, membrane cholesterol contents above 10% mol/mol results in the gradual 
emergence of the lo phase.
8
 DMPC/cholesterol mixtures with cholesterol concentrations 
above 30% mol/mol exist wholly in the lo phase at physiological temperature (Figure 1.4). 
The cholesteric hydroxyl group forms hydrogen bonds with the polar end of lipid molecules 
and its carbon tail and steroid centre sits in the hydrophobic centre of the bilayer, where 
Van der Waal‟s interactions stabilise the surrounding lipids. The closely-packed lipid 
bilayer reduces lateral diffusivity of phospholipids within the membrane in turn by reducing 
the amount of free area available for lipids to pass through. In ternary mixtures of lipids 
such as sphingomyelin (SPM)/1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC)/cholesterol coexisting lo and ld phases can be observed.
9
 
 
 
 
Figure 1.4 Phase diagram of membrane DMPC-cholesterol mixtures.
8
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1.1.2 The fluid mosaic model and lipid rafting 
 
The fluid mosaic model suggested in 1972 by J. Singer and G. Nicolson describes the 
organisation of molecules within the membrane.
10
 The model describes the lipid bilayer as 
a fluid two-dimensional structure, in which embedded or attached proteins are able to 
laterally diffuse more or less freely within the bilayer. While the fluid mosaic model is a 
useful introductory description of the cell membrane, recent work in the field indicates that 
the overall structure of the membrane is not as homogenous or entirely disordered as the 
model suggests. Dynamic compartmentalisation of sphingolipids, cholesterol and proteins 
into patches of long-range order, known as lipid rafts, of sizes up to hundreds of 
nanometres across have been characterised in biological and synthetic systems (Figure 
1.5).
11
  
 
 
 
Figure 1.5 Illustration of the organisation of material within lipid rafts.
11
 
 
Initially the raft hypothesis was used to explain resistance of certain membrane 
compositions to cold detergent extraction. Methyl-β-cyclodextrin, known to extract 
cholesterol from plasma membranes, could then be added and if detergent insoluble 
proteins became soluble it was indicative of the protein being raft-associated. Furthermore, 
if after the addition of methyl-β-cyclodextrin to living cells a particular cellular function 
was impaired or lost it was assumed to be a raft-based process. Such rationalisations were 
received with scepticism, as the results from these methods were interpreted uncritically 
and it was not possible to determine whether the effects observed were an artefact of the 
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method or due to true raft formation. Recent advances have shown clear phase separation in 
living cells, ranging from nanoscale transient assemblies of raft-based species to a full raft 
„phase‟ on the microscale.11 The mechanism of raft formation is thought to be spontaneous 
lateral self-assembly of glycosphingolipids, cholesterol into tightly-packed domains, which 
are more rigid than the surrounding membrane, followed by selective partitioning of 
glycosyl-phosphatidylinositol (GPI)-anchored proteins, specific raft associated proteins and 
acylated proteins into these domains. Actin is also thought to stabilize the initial association 
events. Raft formation is essential for a variety of cellular events, such as T-cell signalling, 
the formation of traffic vesicles in the trans-Golgi network and virus budding after 
infection.
12
  
 
1.1.3 Model membrane systems 
 
Lateral phase separation of membrane components has been widely characterised in model 
membrane systems. Although model membranes are often simplistic mimics of a natural 
plasma membrane, their simplicity enables the detailed study of specific biophysical and 
biochemical events, offering insights into the membrane dynamics of natural systems. 
There are three major types of model membrane systems available; solid supported bilayers 
(SSBs),
13
 black lipid membranes (BLMs),
14
 and vesicles (Figure 1.6). SSBs are usually 
formed by lipid vesicle deposition onto a freshly cleaned glass surface. A thin layer of 
water separates the bilayer from the glass surface, ensuring that membrane fluidity is 
retained unlike other solid supported techniques where the lipid or lipid-like element is 
covalently attached to the surface. The glass support also permits the use of various 
analytical methods, such as fluorescent recovery after photobleaching (FRAP) and total 
internal reflection fluorescence microscopy (TIRFM), which respectively allow the 
measurement of diffusion coefficients and membrane binding events. A BLM is an 
unsupported membrane covering a small hole in a Teflon sheet separating two chambers, 
formed by „painting‟ a phospholipid solution over the gap. The technique is most 
commonly used to study ion transport events, but has also been employed recently to 
demonstrate the induction of domain formation across a bilayer.
15
 The leaflets of natural 
plasma membranes are asymmetric and it is thought that lipid rafting occurs at both leaflets, 
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by events leading to rafting occurring on the outer leaflet inducing domain formation on the 
inner leaflet. This transmission of lipid rafting was demonstrated by Keller and co-workers 
using asymmetric black lipid membranes.
15
 Induction of domains from one leaflet of phase 
separating mixtures of 1,2-diphytanoyl-sn-glycero-3-phosphocholine / 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine / cholesterol (DiPhyPC/DPPC/chol) to a fluid phase leaflet or 
suppression of phase separation of the DiPhyPC/DPPC/chol leaflet by the fluid phase was 
observed – indicating that the phase state of the two leaflets are strongly coupled.  
 
 
 
Figure 1.6 Three model membrane systems. Solid supported lipid bilayer (SSB, a) on 
glass, a black lipid membrane (BLM, b) and vesicle (c). 
 
Vesicles (or liposomes) are spherical lipid assemblies with an enclosed volume known as 
the lumen.
16
 Vesicle function and response can be modified by the addition of chemical 
species either by incorporation in the hydrophobic membrane, association at the hydrophilic 
surface or by encapsulation in the lumen. In addition, membrane asymmetry can be 
achieved through the addition of lipid species after vesicle formation, so they are 
incorporated in the outer membrane face (leaflet) only. Vesicles can be formed by 
hydration of a thin lipid film, producing multilamellar vesicles (MLVs) of a non-uniform 
size. Large unilamellar vesicles (LUVs) of diameter 100-1000 nm can be produced by 
extrusion of MLVs through a polycarbonate membrane with pores of a defined size above 
the Tm of the lipid mixture,
17
 and can be obtained in millilitre volumes using simple 
manually operated apparatus.
18
 Lipid species can be incorporated before extrusion, giving a 
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uniform distribution in the inner and outer leaflets. Sonication of LUVs results in the 
breakdown into small unilamellar vesicles (SUVs) with diameters of around 50 nm.
16
 
LUVs and SUVs have proved to be very useful in studying processes such as ion transport 
across lipid bilayers and stimulated vesicle fusion events. 
 
Giant unilamellar vesicles (GUVs) have a diameter ranging from 1 – 100 µm and are 
commonly made by electroswelling of a lipid film on an indium-tin oxide (ITO)-coated 
glass slide using an alternating electric field.
19
 The process induces fluctuations in the film 
causing lamellar detachment, producing GUVs with a uniform incorporation of lipids but of 
a non-uniform size. Encapsulation of large species in the aqueous lumen can also be 
achieved, for example performing electroformation in a flow cell with a solution of FITC-
labelled dextran leads to GUV encapsulation.
20
 As GUVs are large enough to be viewed 
using light microscopy, they have proved very useful in the study of phase separation in 
model membrane mixtures. Selective partitioning of fluorescent probes into ld and lo phases 
was demonstrated by Baumgart et al using GUVs composed of a 27/50/23 molar ratio of 
SPM/DOPC/cholesterol or DSPC/DOPC/cholesterol, compositions that display both ld and 
lo phases at room temperature.
21
 Most fluorophores were found to be excluded from the lo 
phase, fluorescently labelling the ld phase, but other fluorescent polyaromatic hydrocarbons 
partitioned into the lo phase, presumably as these flat molecules afforded more favourable 
hydrophobic interactions than the other probes. Fluorophore labelling therefore provides an 
effective indicator for coexisting membrane phases in GUV systems.  
 
1.2 Multivalency and cooperativity 
 
The interactions between many of the ligand and receptor pairs found in nature are known 
to be multivalent, in that they involve many individual binding events. Often the multiple 
links are employed to enhance the overall strength of the interaction in order to provide a 
biologically relevant function, such as cell-cell adhesion. Lectins, particularly plant lectins, 
can possess many binding sites for the interaction with multiple carbohydrate ligands, 
which can result in cross-linking cells, or the binding of multiple ligands on a single cell. 
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Understanding the nature of multivalent interactions is therefore important to understanding 
the biological function of multivalent species.  
 
1.2.1 Multivalency 
 
Valency is a measure of the number of interactions possible for a species. Multivalent 
species are therefore able to form multiple links with a suitable substrate, usually occurring 
in a stepwise manner. This is demonstrated when a multivalent species (M) interacts with 
multiple monovalent ligands (L) to a maximum valency of m, with corresponding 
equilibrium constants (K) for each step. The interaction between two monovalent species 
can be considered as... 
 
 
 
Figure 1.7 Monovalent interaction between receptor (M) and ligand (L). 
 
...with a stability constant (also known as an association constant, Ka or intermolecular 
binding constant Kinter) defined by the following equation derived from the law of mass 
action:  
 
 
A multivalent species interacting with multiple ligands occurs in a stepwise manner as 
shown in the following:  
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If each binding site is independent, i.e. that binding occurs on a purely statistical basis, each 
microscopic binding event will be of equal strength. In general for the formation of a 
complex with m binding sites (M) and l ligands (L):  
 
 
 
The macroscopic binding constant (β) is given by: 
 
 
 
1.2.2 Cooperativity 
 
When a multivalent species binds to multiple ligands an intermolecular cooperative effect 
can occur; binding of the second ligand may be enhanced (positive cooperativity) or 
hindered (negative cooperativity) by the presence of the first, particularly if the first binding 
event alters the structure of the multivalent species, such as a conformational change. 
Cooperativity can be assessed using the Scatchard equation (Equation 1.9),
22
 where r is the 
ratio of the concentration of bound to total binding sites and [L] is the concentration of free 
ligand. Plotting r/[L] vs r, yields a linear plot (Scatchard plot) with a slope of –Kinter and a 
y-intercept of mKinter. Non-linear Scatchard plots are indicative of a cooperative effect; 
concave downward curves, straight lines or concave upward curves is indicative of a 
system that displays positive cooperativity, noncooperativity, or negative cooperativity 
respectively. 
 
inter inter
[L]
r
mK rK   (1.9) 
 
To compare multivalent systems displaying cooperative effects it is convenient to quantify 
the degree of cooperativity. Equation (1.10) was formulated by A V Hill to describe the 
non-linear binding curve of oxygen to haemoglobin that had been observed by Bohr.
23
 
βml 
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Haemoglobin is a tetrameric protein with 4 distinct oxygen binding sites and exhibits 
cooperative binding through a subtle conformational change in the quaternary structure 
after the first oxygen binding event.
24
 Therefore, starting at low O2 concentrations, 
increases in oxygen concentration bring about the formation of more proteins in the active 
conformation, in turn increasing the affinity for the subsequent binding events. Plotting 
log[r / (m – r)] against log[L] yields a sigmoidal curve with a gradient at the central curve 
equal to the hill coefficient (n). Values of n > 1 indicates positive cooperativity (n = 2.8 – 3 
for haemoglobin-O2 binding), n = 1 indicates noncooperativity and n < 1, negative 
cooperativity (hindrance). 
 
interlog log[L] log
r
K
m r
 
  
 
 (1.10) 
 
Multivalent binding can also involve intramolecular binding modes if the ligand also 
presents multiple binding groups. Intermolecular is followed by intramolecular binding, 
with associated binding constants of Kinter (in M
-1
) and intramolecular constants K2, 
K3….Kn. 
 
 
 
Figure 1.8 Intermolecular binding followed by intramolecular binding. 
  
Positive or negative cooperativity can be exhibited here if the second interaction is assisted 
or impeded by the first. Given that the intramolecular binding event occurs between two 
species that are already associated, the resulting association constant becomes 
dimensionless: 
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As intramolecular association constants and intermolecular association constants are 
expressed in different dimensions (dimensionless and M
-1 
respectively), methods such as 
the Scatchard and Hill plots cannot be used to directly compare the affinity of purely 
intramolecular binding with purely intermolecular binding. Nonetheless, models are 
available to determine enhancements of intramolecular binding constants, including the one 
developed by Ercolani,
25
 which introduces an additional factor to take into account the 
symmetry of the intramolecular interaction. If experimental values for the stability constant 
(βobs) differ from a calculated theoretical value, it can be attributed to positive or negative 
cooperativity. However, it is often more practicable to compare overall observed binding 
constants (Kobs) to reference values for monvalent analogues. 
 
1.2.3 Intramolecular vs. intermolecular interactions 
 
Depending on the flexibility or geometric arrangement of the receptor/ligand and 
concentration of the species, intermolecular multivalent binding may also occur after the 
initial intermolecular interaction (Figure 1.9), which is a competing binding mode with 
multivalent intramolecular binding.  
 
 
 
Figure 1.9 After the first intermolecular binding event, further intermolecular binding 
between additional receptors/ligands may occur. 
 
A multivalent system‟s predisposition towards either inter or intramolecular binding can be 
understood by considering free energy changes during the multivalent binding process, as 
proposed by G M Whitesides and co-workers in 1998,
26
 further surmised by Housmann and 
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Mrksich in 2002,
27
 and more recently reviewed by Reynolds and Perez
28
; the latter two 
articles specifically adressing the thermodynamic aspects of the glycocluster effect. Each 
binding interaction (mono or polyvalent) has an associated change in free energy (ΔG) with 
enthalpic and entropic contributions. In order for intramolecular binding to dominate, the 
change in free energy must be more favourable than the sum of individual intermolecular 
interactions, i.e. ΔGpoly > NΔGmono, where N is the total number of monovalent interactions. 
Naturally the free energy has both enthalpic and entropic contributions:  
 
ΔGpoly = ΔHpoly - TΔSpoly  (1.12) 
 
The enthalpic contribution to the interaction represents any changes in energy due to 
stabilising interactions, such as hydrogen bonding, Van der Waals, hydrophobic and π-π 
interactions. For a bivalent ligand, after the initial intermolecular binding event, the 
subsequent intramolecular interaction be equal (ΔHbi = 2ΔHmono), enhanced (ΔHbi > 
2ΔHmono) or diminished (ΔHbi < 2ΔHmono) in enthalpy relative to the first interaction. In 
general, intramolecular interactions induce strain in the system and reduce favourable 
enthalpy changes, but secondary interactions and changes in conformation can induce 
favourable enthalpic contributions. Binding of cholera toxin to receptors on cell surfaces 
and O2 binding to haemoglobin, although O2 is not polyvalent, are known to induce these 
effects. Diminished enthalpic contributions can result from the formation of monovalent 
complexes of polyvalent species that have a geometry that is unfavourable towards further 
intramolecular interactions. Such situations can arise when the receptors or ligands on the 
polyvalent scaffold are incorrectly spaced/aligned or if the spacer is too rigid (Figure 
1.10.a.). The greater the mismatch, the greater the effect on ΔH.  
  

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Figure 1.10 Aspects which influence enthalpic (a) and entropic (b) contributions to inter 
and intramolecular interactions between polyvalent receptor-ligand interactions.
27
 
 
The entropic contribution to the interaction reflects changes in molecular order upon 
binding and is perhaps more influential, although more poorly understood, than enthalpy 
when considering inter vs. intramolecular binding.
27
 ΔSpoly can be deconstructed into 
entropies of translation (ΔStrans), rotation (ΔSrot), conformation (ΔSconf), and hydration 
(ΔSH2O). As for the enthalpic contribution, the sum of these contributions can be larger, 
equal to or smaller than the sum observed for the first interaction (ΔSpoly vs. NΔSmono). 
ΔHbi = 2ΔHmono 
Intramolecular binding favourable 
ΔHbi > 2ΔHmono 
 Intramolecular binding disfavourable 
ΔHbi < 2ΔHmono 
Intramolecular binding favourable 
ΔSpoly = ΔSrot + ΔStrans 
(ΔSconf = 0) 
Intramolecular binding favourable 
ΔSconf < ΔSrot + ΔStrans 
Intramolecular binding favourable if 
linker not too long 
ΔSconf > ΔSrot + ΔStrans 
Intermolecular binding favourable 
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Assuming changes in hydration (ΔSH2O) are the same for inter and intramolecular 
interactions, the preferential binding mode may be inferred by the other three contributions. 
Generally the conformational entropy (ΔSconf) of the second interaction is unfavourable due 
to constraints imposed by binding; the degree of freedom of the ligand and receptor are 
reduced upon binding. Intramolecular binding will only be favoured if ΔSconf is less than the 
sum of ΔStrans and ΔSrot (entropic enhancement) and if ΔSconf is greater than the sum of 
ΔStrans and ΔSrot (entropic diminishment) intermolecular binding will be favoured. Situations 
which effect ΔSpoly are highlighted in Figure 1.10.b. For example, if a linker is too long the 
entropic penalty for the second interaction will be too great in order to favour 
intramolecular binding. This can be emphasised by considering effective concentrations 
(Ceff); if too long, Ceff of the linked ligand will approach the bulk concentration, i.e. Ceff ≡ 
Cbulk, offering no enhancement over binding another ligand in the bulk solution. Therefore 
linker length must match the distance between the receptor binding sites to maximise Ceff 
(to give Ceff > Cbulk).  
 
Other thermodynamic models for multivalency exist, such as that of Kitov and Bundle who 
coined the term „avidity entropy‟ to explain how multivalency can overcome the loss of 
conformational entropy when ligands displayed at the ends of long tethers are bound.
29
 
However, the model assumes that each individual interaction is equivalent (i.e. no 
cooperativity) and does not take into account intermolecular binding modes.  
 
Techniques such as isothermal titration calorimetry (ITC) allow the direct measurement of 
binding affinity (K), ΔH and the stoichiometry of an interaction; from these values ΔG and 
ΔS can be derived. However, resolving the individual components in the entropic 
contribution to binding is often not possible. 
 
In order to achieve multivalent intramolecular binding, polyvalent systems with multiple 
ligands linked on a scaffold must therefore be carefully designed with the target multivalent 
receptor structure in mind; the optimal scaffold will present ligands in the correct spatial 
configuration that are optimally linked in order to minimise strain and entropic cost. Of 
course these principles can be reversed if intermolecular cross-linking of species is needed. 
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In addition, the favourability of inter or intramolecular binding can be influenced by the 
concentration and ratios of ligands/receptors in solution. Higher concentrations of ligands 
and receptors will tend to favour cross-linking as the number of receptor-ligand encounters 
increases, although the concentration must match the individual binding strength of the 
receptor-ligand to ensure sufficient binding. 
 
1.3 Multivalency in biomolecular interactions 
 
Individual biological interactions tend to be reversible non-covalent binding events with 
dissociation constants in the micromolar range. To increase binding strengths further nature 
employs multivalency, which is observed in many key cellular events such as cell-cell 
binding, where multiple individual binding interactions create overall strong intercellular 
links. Multivalency is often a facilitated by clustering of ligands and binding sites on the 
cell surface. This clustering enhances the individual binding affinities between 
complementary ligand-receptor pairs; after the initial binding event (Kinter), subsequent 
intramolecular binding (K2, K3…) can be enhanced through increases in local concentration 
of ligands and receptors at the interface. Off-rates can also be reduced as the multiply 
bound ligands can be stabilised by secondary interactions. The overall result is that the 
average net binding strength (known as avidity) for the receptor-ligand interaction can be 
enhanced over that of the single binding affinity. Given that multivalency requires the 
accessibility of multiple receptors, the degree of multivalent enhancement observed will 
depend strongly on structure, valency, ligand density and the geometric arrangement of 
binding epitopes.  
 
Evidence of the multivalent effect in supramolecular interactions can be found in vitro, 
where it is exhibited in various biological interactions. Possibly the most well-known 
biological supramolecular structure is the double-helix of DNA. Self-assembly of two 
identical polynucleotide strands occurs in an antiparallel fashion and is stabilised by 
hydrogen bonding between matching base-pairs and π-stacking of the nucleotide base pairs. 
The thermodynamic minimum is reached through dynamic assembly and disassembly of 
the structure, ensuring little or no base-pair mismatch. The thermodynamic process has 
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been studied using short (< 18 base-pairs) oligomeric strands of DNA, which is a simplified 
model of the DNA assembly process in vivo.
30
 The assembly process exhibits cooperativity; 
after nucleation by the matching of 2-4 base pairs, a positive ΔG° (unfavourable) process, 
subsequent base-pair matching has a negative free-energy contribution (Figure 1.11). 
 
 
Figure 1.11 The effect of the number of base pairs upon DNA helix propagation.
30-32
  
 
1.3.1 The cluster glycoside effect 
 
Multivalent effects upon binding are also exhibited in the cluster glycoside effect, which is 
observed with interactions between carbohydrates and lectins.
33
 Carbohydrate binding by 
specific lectins is generally a low affinity event; hydrogen bonding of the terminal 
saccharide OH-groups and weak hydrophobic interactions in relatively shallow binding 
pockets results in K ~ 10
3 
M
-1
. However, many researchers have developed ligands which 
present multimeric saccharides that offer an enhancement of binding affinity over 
monomeric saccharides when compared on a valence-corrected basis. The effect was first 
noted by Lee and co-workers in 1995 when studying the binding of several lectins to 
glycosylated forms of bovine serum albumin (BSA).
34
 The measured inhibition constants of 
various sugar derivatised-BSA against monomeric sugars towards alligator, rat and other 
mammalian hepatic lectins (AHL, RHL and MHL respectively) increased with BSA 
saccharide coverage up to a maximal value (Figure 1.12.a). One lectin, mannan-binding 
protein (MBP - known to bind soluble monomeric mannose with a dissociation constant 
1. Introduction 
 
40 
 
(Kd) of ~1 mM), bound their BSA conjugates exhibited Kd < 1 nM on a per sugar basis. 
MBP and the other hepatic lectins studied are essentially carbohydrate recognition domains 
with a collagenous stalk and transmembrane region which (in aqueous solution) drives self-
assembly to form trimers, which can further assemble into higher aggregates with a „flower 
bouquet‟ arrangement.34, 35 Therefore the lectins present multiple ligand binding sites in a 
single direction. Given that the ligand and the protein assembly are both multivalent 
species, the group postulated that multiple carbohydrate-lectin interactions accounted for 
their decreased Kd. The group also investigated the affinities of several branched 
oligosaccharides, which also gave increases in affinity over their monomeric counterparts.
34
 
For instance, the divalent and trivalent ligands shown in Figure 1.12.b offered Kd values in 
the range of 1-40 μM and 10-100 nM respectively towards cell surface rat hepatic lectin 
(RHL) and rabbit hepatic lectins. The Gal „arms‟ of these ligands were postulated to span 
the multiple binding sites presented by the trimer structures by first an intermolecular 
interaction followed by intramolecular binding. 
 
   
 
Figure 1.12 Inhibition of lectin binding by BSA-saccharide ligands as a function of 
saccharide density (a) and multivalent Gal ligands used in subsequent studies (b).
34
 
 
Since the initial observation of the cluster glycoside effect, many other groups have 
designed molecular architectures where the carbohydrate ligand can span multiple binding 
sites on their target proteins. Often crucial to this is the prior knowledge of the target lectin 
structure in an aqueous environment or how it is presented at the cell surface. A classic 
b) 
 
Gal(β1,4)GlcNAc(β1,2)    Man 
     Dimer 
Gal(β1,4)GlcNAc(β1,4) 
 
Gal(β1,4)GlcNAc(β1,2)Man(α1,6) 
         Man 
Gal(β1,4)GlcNAc(β1,2)Man(α1,3) 
     Trimer 
Gal(β1,4)GlcNAc(β1,2)  
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example is the structure created by Bundle and co-workers (named STARFISH), which was 
designed to bind the pentameric Shiga-like toxin B5 subunit of E. coli O157:H7.
36
 The fully 
active bacterial toxin (as found in cholera and Shiga) is an AB5-type structure, where the B5 
homopentamer, a flat ring-like structure with the binding sites on one side of the ring (3 
binding sites per protein monomer = 15 in total). The pentameric B-unit first binds to cell-
surface Gb3 receptors (α-D-Gal(1→4)β-D-Gal(1→4)β-D-Glc(1→O)-ceramide), which is 
followed by endocytosis of the toxic A subunit. Bundle and co-workers synthesised a 
dimeric and decameric (STARFISH) form of the trisaccharide headgroup and tested their 
inhibition of toxin activity on Vero cells using an immunosorbent assay. The STARFISH 
ligand offered a 10
6
-fold enhancement over the monomeric trisaccharide, with an IC50 of 4 
× 10
-10
 M, comparable to the binding strength of the native ganglioside - Kd = 10
-9
 M. 
Interestingly the decameric ligand bound the toxin in a slightly different manner to that 
predicted; crystal structures revealed that one ligand was found to bind two B5 subunits in a 
2:1 „sandwich‟-type complex (Figure 1.13). The group postulated that the formation of this 
complex perhaps is responsible for the unusually high inhibition demonstrated by the 
ligand and that the dimerisation observed may be a feasible target when designing 
inhibitors for similar bacterial AB5 toxins. The work also illustrates the competing binding 
modes of intermolecular binding (of the second B5 subunit) and intramolecular binding 
(binding of all the STARFISH arms to the binding sites on one B5 unit alone), showing that 
intelligent design may still produce unexpected ligand-protein interactions. 
 
 
 
Figure 1.13 The multivalent STARFISH ligand of Bundle and co-workers in complex with 
Shiga-like toxin B5, from the side (a) and top face (b).
36
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Branderhorst et al also chose to target a B5 motif, that of cholera toxin, in a similar fashion 
to that of Bundle and co-workers.
37
 The B5 subunit of cholera toxin (CTB5) preferentially 
binds terminal galactose residues, in particular that of the GM1 epitope - a cell surface sialic 
acid-containing pentasaccharide. They designed a simplified mimic of the GM1 headgroup 
with a galactose unit linked by a short oligoethylene glycol sequence, which the group 
predicted would bind in a similar fashion to GM1, i.e. the oligoethylene glycol sequence 
would mimic the oligosaccharide chain by forming hydrogen bonds with CTB5. The GM1 
headgroup mimic was then grafted onto dendritic scaffolds via the Huisgen cycloaddition to 
give inhibitors with differing valency, which were found to inhibit CTB5 binding to GM1-
functionalised 96-well plates with up to 2500-fold efficiency over that of galactose. 
Although their best inhibitor still fell short of the activity of the natural epitope analogue 
(GM1os-C11H21), the results validate their claim that mimicry of complex oligosaccharides 
can be achieved using only the terminal binding saccharide and an H-bonding scaffold. 
  
Compound Valency IC50 / M Relative potency (per sugar) 
galactose 1 0.24 (± 0.5) × 10-1 1 (1) 
monomer 1 8.0 (± 0.2) × 10-2 3 (3) 
dimer 2 1.3 (± 0.2) × 10-4 1846 (923) 
tetramer 4 2.5 (± 0.4) × 10-5 9600 (2400) 
octamer 8 1.2 (± 0.3) × 10-5 20000 (2500) 
GM1os-C11H21 1 1.9 (± 0.6) × 10
-5 12632 (12632) 
 
Table 1.1 Enhancement of inhibition of CTB5 using dendritic mimics of GM1.
37
 
 
Later in a collaborative effort, Sisu et al also investigated the effect of protein aggregation 
upon the inhibition of the CTB-like toxin, E. coli heat labile toxin (LTBh) with various 
multimeric GM1 ligands.
38
 The group found that whilst their dimeric and tetrameric ligands 
had comparible binding affinity (per sugar) to the monomeric analogue; observed IC50 
values were significally enhanced. This was attributed to the dimeric and trimeric species 
cross-linking LTBh, either by forming protein „dimers‟ (high ligand concentrations) or 
higher aggregates (at lower ligand concentrations).  
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In addition to targeting lectins with a fixed binding site structure, it is also possible to 
design ligands towards the binding of species that present receptors in a non-rigid manner. 
The group of T K Lindhorst created a series of short dendritic mannose ligands designed to 
inhibit of bacterial fimbriae-mediated adhesion.
39, 40
 Bacterial fimbriae are long threadlike 
proteinaceous structures up to several micrometers long that possess carbohydrate 
recognition domains (CRDs) along the shaft and lateral ends and are crucial to bacterial 
adhesion to eukaryotic cells in the infection process. The group targeted the mannose-
specific type I FimH proteins of E. coli, of which there can be between 100-400 on a single 
bacterium; their presence can greatly increase the virulence of the bacterium.
41
 A thiourea-
linked mannose dimer, trimer and octomer were found to enhance the inhibition of E. coli 
binding to guinea pig erythrocytes 37, 35 and 14-fold respectively,
39
 relative to α-methyl 
mannose when compared on a per mole mannose basis. Inhibition activity was improved 
using an alternative scaffold, based upon oligosaccharide cores that were multiply 
mannosylated with extended mannose units, dubbed „octopus glycosides‟.40 Again these 
multimeric structures were found to inhibit E. coli FimH binding - this time to a mannan 
(polymannose) functionalised surface - to a much greater extent than α-methyl mannose. 
The greatest increase in relative inhibition was exhibited by a raffinose (α-D-Gal(1→6)α-
D-Glc(1→2)β-D-Fru) analogue, with 11 mannose branches from the central trisaccharide, 
which inhibited FimH binding 250-fold better than α-methyl mannose. However, mannan 
itself gave a relative inhibition of 190 compared to methyl mannose even though the 
structure only possessed one terminal mannose available for binding to the CRD. 
Furthermore the cluster mannoside ligands were envisaged to enclose a spherical 
conformational space and may not be able to bind all mannose groups to the CRDs, as 
some mannoses will be facing away from the bacterium. These findings seem to indicate 
that secondary interactions (such as statisitical rebinding) or other non-specific interactions 
could be responsible for the increased inhibitory effects observed.    
 
It is clear from these analytical platforms employing inhibition assays, typically enzyme-
linked lectin assays (ELLA), inhibition can be heavily influenced by lectin cross-linking 
and the values obtained are not the actual binding affinity for the protein. Other analytical 
systems commonly used in lectin-carbohydrate systems include hemagglutination and 
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turbidimetric assays that also measure secondary effects (e.g. minimum concentration 
required to inhibit the agglutination of erythrocytes and the change in „cloudiness‟ of a 
solution upon binding respectively). Therefore when employing these assays it is difficult 
to assess which of the primary effects occur, i.e. whether chelation (intramolecular 
binding), statistical rebinding or cross-linking (intermolecular binding) contribute to 
binding and one can only speculate on the nature of the binding modes in a given system. 
Nevertheless, multivalent ligands clearly do give enhancements over their monovalent 
counterparts, even if the exact primary binding mode is unknown. 
 
1.3.2 Statistical rebinding 
 
Many of these dendritic and cluster glycoside ligands are able to chelate multiple receptor 
binding sites, but there are also many examples of multimeric saccharide ligands with 
enhanced binding constants (K) or IC50 values, that are incapable of spanning multiple 
receptor sites on the same protein. These enhancements are often attributed to a statistical 
rebinding model (often called bind-and-slide), where the off-rates (Kd) are reduced by the 
close proximity of other carbohydrate groups to the receptor binding site after the initial 
dissociation event. These proximity or statistical effects typically offer a smaller 
enhancement than chelation, usually 10 to 100-fold that of their monomeric counterparts. 
Often a combination of statistical/proximity and chelate effects can be observed in 
carbohydrate-lectin interactions, provided the multivalent ligand can span the multiple 
receptor sites. 
 
 
Figure 1.14 The statistical rebinding model. After the initial binding event (a), if the 
receptor detaches from the initial ligand it may quickly „re-bind‟ another on the same 
scaffold (b).  
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Statistical and proximity effects are often attributed to multivalent ligands that target plant 
lectin binding. Early evidence of statistical rebinding effects was observed in a study by the 
group of Kiessling using the lectin from Canavalia ensiformis, Concanavalin A (ConA).
42
 
ConA is a tetrameric lectin with 4 mannose-binding sites arranged at the corners of its 
tetrahedral structure that are separated by ~70 Å. Their approach involved the use of 
mannose functionalised polymers with 10 to 143 mannose side chains, which displayed 
inhibition of ConA-mediated hemagglutination of mannose-bearing erythrocytes. A 200-
fold increase in inhibition activity was observed with the decamer, on a per-saccharide 
basis relative to the monomer. Activity increased with polymer length, reaching a plateau at 
lengths containing 50 mannoses or greater (~2000-fold). The large increase in activity of 
the short polymers was attributed to a statistical model and the further increase attributed to 
a combination of statistical rebinding plus chelation, as the longer polymers could bridge 
the ConA binding sites. 
 
Statistical rebinding with ConA was also observed by Mangold and Cloninger using a 
polyamidoamine (PAMAM)-based dendritic glycocluster.
43
 Several generations of 
mannose clusters were synthesised, bearing up to 172 mannoses for the 6
th
 generation 
dendrimer (Figure 1.15. a). The researchers then tested the efficacy of each dendrimer 
towards the inhibition of erythrocyte agglutination by dimeric and monomeric ConA using 
a hemagglutination assay and also measured the binding affinity by ITC. This revealed that 
inhibition of erythrocyte agglutination and binding strength increased with dendrimer 
valency for both monomeric and dimeric ConA. The use of monomeric ConA (one binding 
site) allowed the partitioning of statistical rebinding and chelation effects: 
Hemagglutination for the most potent dendrimer – bearing 172 mannoses – was enhanced 
nearly 200-fold relative to methylmannose for the monomeric ConA (statistical rebinding), 
whilst enhanced 770-fold for dimeric ConA (statistical rebinding + chelation). In the 
absence of ligand-induced clustering of ConA (no change in turbidity was observed), this 
implies only a 3-4 fold „bonus‟ enhancement for chelation, perhaps due to sub-optimal 
presentation of mannoses in the dendrimer structure. Results of the hemagglutination assays 
were backed up by ITC, which for the 6
th
 generation dendrimer showed an increase in 
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binding affinity of ~8-fold for monomeric ConA and ~32-fold for the dimeric ConA 
relative to methyl mannose, again a 4-fold increase from monomeric to dimeric ConA. 
 
 
 
Figure 1.15 PAMAM-based mannose glycoclusters developed by Mangold and Cloninger 
(a).
43
 Binding of smaller dendrimers (b) offers the possibility of proximity/statistical 
effects, whereas the larger dendrimers (c) also offer chelation. 
 
Wheat germ agglutinin (WGA) is an interesting protein which offers N-acetylglucosamine 
(GlcNAc) or sialic acid (Neu5Ac)-specific binding sites in a spatial configuration that is 
open for chelation – eight per functional dimer, arranged in pairs spaced by only 14 Å. 
However, many researchers have found that inhibition can be enhanced with ligands either 
sub-optimally linked or incapable of spanning two (or more) binding sites on the same 
protein. Nishimura and co-workers targeted WGA using GlcNAc mounted on a β-
cyclodextrin scaffold to give a heptameric ligand, which offered a 40-fold increase in 
relative inhibition of hemagglutination of red blood cells on a per sugar basis.
44
 Roy and 
co-workers created an octomeric GlcNAc ligand that offered a ~170-fold enhancement in 
inhibition of WGA binding to a porcine mucin surface over that of GlcNAc alone.
45
 The 
ligands were also galactosylated enzymatically by bovine β-(1,4)-galactosyltransferase to 
give Galβ(1,4)GlcNAc (or N-acetyllactosamine - LacNAc), which were then responsive 
towards the LacNAc-specific lectin Erythrina cristagalli lectin (ECL).  
 
The work of Wittmann et al aimed to understand the exact „molecular mechanisms‟ of 
WGA inhibition by multimeric ligand systems.
46, 47
 The group initially screened a series of 
resin-bound cyclic peptides (Figure 1.16) with four GlcNAc side-chains towards WGA 
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using ELLA, of which the most effective gave a 619-fold enhancement over binding of 
monomeric GlcNAc – the highest enhancement of WGA ligand binding observed at the 
time.
46
 It was thought that the arrangement and distance between the sugars on the scaffold 
offered the correct spatial configuration to efficiently chelate the WGA binding sites. In a 
subsequent paper, the ligand was optimised and screened against a series of peptide-linked 
GlcNAc ligands, with differing spacer lengths.
47
 The most potent are shown in Figure 1.16 
along with their corresponding IC50 values in Table 1.2. The optimised peptide-based 
compound (6) has a more rigid linker between the scaffold and GlcNAc which offered a 
relative inhibition of 6400 over GlcNAc and a 20-fold enhancement of inhibition over 5. 
The dimeric ligand 7 is structurally similar to 6, but was found to only offer a small 
enhancement of inhibition (60). Given that the group observed precipitation of WGA when 
using ligand 6, they surmised that this enhancement was due to conformational 
preorganisation of the ligand (maximising ΔH and minimising ΔS) with any extra 
enhancement in inhibitioin (cf. 6 and 7 – which did not precipitate WGA) due to extensive 
cross linking of WGA. This was supported by crystal structures of WGA with bound ligand 
5, 6 or 7, which seemed to show chelation of >1 WGA binding site by each ligand. 
 
Figure 1.16 GlcNac ligands designed for multivalent WGA binding by Wittmann et al.
47
 
 
Compound Valency  IC50 / μM Relative potency (per sugar) 
5 4  16 ± 3.3 1440 (360) 
6 4  0.9 ± 0.16 25500 (6400) 
7 2  191 ± 24 120 (60) 
 
Table 1.2 Inhibitory data for multivalent WGA binding by Wittmann et al. Relative 
potency is based on that of free GlcNAc in solution (IC50 = 23 ± 2.1 mM).
47
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There are many examples of multivalent systems for directly measuring binding strength 
independent of secondary effects, such as the quantum dot-based glycoclusters of Fang et 
al.
48
 They synthesised GlcNAc-functionalised quantum dots (QD) with ~210 sugars per 
QD, to target WGA. Titrations were performed with unlabelled WGA, which was found to 
quench the quantum dot fluorescence, likely through energy transfer from the QDs to 
WGA. Analysis of the quenching by Stern-Volmer method gave approximate Ka values for 
the glycoclusters in the region of 10
6
-10
7
 M
-1
, at least a 1000-fold enhancement over that of 
GlcNAc alone (~10
3
 M
-1
). The method was validated using non-functionalised QDs which 
gave minimal fluorescence quenching upon WGA addition. Given the size of the QD 
ligands and the short distance between WGA binding sites, these large increases in affinity 
could be ascribed to both chelation and/or statistical/proximity effects. 
 
Roy and co-workers synthesised a series of divalent and trivalent clusters of the Lewis a 
(Le
a
) disaccharide (α-L-Fuc-(1,4)-β-D-GlcNAc) designed to target the bacterial 
Pseudomonas aeruginosa PA-IIL lectin.
49
 Using ITC, they observed a 4-fold increase in 
binding affinity for the most potent dimer (8, Figure 1.17, where n = 4) over their 
monomeric analogue, with stoichiometry approaching 2:1 protein to ligand and a positive 
ΔS contribution. This suggested that the lectins were cross-linked, evidence of which they 
observed in X-ray crystal structures.  
 
 
Figure 1.17 Le
a
 ligands synthesised by Roy and co-workers.
49
 
 
Interestingly Roy and co-workers also presented crystal structures where the trimeric ligand 
9 appeared to span two binding sites on the same protein.
49
 As the group observed negative 
changes in ΔS for 9 upon binding, the modest increases in affinity perhaps reflect that 
chelation was unfavourable; chelation would have a larger entropic cost than cross-linking 
two proteins, a binding mode which would retain more degrees of freedom of the highly 
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flexible ethylene glycol linker. Although the increase in affinity is small, the paper 
highlights that changes in binding strength due to chelation can be directly measured 
independent of cross-linking. 
 
1.4 Multivalency at surfaces 
 
Immobilisation of either ligand or receptor on a surface can help circumvent any effects due 
to cross-linking of lectins, whilst allowing measurement of binding affinity (SPR, TIRFM, 
quartz crystal microbalance - QCM) and other properties such as lateral diffusion across 
supported bilayers (FRAP, fluorescence correlation spectroscopy - FCS) and phase 
separation in supported bilayers (FRAP). SPR is commonly used to measure the absorption 
of molecular species to a surface; the refractive index of the surface changes as a function 
of the changing mass absorbed to the surface. In the experimental setup, the analyte of 
choice flows over the surface to give on-rates (ka) and then is washed with buffer to give 
off-rates (kd), which in turn provides the dissociation constant (KD = kd / ka). 
Functionalisation of the surface with lectins therefore allows the determination of 
carbohydrate ligand binding constants. Lehn and co-workers used the technique to 
determine the binding affinity of a series of lactose derivatives  towards peanut agglutinin 
(PNA).
50
 It was found that the dimeric lactose (11, Figure 1.18) bound PNA with an 
affinity of (2 × 10
4
 M
-1
) almost 8-fold more than a monomeric analogue (10, Figure 1.18) 
and around 10-fold that of free lactose (1.99 × 10
3
 M
-1
).  
 
 
Figure 1.18 Mono (10) and dimeric (11) lactose ligands synthesised by the group of 
Lehn.
50
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Self-assembled monolayers (SAMs) also have been used to investigate multivalent binding 
at surfaces. SAM monolayers are formed by specific and spontaneous chemoadsorption of 
species onto a surface and can be coupled to a large suite of analytical methods, the most 
common being SPR, QCM, atomic force microscopy (AFM) and matrix-assisted laser 
desorption of ion (MALDI) mass spectroscopy. In a detailed study, Wilczewski et al 
employed SAMs in conjuction with QCM and SPR in order to probe ConA binding to 
multivalent ligands at the SAM surface.
51
 The group synthesised cyclic amide platforms, 
which they dubbed „regioselectively addressable functionalised templates (RAFTs), 
presenting either one (RAFT-Man1) or four mannose residues (RAFT-Man4).  
 
 
 
Figure 1.19 ConA binding to RAFT platforms of Wilczewski et al.
51
 At low loadings of 
RAFT-Man1 (a) monovalent binding predominates and statistical rebinding (i) or chelation 
(ii) is not possible, whereas at low loadings statistical rebinding is possible for RAFT-Man4 
(b). At higher loadings for RAFT-Man1 (c) statistical rebinding as well as chelation may be 
possible to neighbouring RAFTs. RAFT-Man4 at high loadings (d) may exhibit statistical 
rebinding to itself or neighbouring RAFTS as well as chelation to neighbouring RAFTs. 
 
The RAFTs were immobilised on a surface by either thiols (for attachment onto gold) or 
biotin (for streptavidin-coated slides), with the latter proving to be more effective. The 
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model system allowed the study of both the effects of surface coverage (by dilution with a 
non-active RAFT) and effects due to multivalency in the ligand structure. Increasing the 
surface coverage of both ligands led to a decrease in apparent Kd, with the multivalent 
RAFT-Man4 outperforming the RAFT-Man1 ligand each time. At 10% coverage the group 
argued that for RAFT-Man1 only monovalent binding of ConA was available, which is in 
agreement with their apparent Kd of 154 μM being above that of free methylmannose (125 
μM). Significant cluster effects were observed with the RAFT-Man4 ligand; at 10% loading 
the Kd was measured at around half that of methylmannose, reaching 6.6 μM at 100% 
coverage. As the ConA binding sites are widely-spaced it seems likely that at lower 
loadings statistical rebinding enhancments may be observed (Figure 1.19.b,c), which 
increases with percent loading. This is further enhanced by multivalent chelate effects as 
the spacing between the RAFTs is decreased (Figure 1.19.d). 
 
1.5 Membrane and vesicle-based systems 
 
The incorporation of lipid species bearing specific functional groups, either buried in the 
hydrophobic centre or projected into the aqueous exterior, endows model membranes with 
extra functionality. Interactions between these groups or interactions with external stimuli 
can occur via several different intra- or inter-membrane binding modes: Interactions 
between membrane-bound species that are intramembrane can occur trans-membrane, i.e. 
through the hydrophobic centre (Figure 1.20.a), or intraleaflet - between two adjacent 
species in the same membrane leaflet (b). These interactions can be caused by self-
assembly through non-covalent interactions or can be mediated through external stimuli, 
such as metal cations. External species such as proteins may also interact with the 
membrane and the targeted binding of these external compounds is possible through 
displaying known binding partners on the membrane surface (c). In addition, further 
binding to other membrane bound ligands may occur if the external species has the correct 
binding site geometry, leading to multivalent intramembrane binding (d) with an associated 
binding constant (K2) that may be enhanced by the multivalent effect. An increase in the 
effective local concentration (Ceff) of receptors when they are membrane-bound can lead to 
higher affinity for the second binding event through chelation.  
1. Introduction 
 
52 
 
 
 
Figure 1.20 Membrane binding events involving a single bilayer. Interactions between two 
membrane-embedded species may be transmembrane (a) or occur in the same membrane 
leaflet (b). Binding of external receptors to membrane embedded ligands can be 
monovalent (c) or multivalent with an intramolecular binding mode (d). 
 
Membrane-bound functional groups may also mediate interactions between neighbouring 
membranes via intermembrane binding. Intermembrane binding can occur through self-
association with an equivalent molecule in an adjacent membrane (Figure 1.21.a), or 
complementary functional group (b), which again may be regulated by external stimuli. 
Multivalent species such as proteins may also mediate intermembrane binding if the 
binding sites are presented on opposite faces (c) or with a flexible linker. Intermembrane 
binding in this case is in direct competition with the intramembrane binding mode (Figure 
1.20.d).  
 
 
Figure 1.21 Intermembrane binding events. Interaction between two identical membrane-
embedded species (a) or complementary ligands (b). Binding of a multivalent receptor to a 
membrane-embedded ligand (c, i.) may exhibit subsequent intermembrane binding (c, ii.) if 
the binding sites are on opposite faces of the multivalent receptor.  
intra
2K
interK
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The predominance of inter or intramembrane binding is dependent upon many variables, 
such as the chemical nature of the receptor and membrane-bound ligand, the concentration 
of membrane-bound receptor/ligand, the loading (χ) and the presentation of the ligand in 
the membrane. Research by the Webb group previously demonstrated that the lateral 
distribution of receptors in the membrane can enhance vesicle crosslinking.
52
 Clustering of 
an iminodiacetate lipid into phase-separated domains was shown to enhance aggregation 
with vesicles doped with a complementary histidine lipid. This biomimetic study is 
comparable to multivalent cellular adhesion mechanisms and it was suggested that 
preorganisation of receptors may help minimise entropic penalty when forming multiple 
links between vesicles. In a subsequent study, laterally dispersed iminodiacetate lipids were 
employed to investigate the favourability of inter or intramembrane binding to a soluble 
multivalent histidine ligand.
53
 At 5% mol/mol loading, increasing the valency of the 
histidine lipid increased the aggregation observed, but no enhancement of binding through 
intramembrane chelation was observed. To explain this observation, a binding model for 
the second binding event was suggested relating both inter and intramembrane binding to 
the observed binding constant. For the i
th
 binding event: 
 
obs inter
i i iK K      (1.13)     where 
memb
T m100[R]
i
i
K
V
    (1.14) 
 
and [R]T = the total concentration of the receptor in solution and Vm = molar volume of the 
phospholipid.  
 
The model reflects that it is often difficult to form intramembrane links, a process 
dependent upon membrane loading (χ); if χ is too low intermembrane binding is favoured 
and intramembrane binding becomes more favourable as χ increases (Figure 1.22). 
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Figure 1.22 Schematic depicting the competition between inter and intramembrane binding 
to a flexible polyvalent ligand (a).
53
 The favourability of inter or intramembrane binding 
may be dependent upon receptor loading in the membrane (b). 
 
1.5.1 Cooperative effects at the membrane interface 
 
Using a Cu
2+
-complexing lipid Doyle et al studied cooperative effects at the membrane 
interface.
54
 Metal ions are ideal candidates for binding studies at the membrane interface as 
they are the most simple of multivalent species and their solution-phase complexes are 
often well-characterised. Fluorescence quenching titrations of dansyl by copper(II) were 
performed on egg-PC vesicles with varying membrane loadings (χ) of a dansyl-lipid 13 
(Figure 1.23.a) and then fitted to a ML4 binding model. Membrane loading was modified 
by changing phospholipid concentration, ensuring the dansyl lipid 13 concentration was 
constant. Comparison with a soluble analogue 12 revealed that embedding the receptor in 
the membrane at 1% mol/mol enhanced both K1 (formation of a 1:1 Cu(X) complex, where 
X = 12 or 13) and K2 (formation of a 1:2 Cu(X)2 complex) by 10
2
 and >10
5
-fold 
respectively, although this was ascribed to the lower polarity experienced by the binding 
group at the bilayer interface. Interestingly, altering the membrane loading directly 
influenced the structure of the multivalent complex; at loadings of χ < 0.75% mol/mol 
Cu(13) was the dominant species and at membrane loadings of χ ≥ 2% mol/mol the 
formation of divalent complex Cu(13)2 was augmented. Furthermore, 
obs
2K  was found to 
increase linearly with χ when analysed using their model. Cooperativity was assessed by 
comparing obs2K  to a model value of K2, calculated using 12 in 4% buffer in methanol (a 
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solution with similar polarity to the phospholipid membrane). At χ ≤ 1% mol/mol obs
2K  < 
K2, indicating negative cooperativity and at χ = 2.5% mol/mol 
obs
2K  > K2, indicating 
positive cooperativity. The group contextualised their results by suggesting that cells may 
control their response to external stimuli by controlling receptor density at the plasma 
membrane.  
 
 
Figure 1.23 Soluble (12) and lipid-bound (13) dansyl-receptor synthesised by Doyle et 
al (a).
54
  Zn
2+
-coordinating receptor (14) and lipid (15) synthesised by Smith and co-
workers (b).
55
 Formation of a 2:1 complex in solution (c) and at the membrane interface 
(d). Pre-organisation of lipid-bound receptors may favour the formation of 2:1 complexes 
over 1:1 (e). 
 
Complex formation and the effect of receptor concentration at the membrane surface was 
also demonstrated by the group of Bradley Smith using a synthetic zinc-coordinating lipid 
15 (Figure 1.23.b).
55
 As observed by Doyle et al,
54
 receptor loading was found to have a 
great effect on the complex formed; at membrane loadings of 10 mol% the lipid/ligand 
formed a 1:1 complex. Above 20 mol%, a 2:1 lipid/ligand complex was observed and at 
membrane loadings above 30 mol% the 2:1 complex was the major structure detected. The 
group also used a water soluble analogue of their Zn
2+
-lipid 14 that formed a 1:1 complex 
with the ligand. When fit to a model that takes into account 1:1 and 2:1 complex formation, 
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K1 was significantly reduced compared to in solution, but K2 increased substantially with 
membrane loading, demonstrating the affinity-enhancing effect of higher local 
concentrations during multivalent binding. K2 was enhanced further by the addition of a 
charged surfactant, thought to induce lateral clustering of the Zn
2+
-lipid 15, indicating that 
pre-formed lipid clusters can promote the formation of multivalent interactions at the 
bilayer surface (Figure 1.23.e). 
 
1.5.2 Glycocluster effects at the membrane interface 
 
Cooperative enhancements through glycocluster effects can also be studied at the 
membrane surface; incorporation of saccharide-capped lipids into phospholipid bilayers 
provides a lectin-responsive plasma-membrane mimic; an artificial glycocalyx. Many 
literature examples have shown that presentation of multiple saccharides or multivalent 
saccharides at the membrane surface can offer binding affinity enhancements towards 
lectins. Examples also exist of multivalent receptor systems embedded in non-phospholipid 
vesicles, such as lipid linked-cyclodextrin,
56-58
 catanionic,
59, 60
 block-copolymer,
61
 
circubit[6]uril,
62
 and polydiacetylene (PDA)-based vesicles.
63, 64
 Many amongst these 
demonstrate affinity enhancements, however employing receptors in phospholipid 
membranes offers a more biomimetic approach. 
 
Further to their studies with polymeric ligands and ConA, the group of Kiessling also 
studied ConA binding to membrane-bound mannose lipids on a SPR platform.
65
 The 
bilayer was formed by immersing alkane thiol-coated gold SAMs in liposome solutions; 
upon contact with the hydrophobic SAM the liposomes burst, forming a bilayer with the 
SAM monolayer at the bottom and a lipidic monolayer on top. At loadings of 10% mol/mol 
mannose-lipid, the bilayer bound ConA with an association constant of Ka = 2.3 × 10
4
 M
-1
, 
~3.5-fold greater than that of methylmannose (8 × 10
3 
M
-1
). Given that Wilczewski et al 
only observed chelation of ConA above loadings of 25% mol/mol,
51
 a monovalent binding 
mode appears likely, with the modest enhancements observed caused by statistical 
rebinding. The bilayer was then used to test the inhibitory activity of their previously 
characterised polymeric ligands against ConA binding to the mannosylated bilayer surface. 
1. Introduction 
 
57 
 
Interestingly they only observed a maximum 40-fold enhancement of inhibition using the 
bilayer system, whereas previously up to 2000-fold enhancements had been observed using 
a hemagglutination assay.
42
 These results demonstrate that it is often difficult to compare 
the results between different assay techniques, especially comparing those with the 
potential for multivalent binding at a surface to solution-phase binding, as the „...observed 
magnitude of enhancement when comparing a monovalent to a multivalent ligand will 
depend on the conditions under which the ligand must function.‟65  
 
Avidity enhancements with sugar-lectin interactions have also been detected using 
phospholipid vesicles. Individual vesicles can be viewed as large multivalent ligands 
provided they are decorated by the correct binding epitopes. Mahon et al recently reported 
multivalent recognition of mannose labelled vesicles by a QCM detection system.
66
 The 
group synthesised a series of simple short chain saccharide lipids (16, 17 Figure 1.24) via 
the Huisgen cycloaddition and incorporated them into 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC – ld phase at 25 °C) small unilamellar vesicles (SUVs) at 1-5% 
mol/mol. The group then measured the extent of SUV adsorption to a ConA-functionalised 
QCM surface and analysed it using the Langmuir model. The maltose (17)-functionalised 
vesicles offered a binding affinity of 8.4 × 10
4
 M
-1
, 40-fold that of free maltose binding to 
ConA (1.6 × 10
3
 M
-1
). However, no binding of their glucose, mannose and galactose 
vesicles were observed using the QCM system, as the sugars presumably were withdrawn 
into the lipid bilayer and thus inaccessible for ConA binding.  
 
 
Figure 1.24 Mannose 16 and maltose 17 lipids synthesised by Mahon et al (a)
66
 and lipid 
carbohydrate oligomers 18 created by Tagawa et al (b).
67
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In a following paper the same group of researchers employed maltose-functionalised 
nanoparticles, which offered a greater enhancement (around 45,000-fold) compared to free 
maltose under the same QCM assay conditions.
68
 Since the vesicles are in the ld phase – 
POPC has an oleic acid chain (cis double bond), giving a Tm of -3 °C – membrane fluidity 
may have spread the maltose receptors over the surface. The group attributed the increase 
in affinity from vesicles to nanoparticles to glycocluster effects by chelation or statistical 
effects, as the nanoparticle systems presented more condensed epitopes at the surface.  
 
Prior to this Tagawa et al designed a liposome system with lipid-bound multivalent 
receptors (18, Figure 1.24).
67
 Amphiphilic oligomers with mannose side-chains were 
incorporated into SUVs composed of 1,2-dimyristoylamido-1,2-deoxyphosphatidylcholine 
(DDPC). Turbidity was used to measure the binding of ConA to the vesicle surface, which 
revealed that binding was largely affected by the degree of oligomerisation and surface 
density of the oligomeric lipids, with a maximum observed for the 18-mer and at 40% 
mol/mol membrane loadings. Affinity constants were found to be in the region of 10
6
 M
-1
, 
up to 275-fold greater than that of methyl mannose, which the group attributed to cluster 
effects exhibited by their multivalent ligands. They also drew parallels to a previous study 
in which they observed enhanced binding of similar oligomers carrying Gal arms by 
galactose oxidase (up to 1000-fold).
69
 
 
1.5.3 Effect of lipid clustering on binding to membrane-bound epitopes  
 
These examples indicate that vesicle systems provide the potential for multivalent 
interactions and that receptor clustering in the membrane (either for metal binding or for 
lectin binding) may further enhance chelation and statistical rebinding, in turn improving 
affinity. This observation is unsurprising since the effect is also observed with clustered 
epitopes on dendrimeric scaffolds. Carefully controlling clustering of membrane-bound 
saccharides may therefore offer extra multivalent potential. Studies with cyclodextrin-based 
vesicles have also demonstrated that this may be the case; Lim et al observed an almost 5-
fold increase in Ka when increasing loading from 10 to 100% mol/mol, which could thought 
to be related to increases in effective concentration (Ceff).
57
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In a thorough investigation, Okahata and co-workers reconstituted gangliosides GM1, GM2, 
GM3 and GM4 reconstituted in ceramide lipid monolayers at various percent loadings and 
assayed WGA binding using a QCM.
70
 WGA was shown to recognise and bind the sialic 
acid containing gangliosides in order of preference GM3 > GM4 >>> GM2 = GM1 (binding 
of GM2 and GM1 was not detected), believed to reflect the accessibility of the sialic acid 
residue. Binding to the monolayers increased with percent loading, reaching a maximum at 
20% mol/mol, before rapidly trailing off. Gangliosides are known to exhibit spontaneous 
phase separation into domains in model membrane systems,
71
 indeed it is a known 
mechanism of natural lipid raft formation.
11
 This may indicate that the formation of phase 
separated ganglioside regions in the monolayer enhanced the binding to WGA through a 
glycocluster effect. The group also explained that at 100% surface coverage of GM3, 
binding of WGA was unfavourable due to steric blocking; the epitopes were thought to be 
so closely packed that they were inaccessible to the WGA binding sites.  
 
An increase in WGA binding by the alleviation of epitope clustering was also observed by 
Berthelot et al. Using surface tension measurements, they observed WGA binding to a 
monolayer composed of neoglycolipids was enhanced by the addition of DMPC, up to 
around 8:2 neoglycolipid/DMPC. Ideal mixing of lipid components was observed, i.e. no 
domain formation had occurred, so WGA binding could only occur with sufficiently-spaced 
epitopes. These examples demonstrate that ligand clustering may increase lectin binding 
strength up to a point, but also that heavily clustered ligands may inhibit binding due to 
steric blocking.  
 
More recently Cremer and co-workers reported a system that was very sensitive to lipid 
clustering.
72
 The group investigated CTB5 binding to GM1 gangliosides in POPC supported 
membranes in a microfluidic system. TIRFM was employed to detect CTB5 binding and the 
data obtained was fitted to non-cooperative Langmuir and cooperative Hill-Waud models, 
but the best fit was found with the cooperative model. Maximal affinity was observed with 
membranes containing 0.02% mol/mol GM1, but diminished as the membrane loading was 
increased up to 10% mol/mol. Clustering of GM1 was observed using AFM, with average 
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domain sizes of 7.3 nm at 0.1% mol/mol which increased in size to 19.5 nm at 10% 
mol/mol. Although binding was weaker at the higher loadings, the Hill coefficient (n) 
increased, indicating cooperative binding to these clusters. The decrease in affinity was 
again attributed to steric blocking. 
 
 
 
Figure 1.25 CTB5 binding to GM1 in supported bilayers by Cremer and co-workers.
72
 GM1 
is dispersed at low loadings (a) and increased loadings induces phase separation (b). 
Binding to well-spaced epitopes is favourable (c) and clustering may inhibit binding despite 
exhibiting cooperative behaviour (d). 
 
1.5.4 Effects of binding on lipid clustering of membrane-bound epitopes  
 
A consequence of multivalent binding to lipid-receptors – which can either be enhanced or 
inhibited by receptor clustering – is that the binding event can exert an influence upon the 
degree of lipid clustering and even induce morphological changes in the surrounding 
membrane matrix. Literature examples exist of both membrane receptor dispersal and 
clustering upon ligand binding, which are respectively dependent upon the receptors 
existing in domains or being laterally dispersed prior to the addition of an external binder.  
 
Sasaki and co-workers have published several examples of receptor dispersal, detecting the 
degree of domain formation using pyrene, a fluorescent polyaromatic hydrocarbon which, 
at high local concentrations, is capable of forming excited dimers (excimers) that exhibit a 
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higher wavelength emission that the monomeric form. The degree of domain formation as 
measured by excimer formation is often expressed as a ratio of excimer to monomer 
fluorescence (E/M); the higher the E/M the greater the extent of pyrene lipid clustering.  
Dispersal of metal-chelating receptors was observed in so 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC) vesicles, characterised by a drop in the pyrene E/M ratio when 
various bivalent metals were added.
73
 The drop in E/M directly reflected a reduction in 
local concentration of pyrene-labeled receptors upon metal binding due to increased 
headgroup-headgroup repulsion. Sasaki and co-workers also observed domain breakdown 
of pre-formed glycolipid domains with lectin binding.
74
 Pyrene-tagged mannose lipids were 
incorporated at 5% mol/mol into vesicles composed of DPPC (so at 25 °C) or 1-stearoyl-2-
oleoyl-sn-glycero-3-phosphocholine (SOPC – ld at 25 °C), which gave high and low E/M 
ratios respectively. Upon addition of ConA pyrene-lipid dispersal was observed for 
mannose lipids in both DPPC and SOPC vesicles (the E/M ratio dropped – E decreased 
whilst M increased). A chelation binding mechanism was proposed to cause the domain 
breakdown, with the well-separated ConA binding sites spreading out the receptors. In 
DPPC the drop in E/M occurred over several days, possibly reflecting the solid ordered 
state of the membrane. AFM was also employed to visualise the domains on solid 
supported bilayers which revealed elliptical domains of 60-90 nm in size, which appeared 
to disperse with ConA addition. Perhaps the most striking observation they made is that 
breakdown of the phase separated domains in DPPC occurred over several days. This 
indicates that whilst lectin-carbohydrate binding may be relatively rapid, reorganisation of 
the lipid-protein complex by lateral diffusion through the membrane can be very slow in 
ordered phase phospholipid membranes. 
 
Ohtoyo et al observed changes in the lateral distribution of glycolipids as well as membrane 
fluidity with WGA binding.
75
 The group employed pyrene-labelled peptidic GlcNAc lipids 
in DPPC SUVs at ~1.5% mol/mol loading, a bilayer composition in which the lipids were 
found to exhibit domain formation as indicated by strong pyrene excimer emission. Domain 
formation was strongly temperature dependent, with high E/M values at low temperatures 
which decreased up to the Tm of the DPPC membrane (41 °C). This change indicated that 
domain formation was dependent upon membrane phase; GlcNAc-lipids segregated into 
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condensed regions in the lo phase DPPC. Upon WGA addition, vesicle aggregation and an 
increase in E/M was observed both below and above the Tm of DPPC, a sign that the close 
binding sites of WGA induced further inter-pyrene contacts. Membrane fluidity was also 
monitored, which first decreased with the addition of the GlcNAc lipid then increased 
largely upon addition of WGA. The increase in fluidity was attributed to both inter and 
intravesicular binding of GlcNAc lipids by WGA, which induced „sterically skewed 
complexes‟ perturbing the local DPPC membrane environment.  
 
In addition to inhibition of CTB5 binding by heavy clustering of GM1, CTB5 binding to 
GM1 has been shown to reorganise and alter the phase state of the surrounding membrane.
76
 
Using a DMPC supported bilayer doped with 0.5 mol percent GM1, JT Groves and co-
workers observed that a binding event had an effect on the fluidity of the bilayer at 
temperatures close to the bilayer Tm. FCS measurements revealed that the diffusivity of 
non-bound lipids in the vicinity of bound-GM1 was reduced, which was particularly strong 
at temperatures around the Tm. Attenuated total reflection Fourier transform infrared 
spectroscopy (ATR-FTIRS) also revealed that the reduction in diffusivity extended far 
beyond the GM1 lipids bound to CTB5. Close to the phase transition, bilayers exhibit a 
mixture of so and ld patches. As GM1 is known to partition into the so phase, it was thought 
that CTB5 binding retards the formation of the fluid phase by propagating the ordered 
phase. 
 
These examples demonstrate that binding events at the external membrane surface can 
influence the lateral distribution of glycolipids in the bilayer. The converse, the influence of 
lateral distribution of glycolipids upon binding, can also be a very strong effect. Therefore 
the development of a flexible model membrane system to study these complementary 
effects in tandem could provide an interesting insight into the behaviour of glycolipids in 
natural cell membranes. 
 
 
 
  
 
 
 
 
2 GLYCOLIPID SYNTHESIS 
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2. Glycolipid synthesis 
 
2.1 Lipid design 
 
In order to create artificial lipid rafts containing glycolipids and mimic the glycocalyx using 
phospholipid vesicles, a series of synthetic carbohydrate-capped lipids were designed. The 
lipid design encompassed three key features (Figure 2.1); a saccharide suitably linked to a 
lipid backbone composed of a perfluoroalkyl chain (to enable phase separation) and a 
pyrene group (to establish the degree of lipid clustering).
77
 The hydrophobic lipid anchor 
ensured that the lipid remained embedded in the membrane and would be sufficiently 
hydrophobic so as not to be removed from the membrane by lectin binding. The spacer 
region was envisaged to project the sugar away from the membrane surface. Short ethylene 
glycol chains could also be employed as a spacer to project the saccharide further away 
from the membrane into the aqueous exterior.  
 
 
 
Figure 2.1 Glycolipid design.  
 
The crucial component to enable phase separation is the perfluoroalkyl chain. 
Perfluoroalkanes are immiscible with water and many organic solvents. Replacing standard 
lipid alkyl chains with perfluorocarbon chains bestows the molecule with interesting 
properties, which exploit the limited fluorocarbon solubility in organic solvents.
78
 Due to 
their hydrophobicity, perfluoroalkyl lipids readily insert into phospholipid membranes, but 
are excluded from ordered regions of hydrocarbon lipids; the more rigid phase introduces 
more unfavourable hydrocarbon-fluorocarbon close contacts, which drives the exclusion of 
perfluoroalkyl lipids into phase separated domains. H. Ringsdorf and co-workers were the 
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first to characterise this phenomena using techniques such as DSC and freeze-fracture 
electron microscopy.
79, 80
 Phase separation of perfluoroalkyl lipids has been observed in 
both DMPC (ld) and DSPC (lo) membranes.
81
 Research in the Webb group revealed that, at 
membrane concentrations as low as 1% mol/mol, fluorinated lipids form phase separated 
patches in DSPC (so at 25 °C) and DMPC/cholesterol (lo), but not in DMPC alone (ld).
77
 
The domains formed in this way have been used by the group to create focal adhesion 
points on the surface of vesicles, so it was hoped that saccharide-capped perfluoroalkyl 
lipids would behave in a similar manner. Also, as demonstrated by Clary et al,
 
incorporation of fluorinated lipids into phospholipid vesicles can improve their stability and 
increase their shelf-life.
81
 
  
The other key component of the membrane anchor is the pyrene fluorescent reporter. 
Fluorophore-tagged lipids are extensively used to study the behaviour of biological and 
synthetic phospholipid membranes, yielding information on lipid mobility, phase 
behaviour, lateral diffusion, vesicle fusion events, membrane permeability and 
complexation to the membrane.
82
 Several factors influence the choice of fluorescent probe 
including sensitivity of the probe to pH, local concentration, solvent polarity and the 
presence of metal ions or quenching groups. The probe must also be stable in the required 
media; have appropriate hydrophobicity (essential for membrane-bound species) or 
hydrophilicity. The probe must also have a suitable wavelength of excitation/emission and 
be easy to detect. The probe also must not interfere with the function of the molecule it is 
attached to, i.e. the labelled species must retain its biospecificity in order to be an 
informative molecule. Finally, the ability of the fluorophore to partition into the lo or ld 
phases in ternary phospholipid mixtures is important and has been investigated by W. 
Webb and co-workers.
21
 Most of the fluorescent lipids they used were found to partition 
more favourably into the ld phase, but some polyaromatic fluorophores showed no 
preference or partitioned into the lo phase.  
 
Pyrene-tagged lipids have been widely used to measure various physical properties of the 
membrane, owing to their ability to form excimers.
82
 Excimers arise when a pyrene 
monomer in the excited state collides with a ground-state pyrene. The resultant excited 
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complex then fluoresces back to the ground state by emitting light at a longer wavelength 
than that of the pyrene monomer. As the rate of pyrene collision is dependent upon local 
concentration, excimer formation can be used to determine the degree of lipid clustering, 
which is usually expressed as the excimer to monomer ratio (E/M). Excimer emission by 
pyrene lipids also allows the direct visualisation of lipid clustering in vesicles using 
fluorescence microscopy;
52
 only excimer fluorescence is visible to the naked eye, monomer 
fluorescence is at too short a wavelength. 
 
2.2 Synthesis 
 
The synthesis of the proposed glycolipids was to be achieved in a convergent manner. First 
the lipid backbone was synthesised according to previously published protocols,
52, 77
 
followed by the attachment of a linker molecule to the protected sugar component. 
Coupling of the two components was then to be performed and the sugar protecting groups 
cleaved. Forming the lipid in this manner allowed the saccharide headgroup to be changed 
relatively easily. 
 
2.2.1 Lipid backbone 
 
The backbone was synthesised according to previous work in the group (Scheme 2.1). First 
pyrenemethanol 19 was converted into bromomethylpyrene 20 using phosphorus 
tribromide, confirmed by the change in the CH2 
13
C chemical shift from 63.7 ppm to 32.7 
ppm. This was then reacted with an excess of the hexadecafluorodecan-1,10 diol 21 to 
ensure attachment of pyrene at one end of the diol only. The reaction was confirmed by the 
presence of two extra CH2 groups in the NMR spectra. Interestingly the two CH2 adjacent 
to the fluorocarbon chain were split in both the 
1
H (
3
J(H,F) ≈ 14 Hz) and in the 13C (2J(C,F) 
≈ 25 Hz) spectra due to coupling to the fluorine atoms. The CF2 carbons were also very 
difficult to detect in 
13
C NMR spectra, only detectable at very high sample concentrations, 
due to their slow relaxation time in the 
13
C NMR sequence. The lipid 22 was then extended 
by reaction with bromoacetic acid to give the perfluoroalkyl-pyrene lipid anchor 23 in good 
yield.  
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Scheme 2.1 Formation of lipid anchor 23.  
 
2.2.2 Saccharide component 
 
The monosaccharides galactose (Gal), N-acetylglucosamine (GlcNAc), mannose (Man) and 
the disaccharide lactose (Gal-β(1,4)-Glc, Lac) were chosen for the headgroup. These sugars 
would permit binding studies with numerous lectins and are the targets for several enzymes. 
Biocompatibility of the linker was also taken into consideration; the linker must be an inert 
or non-inhibiting feature of the lipid. Many linkers exist that have found application in 
lectin binding studies, including aminoalkyl and ethylene glycol chains. Aminoethyl linkers 
in particular have found plenty of applications in carbohydrate research. They were 
employed in microarrays by Disney et al who observed bacterial interactions to arrays 
coated with several different carbohydrates.
83
 Blixt and co-workers also employed the 
linker to study Siglec and plant lectin binding to sialoside microarrays.
84
 In addition recent 
work in the Flitsch group has shown that enzymatic glycosylation of carbohydrate-labelled 
arrays can also be achieved using aminoethyl-linked sugars.
4
 The linker has also found use 
in soluble ligands, such as the fluorescently labelled saccharides developed by Sörme et al 
for targeted galectin binding,
85
 and the multivalent fluorescent probes designed by Lee et al 
that targeted ConA and Aleuria aurantia lectin binding.
86
 In each case biocompatibility was 
retained suggesting that the linker would be applicable for the study of lectin binding and 
the study of enzyme action on glycolipids embedded in phospholipid vesicles. 
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The synthesis of each protected aminoethyl linked sugar was achieved in as few steps as 
possible from commercial materials, however coupling the linker to the different sugars 
was found to require different protocols and a general method could not be found.  
 
 
Figure 2.2 Aminoethyl saccharide compounds formed for coupling to the lipid anchor 23. 
 
2.2.2.1 Galactose 
 
The most straightforward saccharide to append the aminoethyl linker to was galactose. 
Pentaacetyl galactose 30 was reacted with N-Z-ethanolamine in acetonitrile in the presence 
of a Lewis acid catalyst (boron trifluoride diethyletherate) to yield 31 (Scheme 3.2). Both 
axial (α) and equatorial (β) products were isolated with an anomeric ratio of 1:9 (α:β), 
which was determined by the ratio of the two anomeric peak integrals in the 
1
H and 
13
C 
NMR and the major isomer determined as β by the peak splitting in the 1H spectrum (3J 
(H,H) = 7.9 Hz). The equatorial product is favoured over the axial as the reaction occurs 
through an SN1 pathway, through using acetonitrile as the solvent and with neighbouring 
group participation of the 2-acetate. The 2-acetate or acetonitrile can attack the glycosyl 
cation intermediate, forming a cyclic oxonium or α-nitrillium ion respectively, which is 
then attacked by the ethanolamine hydroxyl. The carboxybenzyl protecting group was then 
cleaved using hydrogenolysis (monitored by TLC and electrospray MS) to yield 24.
87
 
Initially 10% Pd/C was used, but acetyl-transfer from one of the galactose hydroxyls to the 
free amine was thought to have occurred; the 
1
H NMR spectrum became very complex; a 
mixture of products had formed. A single peak was also observed in the mass spectrum. 
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This was overcome by using 10% Pd(OH)2/C, which did not appear to catalyse this 
transfer. In addition, acetyl transfer was observed when leaving the deprotected amine in 
CDCl3 in the NMR vial overnight, so deprotection was always performed immediately 
prior to coupling to the lipid anchor. 
 
 
Scheme 2.2 Formation of the aminoethyl galactose compound 24. 
 
Interestingly for compounds 31 and 24 the protons in the aminoethyl linker CH2 adjacent to 
the saccharide were diastereotopic, indicating slow or restricted rotation about the C-O 
bond. The CH2 were observed as doublet of doublet of doublets (ddd) in the 
1
H NMR 
spectra and the peaks for the two protons were separated by around 0.2 ppm. This was also 
observed for the rest of the aminoethyl-linked saccharides (25-27, 35, 41 and 44), 
aminoethyl-linked lipids (46-49 and 52-55), also for the CH2 adjacent to the sugar on the 
triethylene glycol-linked saccharides (28 and 29) and lipids (50, 51, 56 and 57). 
 
2.2.2.2 Mannose 
 
For the mannose headgroup, the axial (α) product was synthesised, as it is the anomer most 
abundant in nature and most often bound by lectins such as ConA.
1, 88
 To achieve a high 
yield and selectivity the anomeric hydroxyl was converted into a trichloroacetimidate 
leaving group. Trichloroacetimidates are extensively used in glycosylations and 
oligosaccharide formation as they can give exclusively the α or β product depending on the 
conditions used.
88
 Therefore pentaacetyl mannose was synthesised followed by cleavage of 
the anomeric acetate to give 33 and then formation of the trichloroacetimidate 34. The 
trichloroacetimidate was then reacted with N-Z-ethanolamine under Lewis acid conditions 
to yield the α-product 35 (H-1 3J (H,H) = 1.2 Hz), favoured because of neighbouring group 
participation. 35 was then hydrogenated in the presence palladium hydroxide on charcoal to 
give the aminoethyl-linked mannose compound 25. 
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Scheme 2.3 Formation of mannoside 25 by acetylation, basic hydrolysis of the anomeric 
acetate to give 33, formation of trichloroacetimidate 34, glycosylation of N-Z-ethanolamine 
and hydrogenation to give aminoethyl-linked mannoside 25. 
 
In addition to the aminoethyl spacer a longer triethylene glycol linked mannose was 
synthesised. Engel et al studied binding and aggregation with ConA using mannose with 
short length ethylene glycol spacers, observing optimal results with 3-6 ethylene glycol 
units.
89
 The longer spacer was also designed with multivalency in mind, as a longer and 
more flexible hydrophilic linker may be able to help two membrane-embedded lipids bridge 
the gap between ConA binding sites. Although the synthesis would be longer, it was 
believed that the extra synthetic effort would be rewarded with a stronger interaction with 
ConA in the vesicle binding studies. Firstly, the triethylene glycol spacer was 
desymmetrised by converting one end into an azido group (Scheme 2.4), via 
monotosylation to give 37,
90
 and displacement of the tosylate with azide to give 38.  
 
 
Scheme 2.4 Formation of the azido triethylene glycol spacer 38. 
 
The spacer 38 was then mannosylated using the trichloroacetimidate 34 under Lewis acid 
conditions, yielding compound 39 (Scheme 2.5). The azide group was then converted to the 
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amine using hydrogenation catalysed by palladium on charcoal to give the triethylene 
glycol linked mannose 28 ready for coupling to the lipid backbone 23.
 
 
 
Scheme 2.5 Formation of protected triethylene glycol mannoside 28.  
 
2.2.2.3 N-Acetylglucosamine 
 
Analagous to the investigations of galactoside 24 the glucosamine compound was 
synthesised directly from the peracetate, but using an alternative Lewis acid; no product 
formation was observed using boron trifluoride as the promoter. Glycosylation of N-Z-
ethanolamine was achieved by heating the mixture in the presence of tin tetrachloride 
(Scheme 2.6) giving the β-anomer 41 (H-1 3J (H,H) = 8.4 Hz). Although the yield was 
poor, enough material was synthesised and the route avoided the need for activation of the 
saccharide. The carboxybenzyl was then removed using hydrogenation to give 27. 
 
Scheme 2.6 Formation of aminoethyl GlcNAc compound 27. 
 
2.2.2.4 Lactose 
 
Several methods were used to synthesise the lactose derivative. Attempted syntheses 
straight from the peracetate using either BF3.Et2O or SnCl4 as catalysts were unsuccessful, 
giving mainly decomposition side-products (none identifiable as the product) and a little 
starting material. Therefore activation of the peracetate by conversion to the lactosyl 
bromide was pursued, allowing glycosylation catalysis by metal salts using the Koenigs-
Knorr method.
91
 Bromination of the peracetate 42 followed by recrystallisation yielded the 
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activated compound 43 in good yield as a white crystalline solid (Scheme 2.7). Using silver 
carbonate to activate 43 towards glycosidation gave numerous side-products so the more 
reactive mixture of Hg(CN)2/HgBr2 was used.
92
 This gave a reasonable yield of the product 
although the reaction was not very selective; an anomeric ratio of 1:1.7 α:β was observed. 
Nonetheless, the required β-anomer 44 (H-1 3J (H,H) = 8.0 Hz) was recovered easily using 
column chromatography and then deprotected using hydrogenation to give 26.  
 
 
Scheme 2.7 Formation of aminoethyl lactose compound 26. 
 
As for mannose, the triethylene glycol-linked lactoside was formed, again using the 
Hg(CN)2/HgBr2 catalytic mixture to give compound as the β-anomer 45 (H-1 
3
J (H,H) = 7.9 
Hz) after purification and 29 after deprotection (Scheme 2.8). 
 
 
Scheme 2.8 Formation of triethylene glycol lactoside compound 29. 
 
2.2.3 Coupling to lipid backbone 
 
Forming the amide linkage between the saccharide and lipid components was achieved 
using carbodiimide chemistry. The reaction involves forming an active ester from 23 with 
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N-hydroxysuccinimide (NHS) via a carbodiimide coupling, followed by addition of the 
amino sugar (24-29) in the same vessel. To avoid acetyl transfer, the CBz deprotection of 
the sugar unit was performed in parallel to the formation of the active ester of 23, thus 
minimising the length of time the free amine was left unprotected; after cleavage of the 
CBz group was complete the resulting amine was immediately added to the reaction vessel 
containing the activated NHS ester, whilst saving a portion of the amine for 
characterisation. The reaction was carried out using N,N'-diisopropylcarbodiimide (DIC) 
and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI), but N,N'-
dicyclohexylcarbodiimide (DCC) was found to give the best yields (Scheme 2.9).  
 
 
Scheme 2.9 Coupling of saccharide headgroups to lipid anchor 23 through carbodiimide 
coupling and deacetylation. Protected and deprotected lipids are given the trivial name PFE 
(pyrene-fluoro-ethyl) or PFTEG (pyrene-fluoro-triethylene glycol) – saccharide. 
 
The product lipids were isolated using two rounds of flash column chromatography; first 
with 5% methanol in CHCl3 on silica, which co-eluted the product and  reaction side 
product N,N'-dicyclohexylurea (DCU). This was followed by 3:2:1 ethyl 
acetate/CHCl3/cyclohexane on silica which removed the DCU, then a MeOH flush was 
used to retrieve the product. For each saccharide lipid a key diagnostic peak in the 
1
H NMR 
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spectra was the appearance of a triplet at around 6.8 ppm (
3
J (H,H) ≈ 5.6 Hz), 
corresponding to the amide NH. The anomeric configuration of each saccharide was 
conserved under the reaction conditions with consistent 
2
J and 
3
J-values throughout the 
synthesis. The CF2 carbons were again difficult to detect and were not observed in the 
13
C 
NMR spectra for compounds 46-57. The acetate protecting groups were then cleaved using 
Zemplén conditions (NaOMe/MeOH solution)
93
 to give the final lipids as white solids 
(aminoethyl linked lipids) or amorphous white solids (triethylene glycol linked lipids). 
 
Forming an acid chloride from the lipid anchor 23 was also attempted using oxalyl 
chloride, but the ether bonds on the lipid were cleaved (fragments were isolated and their 
identity confirmed by mass spec. and NMR). This was possibly due to the HCl side product 
reacting with the lipid, despite the presence of triethylamine in the mixture.  
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3.1 Lectins 
 
First discovered in plants over 100 years ago, lectins are carbohydrate-binding proteins 
present throughout natural systems that fulfil a variety of biological roles.
1
 Lectins can be 
either membrane-bound or soluble. Membrane-bound lectins are often associated with cell-
cell adhesion (selectins) and are confined to the cell in which they were synthesised, 
whereas soluble lectins are able to diffuse through tissues and enter the blood stream. 
Lectins interact with carbohydrate sequences on cell surfaces and on glycoproteins in 
various ways (Figure 3.1).
1
 Lectins exhibit high specificity for their target saccharides, 
which can be simple monosaccharides or more complex oligosaccharide sequences, 
depending upon their function.
35
 
 
In general, the binding sites, or carbohydrate recognition domains (CRDs), of lectins 
consist of shallow depressions on the protein surface.
1
 Binding is induced via hydrogen 
bonding to the carbohydrate hydroxyls, ionic interactions and hydrophobic or Van der 
Waals interactions between the sugar and amino acid residues on the lectin.
94
 As the cell is 
in an aqueous environment the saccharide hydroxyls must compete with water for the 
binding site, but the formation of multiple hydrogen bonds and hydrophobic interactions 
between the sugar and CRD can aid in this respect. As a result lectin-carbohydrate 
interactions are generally weak, with an association constant in the order of ~10
3
-10
5
 M
-1
. 
Divalent cations and water also help mediate interactions in the CRDs of most lectins and 
selectivity for specific carbohydrates is achieved by the configuration of hydrogen bonding 
and non-polar amino acid residues in the binding sites. In order to provide a biologically 
relevant function lectins are generally multivalent, or if monovalent are displayed in a 
multivalent configuration, for instance the adhesins on bacterial fimbriae.
95, 96
 The additive 
effect of several carbohydrate-lectin interactions has been shown to enhance the relatively 
weak individual interactions through the cluster glycoside effect.
33, 97
 Multivalency in 
soluble lectins is usually a product of the association of several distinct protein domains, for 
example at pH 7.4 ConA is a tetramer with each of the four domains capable of binding one 
carbohydrate. Lectins non-native to the human body are also commonly known as 
haemagglutinins, adhesins and toxins, because of the effects they exhibit on cells in vitro.
1
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Figure 3.1 Modes of cell-cell adhesion mediated by lectins.
1
 (a) Adhesion through 
membrane-bound lectins and complementary saccharides on an adjacent cell. (b) Adhesion 
through complementary saccharide-lectin interactions. (c) Glycoprotein binding through 
single and multivalent interactions. (d) Glycoprotein-mediated cell-cell adhesion. (e) 
Intracellular lectin binding. (f) Cell-cell adhesion through multivalent interactions with a 
soluble lectin. Multivalency through multiple binding contacts is often employed to 
increase the binding interaction strength. 
 
3.1.1 Animal lectins 
 
There are four main classes of animal lectins: P, I, S and C-type lectins.
1, 35
 P-type lectins 
are a class of animal lectins that specifically bind mannose residues that are phosphorylated 
at the 6-position (Man-6-P). They are involved in the trafficking of lysosomal enzymes, 
where membrane-bound P-lectins recognise the Man-6-P residue on the glycosylated 
enzyme. The enzyme is then taken from the Golgi to a forming lysosome via transport 
vesicles. I-type lectins are a family of lectins within the immunoglobulin superfamily 
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(IgSF). They can be sialic acid-binding (the Siglecs) or non-sialic acid-binding. The Siglecs 
are transmembrane proteins thought to be involved in many biological processes, including 
neurite growth regulation, immunoregulation and the cell adhesion of macrophages.
98
 S-
type lectins (the galectins) are a group of lectins that specifically bind terminal β–
galactosyl-containing glycoconjugates. They are soluble proteins that do not require Ca
2+
 in 
order to bind carbohydrates. Galectins, much like non-animal soluble lectins, agglutinate 
cells in vitro, suggesting that they are promoters of cell-cell, cell-ligand and ligand-ligand 
adhesion.
1, 99
 They are also involved in metabolic changes and the regulation of apoptosis. 
For example galectin-3 is an inhibitor of apoptosis and is upregulated in normal growing 
cells and lymphocytes infected with T-cell leukaemia virus.
100
 C-type lectins are so called 
because they require Ca
2+
 in order to bind carbohydrates.
1
 The family represents a large 
family of lectins that all share primary structural homology in their CRDs. However, 
carbohydrate selectivity between different C-type lectins can differ greatly. C-type lectins 
are involved mainly in immune system responses, such as inflammation or lymphocyte 
binding to foreign cells, tumors and virally infected cells. Cell adhesion lectins (selectins) 
also fall under this category of lectins. 
 
3.1.2 Plant lectins 
 
Plant lectins can be classified into three major types, Leguminosae (lectins from legumes 
such as ConA and soybean agglutinin), Gramineae (cereal lectins such as WGA) and 
Solanacae (from fruits and vegetables such as tomatoes and potatoes).
1
 Legume lectins are 
Ca
2+
 and Mn
2+
 dependent and can bind a variety of carbohydrates, whereas cereal lectins do 
not usually require divalent cations for binding and primarily recognize amino sugars.
1, 35
 
Isolation of lectins from seeds is usually straightforward and high yielding, for instance up 
to 15% of the total protein content of soybean seeds is the lectin soybean agglutinin.
1
 Most 
soluble lectins can be easily obtained by centrifugation of a saline preparation from the 
ground seed. Many plant lectins are toxic to animals but lectins in foods, such as beans, 
seeds, cereals and nuts, are usually denatured by cooking and proteolytic digestion. 
However some lectins, for instance ricin (Ricinus communis agglutinin), are among the 
most poisonous biomolecules on the planet. Toxic lectins are usually heterodimeric 
3. ConA Binding 
 
79 
 
proteins, with one protein domain(s) for carbohydrate recognition (B-chain) and another 
which possesses some enzymatic function (A-chain); the ricin A-chain acts to disable 
ribosome function.
101
 Lectin concentration appears to decrease with growth, suggesting 
they aid germination by providing a defence against predators.
1
 Various other possible 
natural functions of plant lectins have been proposed including protein storage and 
maintaining dormancy in seeds, transport of carbohydrates/glycoproteins, elongation of cell 
walls and pollen recognition.  
 
The majority of soluble plant lectins are multimeric with multiple domains presenting 
binding sites on opposite faces.
35
 As a result they are capable of agglutinating cells through 
the multivalent mechanism shown in Figure 3.1.f.
1
 In addition the structure and binding 
affinity of plant lectins has been extensively studied, as owing to their high aqueous 
solubility, they can be easily crystallized
 
and are readily extracted from solution.  
 
3.1.3 Plant lectins as research tools 
 
Because lectins are able to distinguish between specific carbohydrate moieties, they are 
extensively used in many fields of chemical, biological and medical research.
1
 Plant lectins 
are also relatively inexpensive in comparison to animal lectins due to their ease of 
purification and high availability. Lectins have been used in blood typing, as blood cells 
with only specific carbohydrate sequences will be bound and agglutinated by the lectin. For 
example the lectin Dolichos biflorus extracted from hyacinth beans can be used to identify 
cells that belong to the A1 blood group as it has a high specificity for GlcNAc.
102
 
Immobilized lectins with high specificity can also be used to identify carbohydrate groups 
on cell surfaces; Lectin affinity chromatography is a useful technique that involves using a 
variety of immobilized lectins to sort complex mixtures of oligosaccharides.
103
 The mixture 
of oligosaccharides is passed down a column of one type of lectin and the unbound 
saccharide solution is then collected. The bound carbohydrates can be released using a 
solution containing sugar molecules that bind stronger to the immobilized lectin.  
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3.1.4 Concanavalin A 
 
The most characterised lectin-carbohydrate interaction is that between concanavalin A 
(ConA) and mannose.
104, 105
 ConA was first crystallised by J. B. Sumner in 1919 and can be 
readily isolated in large quantities from the common Jack bean (Canavalia ensiformis).
106
 
As a result ConA is relatively inexpensive and can also be easily stored. At pH 7.4 ConA is 
a tetrahedrally shaped heavily-glycated homotetramer (each domain is 26.5 KDa with 235 
amino-acids) with four binding sites oriented at the corners of the tetrahedron (Figure 
3.2).
107
 These binding sites are separated by roughly 6.5 nm and exhibit high specificity for 
mannose (Ka = 8 × 10
3
 M
-1
)
105 
with a slightly weaker affinity for glucose and GlcNAc 
species (Ka ≈ 2 × 10
3
 M
-1 
and 1 × 10
3
 M
-1 
respectively)
105
 – these sugars only differ at the 2-
position. ConA is a C-type lectin which requires the divalent cations Mn
2+
 and Ca
2+
 to 
function and binding is mediated by hydrogen bonding to amino acids, water and metal 
cations. The residues Asn14, Leu99, Tyr100, Asp208 and Arg228 on the lectin are involved in 
binding the saccharide.
107
  
 
ConA is known to bind to and agglutinate several mammalian cell-types, including 
erythrocytes, myocytes (muscle cells) and lymphocytes.
1
 ConA can also induce secondary 
effects such as lymphocyte mitosis through inducing an increase in calcium 
concentration.
108
 In addition ConA and other lectins have been employed in cancer research 
as they can recognise the unusual saccharide patterns displayed by tumor cells,
108
 and have 
been shown in vivo to affect tumor cell survival by inhibiting adhesion and vascularisation, 
important processes for cancer metastasis. This was highlighted in a recent paper by H-Y 
Lei and co-workers who demonstrated that ConA can induce autophagy in cancerous 
murine liver cells.
109
 ConA was found to bind to the liver cells, then became internalised 
and localised into the mitochondria, inducing the autophagic pathway. 
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Figure 3.2 Crystal structure of concanavalin A in tetrameric form (a).
107
 The divalent 
cations Mn
2+
 (black) and Ca
2+
 (grey) and bound carbohydrate are shown. Tetrahedral 
arrangement of binding sites on ConA (b), with a separation of ~6.5 nm (65 Å). 
 
3.2 Concanavalin A binding to mannosylated lipids 
 
ConA was thought to be an ideal candidate for our studies on cluster glycoside effects at the 
membrane interface due to its multivalent nature and relatively weak affinity for mannose; 
weak binding interactions are known to be inherently sensitive to changes in local 
concentration induced by ligand clustering.
33
 Therefore it was reasoned that changes in the 
lateral distribution of mannose lipids in the membrane brought about by phase separation 
may influence the ConA-mannose binding event via multivalent binding or by offering a 
statistical glycocluster effect. As the binding sites of ConA are relatively shallow 
indentations on the protein surface, a very long linker between the lipid chain and mannose 
was thought to be unnecessary, so mannose lipids 49 and 51 were used. ConA is known not 
to bind galactose residues, so the Gal lipid 47 was used as a negative control. 
 
Changes in the lateral distribution of saccharide capped lipids as a consequence of lectin 
binding have been obseved. It was envisaged that the degree of mannose lipid clustering 
would also be influenced by ConA binding (Figure 3.3), manifested in either dispersion of 
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clustered lipids as observed by Sasaki and co-workers,
74
 or an increase in clustering as 
observed by Ohtoyo et al.
75
 For lipids 49 and 51 these changes would be accompanied by a 
decrease or increase in pyrene E/M ratio respectively. In addition, prorganisation of lipids 
in the membrane, regardless of clustering, may offer intramembrane binding, with any 
unfavourable entropic contributions compensated for by the flexible membrane structure. 
 
 
 
Figure 3.3 Prior to the introduction of ConA, mannose lipids may be clustered or dispersed 
(a), with a corresponding high or low E/M ratio respectively. Upon introduction of ConA 
the degree of phase separation may change; if ConA favours either monovalent (b) or 
multivalent (c) binding to the mannose lipids the equilibrium position between clustered 
and dispersed lipids may change, with a resultant fall or rise in pyrene E/M. 
 
3.3 ConA binding to mannosyl-lipids in solution phase 
 
To gain an indication of what the binding affinity of ConA for mannosyl-lipids 49 and 51 
would be when embedded in vesicle membranes, a fluorescence assay for measuring the 
affinity of ConA for 49 and 51 in aqueous buffered solution was developed. The measured 
affinity would provide a reference value to compare to analogous binding interactions at the 
bilayer interface. To this end the behaviour of 49 and 51 in aqueous buffer was assessed. 
 
3.3.1 Mannosyl-lipid behaviour in solution 
 
Due to their amphiphilic nature, both lipids 49 and 51 form aggregates in aqueous solution, 
as demonstrated by their high pyrene E/M values (E/M = 3.7 ± 0.6 and E/M = 65 ± 7 
respectively) at 2 μM. These high E/M values indicated a high collisional frequency at this 
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low concentration, most likely due to their self-assembly into higher structures, such as 
micellar or vesicular assemblies. It should also be noted that whilst there is a discrepancy in 
the E/M values of 49 and 51, it is difficult to directly compare high E/M values - as a result 
of very weak monomer emission – because E/M is sensitive to additional environmental 
factors, such as excited state lifetime and pyrene-pyrene collisional rate.
110
 However, in 
chloroform (at 2 μM) no excimer fluorescence was observed for these lipids, indicating 
they were fully solubilised. Therefore it could be inferred from the E/M ratios that self-
assembly of 49 and 51 did occur in aqueous environments.  
 
Dynamic light scattering (DLS) experiments were used to determine the size of the possibly 
self-assembled structures of 49 and 51. As light passes through a transparent medium it is 
scattered by particles or large molecules smaller than the wavelength of light. This 
principle, known as Rayleigh scattering, is used in DLS to measure the size of small 
suspended particles in the ~1-250 nm scale in solution.
111
 DLS spectrometers employ a 
laser which shines through a sample and detects the frequency of scattered light at a 90° 
angle to the incident. As the frequency of light scattered is dependent upon particle size, 
DLS can be used to measure the average size and distribution of the particles in solution.  
 
 
 
 
 
 
 
 
 
Figure 3.4 Typical DLS spectrometer setup. 
 
DLS of mannosyl-lipids 49 and 51 revealed lipid aggregates with average diameters of 67 ± 
15 nm and 63 ± 14 nm respectively. Given that the solutions were sonicated in order to 
solubilise the mannosyl-lipids it is possible that the lipids form small vesicles – 
Laser 
Detector 
Scattered light 
Focusing lens 
Sample 
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phospholipids are known to self-assemble to form SUVs of diameters around 50 nm after 
sonication in aqueous solution.
16
 
 
The critical aggregation concentrations (CACs) of 49 and 51 were measured by successive 
dilution of a stock solution and measuring the fluorescence spectrum after each dilution.
112
 
The concentration at which excimer fluorescence is no longer significant corresponds to the 
CAC value, i.e. where the frequency of pyrene-pyrene collisions is negligible. Plotting the 
E/M vs. concentration gave a distinct point where the CAC lies (Figure 3.5) and solving the 
linear fit equations gave CAC values of 18.5 and 158 nM for 49 and 51 respectively. The 
10-fold increase in CAC for 51 compared to 49 could be due to the increase in size of the 
hydrophilic portion in 51, which could improve water solubility. These CAC values are 
comparable to critical micelle concentrations of pyrene–lecithin lipids (CMC = 150 nM),112 
which were measured using the same method, suggesting both compounds should 
incorporate fully into phospholipid bilayers. 
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Figure 3.5 E/M of lipid 49 (a) and lipid 51 (b) vs log[lipid] for critical aggregation 
concentration (CAC) determination. The intercept of the linear fits corresponds to the CAC.  
 
3.3.2 Measuring mannosyl-lipid binding to ConA – fluorescence quenching 
 
The absorption of energy and the emission of light associated with luminescence 
(fluorescence and phosphorescence) is depicted in the Perrin-Jablonski diagram (Figure 
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3.6). Fluorescence arises when a molecule (usually a highly conjugated or aromatic 
compound) absorbs the energy from a photon, causing an electron to reach a singlet excited 
electronic state (the S2 state). Then non-radiative vibrational relaxation (VR) and internal 
conversion (IC) relax the electron to a lower excited state (S1). The electron then returns to 
the ground state (S0) releasing energy in the form of light. The light emitted is always of a 
higher wavelength (lower energy) than the light absorbed because of the energy lost 
through non-radiative means such as vibrations.  
 
 
 
Figure 3.6 The Perrin-Jablonski diagram.
82
 Phosphorescence occurs through non-radiative 
decay to the formally disallowed triplet T1 state, then radiative decay to the ground state S0. 
Fluorescence occurs through the S1 to S0 transition. 
 
After excitation from the ground state to an excited state, a fluorophore will fluoresce back 
to the ground state, emitting energy in the form of visible light. Fluorescence quenching of 
a fluorophore involves a non-radiative energy transfer from the excited state donor to an 
acceptor external molecule or ion, preventing the emission of light. The various modes of 
fluorescence quenching are outlined in Table 3.1.
82
 Note that excimer formation is also 
considered a mode of fluorescence quenching. 
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Photophysical process M* + Q → products Donor Acceptor 
Collision with a heavy atom (e.g. I-, Br in 
CBr4) or a paramagnetic species (e.g. O2, NO) 
M* + Q → M + Q + heat - - 
Electron transfer 1D* + A → D●+ + A●- 
1A* + D → A●- + D●+ 
1D* 
D 
A 
1A* 
Excimer formation 1M* + 1M → 1(MM)* 
  
Exciplex formation 1D* + A → 1(DA)* 
1A* + D → 1(DA)* 
1D* 
D 
A 
1A* 
Proton transfer AH* + B → A-* + BH+ 
B* + AH → BH+* + A- 
AH* 
AH 
B 
B* 
Energy transfer 
1
D* + 
1A → 1D + 1A* 
3D* + 1A → 1D + 3A* 
3D* + 3A → 1D + 3A* 
1M* + 1M → 1M + 1M* 
1
D* 
3D* 
3D* 
1M* 
1
A 
1A 
3A 
1M 
 
Table 3.1 Modes of fluorescence quenching.
82
 M denotes monomer, M* excited state 
monomer, D = donor, and A = acceptor species. The superscript number denotes the state 
level of the species, i.e. 1 = singlet, 3 = triplet state. 
 
Fluorescence quenching by these photophysical processes can occur via two modes, 
dynamic or static quenching, or a combination of both:
82
 
 
Dynamic quenching is a diffusion controlled, collisional quenching effect, which is 
therefore dependent upon quencher concentration. Dynamic quenching arises from the 
excited molecule being in close proximity to a quencher. Examples of dynamic quenching 
include the transfer mechanisms FRET and excimer formation, both processes that are 
distance dependent. The Stern-Volmer relationship is used to describe dynamic quenching 
(Equation 3.1). Therefore if quenching is purely dynamic, plotting experimental 
fluorescence quenching data (F0/F) vs. quencher concentration will give a linear plot, with 
a gradient equal to the quenching constant. 
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Equation 3.1 The Stern-Volmer relationship used to describe dynamic quenching. [Q] is 
the quencher concentration. F0 is the initial fluorescence, F the fluorescence at [Q] = x, Ksv 
the Stern-Volmer quenching constant in M
-1
. kq is the rate constant of quenching (in M
-1
s
-1
) 
and τ0 is the excited state lifetime of the fluorophore. 
 
As dynamic quenching is also dependent upon the excited state lifetime, fluorophores with 
long excited state lifetimes (such as pyrene, τ = 30-140 ns)113 are quenched more 
effectively by the dynamic mechanism than fluorophores with short excited state lifetimes 
(such as umbelliferone, 0.4 ns).
114
  
 
Static quenching is a mode of quenching that involves a sphere of effective quenching or  
formation of a ground state static complex (Figure 3.7).
82
 The Stern-Volmer relationship 
can also be applied in this case, plotting experimental F0/F vs. [Q] gives a linear plot with 
gradient equal to Kstat (static quenching constant). If quenching arises purely through the 
formation of a non-fluorescent complex, Kstat = Ka, the association constant.
82
  
 
 
 
Figure 3.7 Mechanisms of static quenching, through a sphere of effective quenching or the 
formation of a ground state static complex.
82
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Simultaneous dynamic and static quenching leads to a non-linear upward-curving Stern-
Volmer plot, i.e. F0/F is now dependent upon [Q]
2
 because the two individual quenching 
effects are both dependent upon [Q].
82
 Mixed static and dynamic quenching can occur in 
receptor-ligand binding where the fluorescent reporter has a long excited-state lifetime. In a 
case where static quenching is caused by the formation of a non-fluorescent complex, 
Equation 3.2 holds.  
 
  
 
                         
Or, 
  
 
                               
  
 
Equation 3.2 The Modified Stern-Volmer relationship for a combination of static and 
dynamic quenching.
82
 
 
Kdyn and Kstat can then be determined via curve fitting experimental F0/F data or by plotting 
(F0/F – 1)/[Q] vs. [Q], which should give a linear plot with a y-intercept of Kdyn + Kstat and 
a gradient of Kdyn × Kstat. Kdyn for a system can be determined via a non-binding analogue, 
which then allows deconvolution of Kstat. 
 
3.3.3 Measuring mannosyl-lipid binding to ConA in solution 
 
In order to determine the solution phase binding affinities, a competition assay using 4-
methyl umbelliferyl mannose (MUM, 58, Figure 3.8) was developed. MUM is a fluorescent 
probe that is known to be quenched upon binding by Con A,
115, 116
 and can be used to 
determine the affinity of competing ligands.
117
 Quenching of MUM proceeds via a purely 
static quenching mechanism, in that quenching of fluorescence is only observed when a 
distinct MUM-Con A complex has formed, therefore making the probe very useful in 
competition-style assays. MUM is excited at 315 nm and displays broad fluorescence at 
375 nm. 
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Figure 3.8 Fluorescent probe 4-methyl umbelliferyl mannose (MUM, 58). 
 
Firstly a titration with MUM in the absence of lipid 49 or 51 was performed: 15 × 10 μL 
titres of a MUM/ConA stock solution (1.57 mM ConA, 2 μM MUM, 20 mM MOPS, 100 
mM NaCl, pH 7.4) were titrated into a solution containing MUM (2 μM, 2 mL). This would 
ensure the concentration of MUM does not change, simplifying later calculations. Analysis 
of the fluorescence quenching (see Section 7.3.4 for full details) was achieved by the means 
of a Stern-Volmer plot (Figure 3.9).
82
 The association constant was determined as Ka = 3.37 
± 0.09 × 10
4
 M
-1
, a similar value as reported in the literature (4.3 × 10
4
 M
-1
 at pH 7.2).
115
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Figure 3.9 Stern-Volmer plot of MUM quenching by ConA. The gradient of the initial 
linear plot corresponds to the association constant.
82
 
 
Next the titration was performed in the presence of lipids 49 or 51 (20 μM). Although there 
was some overlap in the fluorescence spectra of MUM and the pyrene groups of 49 or 51, it 
was possible to deconvolute the MUM emission by subtraction of the monomer emission of 
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49 or 51, determined by calibration from the excimer emission band (see Section 7.3.4 for 
more details). Furthermore, as described in Section 3.3.1, in aqueous suspension the 
pyrene-lipids mainly exhibit excimer fluorescence with very little monomer present. The 
higher concentration of 49 or 51 was used since when the titration was performed with 
equal concentrations of MUM and 51, there was little diminution of the MUM quenching 
curve caused by 51, thus making an accurate derivation of Ka for 51 impossible.  
 
The reduction in MUM fluorescence quenching revealed valence corrected (per binding 
site) association constants of (5.4 ± 0.5) × 10
3
 M
-1
 and (6.9 ± 1.1) × 10
3
 M
-1
 for lipids 49 
and 51 respectively. Both are similar to Ka for methyl mannose (8 × 10
3
 M
-1
)
104, 105
 Con A 
binding and suggested that mannosyl-lipids 49 and 51 are suitable ligands for ConA. 
However the values are slightly diminished compared to methyl-mannose, perhaps due to 
having to remove or shuffle the mannosyl-lipid from higher order structures, as the 
concentration was above the CAC for lipids 49 and 51. The higher binding affinity 
observed for 51 could be due to the facilitation of tighter binding by the triethylene glycol 
spacer: The hydrophilic spacer was envisaged to project the mannose group further from 
the hydrophobic core of the self-assembled structures, allowing the ConA binding site 
easier access to the mannose group with less steric hindrance than the aminoethyl linked 
lipid 49. 
 
3.3.4 Measuring mannosyl-lipid binding to ConA in solution - isothermal titration 
calorimetry 
 
Isothermal titration calorimetry (ITC) is a method employed for the measurement of the 
thermodynamic processes associated with protein-ligand binding.
118
 ITC measures the heat 
released (exothermic) or taken in (endothermic) upon the introduction of a ligand to a 
protein solution in the calorimeter cell (Figure 3.10). The resulting difference in heat 
between the sample cell and the reference cell, which is kept at constant temperature, is 
used to estimate the thermodynamic parameters. ITC is the only technique that can be used 
to simultaneously determine the association constant (Ka), the number of binding sites per 
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protein macromolecule/stoichiometry (n) and the change in Gibbs free energy (ΔG), from a 
single experiment.
118
  
 
 
 
Figure 3.10 Simplified diagram of an isothermal titration microcalorimeter.
118
 Initially the 
two cells are heated to a specific temperature. Upon injection of the titrant the temperature 
in the sample cell will change, which is detected by the instrument. The difference in 
temperature of the sample cell to the reference cell corresponds to the heat of binding plus 
dilution. The sample cell is then heated to the initial temperature, ready for the next titre. 
 
A typical ITC experiment measures the change in enthalpy after each injection of the 
ligand, which is then plotted against the molar ratio of ligand to macromolecule ([LT]/[MT]) 
to give a typical ITC binding isotherm. The association constant in M
-1
 is determined by a 
non-linear fit of the binding isotherm, usually by a computer package such as Origin by 
performing multiple iterations. Using Equation 3.3, ΔG can be resolved.  
 
           
 
Equation 3.3 The change in Gibbs free energy. R is the gas constant and T is the absolute 
temperature. Ka is determined experimentally. 
 
As the enthalpy of the interaction has been measured by the calorimeter, the entropic 
contribution can also be determined by using Equation 3.4. 
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Equation 3.4 The Gibbs free energy equation. ΔG is determined from equation 3.3 and ΔH 
is determined experimentally. 
 
3.3.4.1 Experimental considerations 
 
ITC has been widely used to measure the binding affinities for lectin-carbohydrate 
interactions.
118
 As these interactions are generally weak, it is imperative that the 
concentrations of protein and ligand used are high enough to provide a detectable change in 
enthalpy, i.e. the binding isotherm must possess a perceptible curve. As a general guide, the 
relationship in Equation 3.5 is used: 
 
            
 
Equation 3.5 For an accurate determination of Ka experimentally, the theoretical 
association constant (Ka(t)) multiplied by the total macromolecule concentration ([MT]) must 
lie between 1 and 100 (B). 
 
Therefore for a lectin-carbohydrate system, with association constants typically 10
3
-10
4 
M
-
1
, the concentrations used typically lie in the millimolar range. Binding stoichiometry must 
also be considered, so it is often convenient to express protein concentrations in terms of 
binding sites and to ensure that a 1:1 ratio of ligand to binding sites is present at the central 
point of the experiment;
118
 in a simple n = 1 situation, the inflection point of the binding 
isotherm will occur when [LT]/[MT] = 1.  
 
3.3.4.2 ITC measured mannose-lipid – ConA binding 
 
In order to cross-reference the association constants obtained by the MUM fluorescence 
competition experiments with another analytical method, ITC was employed using a 
Microcal VP-ITC calorimeter with a cell volume of 1.4384 mL. 24 × 12 µL titres of a 2 
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mM solution of PFTEGMan 51 were injected into the cell containing 200 µM ConA at 25 
ºC with stirring. Lipid 51 was also injected into neat buffer to obtain heats of dilution, 
which were then subtracted from the titration with ConA. The resulting data were curve-
fitted with the Origin-ITC software package (version 5) using a single-site binding model. 
5% v/v DMSO was used in the buffer to aid the solvation of lipid 51; proteins are usually 
stable in low DMSO conditions. The isotherm and curve fit are shown in the Appendix. 
 
 
Analysis of the isotherm gave an approximate Ka of (9 ± 3) × 10
3
 M
-1
. However, low heat 
flows hindered accurate determination of the affinity. The solubility of 51 at millimolar 
concentrations was also a major issue, as even with the addition of DMSO to the buffer, a 
visible cloudiness of the titrant was observed, suggesting 51 was poorly solubilised under 
these concentrations. This could also explain the high entropic contribution to the binding 
energetics; the binding event could also include a large change in entropy due to the 
breakdown of higher aggregates. Nevertheless, the value obtained was again similar to that 
of methyl mannose (8 × 10
3
 M
-1
) and is further evidence of lipid-Con A binding. 
 
3.4 Vesicle-embedded mannosyl-lipids 
 
3.4.1 Mannosyl-lipid behaviour in phospholipid vesicles 
 
Before proceeding with ConA binding studies, it was important to first determine how the 
lipid would behave in the membrane of phospholipid vesicles. The CAC values suggested 
that the lipids would be readily incorporated into vesicle membranes.
112 
Indeed this was 
evident for both 49 and 51 as they were extruded into DMPC vesicles. Vesicles composed 
of DMPC were made via extrusion through an 800 nm polycarbonate membrane to give a 
vesicle composition of 20 mM total lipid, 200 µM lipid 49 or 51 (1% mol/mol) in buffer 
(20 mM MOPS, 100 mM NaCl, pH 7.4). DMPC at 25 ºC is in the ld phase, so lipids 49 and 
51 were not expected to cluster as phase separation of perfluoropyrene lipids only occurs in 
lo and so membranes.
77
 At 2 mM total lipid (20 µM 49 or 51), the vesicles displayed 
primarily monomer emission, with E/M ratios of 0.06 and 0.09 respectively. These E/M 
values are similar to those observed for related perfluoroalkyl pyrene lipids in ld phase 
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membranes.
77
 Comparing this to lipids 49 and 51 in solution phase at 20 µM (E/M = 3.7 
and 65 respectively), it suggests that the lipids were incorporated into the membrane and no 
phase separation was occurring.  
 
3.4.2 Degree of mannosyl-lipid incorporation into phospholipid vesicles 
 
In order to verify that 49 and 51 inserted into the membrane, gel permeation 
chromatography (GPC) methodology was used. PD-10 Sephadex GPC columns from GE 
Healthcare are often used to desalt/purify buffers containing macromolecular species such 
as proteins, as they are able to exclude inorganic salts and small molecules (up to Mr = 
5,000 gmol
-1); small molecules become trapped in the small „channels‟ in the gel while 
larger molecules cannot enter these „channels‟ and pass unhindered through the gel. As 
vesicles are very large compared to individual lipids, the methodology could be applied to 
test incorporation of fluorescent lipids in vesicles. Vesicle solutions containing 20 µM lipid 
49 or 51 at loadings of 1, 2 and 5% mol/mol in DMPC (achieved by altering the amount of 
DMPC) in buffer (20 mM MOPS, 100 mM NaCl, pH 7.4) were passed down a PD-10 
column and 10 × 1 mL fractions were collected using the same buffer. Fluorescence spectra 
of each fraction were taken and the intensity at 375 nm vs. volume eluted in mL was plotted 
to give an elution profile of each lipid (Figure 3.11). Aqueous suspensions of lipid 49 and 
51 at 20 µM were tested separately and shown to remain on the column; the columns 
retained bright pyrene fluorescence under irradiation by a UV lamp (see Appendix).  
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Figure 3.11 GPC elution profile of lipid 49 (a) and lipid 51 (b) in DMPC vesicles at 
membrane loadings of 1% (◌), 2% (●), and 5% mol/mol (■) and in buffer (□). 
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The fluorescence intensity of the vesicle solutions were measured before extrusion, after 
extrusion and after GPC treatment; comparison of the fluorescence intensity of the vesicles 
before extrusion to the fluorescence intensity of the vesicles after GPC treatment revealed 
an estimated lipid incorporation of > 99% for both lipids at 1% mol/mol loading. 
 
3.4.3 Rate of ‘flip-flop’ of mannosyl-lipids 
 
The rate of flip-flop, or transverse diffusion, of phospholipids is typically in the order of 
several hours.
119, 120
 Similar rates were expected for lipid 49 and 51 as they possess very 
hydrophilic saccharide caps, which would hinder the passage of the lipid through the 
hydrophobic membrane centre. It was important to determine these rates of flip-flop, as 
over a longer experiment it could affect the available concentration of lipids, with possible 
implications for understanding ConA binding. 
 
Lipid 49 or 51 in ethanol (40 μL, 1 mM) was added to vesicles composed of DMPC (2 mL, 
2 mM total lipid) in buffer (20 mM MOPS, 100 mM NaCl, pH 7.4) and fluorescence 
spectra measured at regular intervals over 20 hours. Immediately after addition (within 10 
minutes) the E/M ratios dropped from 3.7 to 0.11 for 49 and 65 to 0.071 for lipid 51 as the 
lipids inserted and dispersed in the fluid phase membrane. 
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Figure 3.12 Transverse diffusion of 49 (a) and 51 (b) in DMPC vesicles, showing the 
decline in E/M over several hours. 
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Initially the lipids were incorporated into the outer leaflet of the membrane, resulting in a 
lower E/M than in solution, as the excimer emission was diminished by lipid 49 or 51 
dispersing in the membrane. As flip-flop occured the distribution of lipid in the inner and 
outer leaflet reached equilibrium, resulting in a lower still E/M as the effective local 
concentration of lipid 49 or 51 in the membrane decreased to a final value. The half-life of 
this slow decline corresponds to the flip-flop rate, determined as approximately 3.5 hours 
for both lipids, by estimating the half-life time-point of the slow second phase. 
 
3.4.4 Effect of membrane composition on the formation of artificial mannosyl-lipid 
rafts 
 
One of the objectives of the project was to resolve the effect of lipid phase separation upon 
binding interactions. Therefore it was necessary to establish how phase separation could be 
driven in a way that was convenient and reliably achieved. By adding cholesterol to the 
membrane composition in different ratios it is possible to effect a transition from the ld to lo 
phase.
8
 As perfluoroalkyl pyrene lipids are known to phase separate in lo membranes, 
gradually increasing the amount of cholesterol in the membrane was envisaged to result in 
an increased E/M ratio through the emergence of the excimer fluorescence band at 460 nm 
due to lipid clustering.
77
 
 
800 nm vesicles composed of DMPC/cholesterol in ratios of 90/10, 80,20, 70/30, 60/40 and 
50/50, containing 1% mol/mol lipid 49 or 51 were synthesised via extrusion and incubated 
overnight at 25 ºC to reach the equilibrium E/M values. The fluorescence spectrum of each 
composition was then recorded and the E/M values determined (Figure 3.13). The E/M 
values are correlated with the known phase state of the DMPC/chol system.
8
 The sharpest 
increase in E/M was observed between 20 and 30% mol/mol cholesterol, where the phase 
state of the membrane changes from mixed ld and lo phases to a fully lo phase membrane 
(>27% mol/mol).
8
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Figure 3.13 Change in E/M with increasing cholesterol content of lipid 49 (○) and 51 (●) 
in DMPC vesicles at 1% mol/mol loading (2 mM total lipid). Phase state of the membrane 
is indicated according to Almeida et al.
8
 
 
As expected, lipid 49 and 51 exhibited raft formation in so phase membranes, evidenced by 
their E/M ratios of 0.51 and 0.74 respectively in DSPC vesicles at 1% mol/mol loading (so 
at 25 ºC).
5, 121
 
 
The increased propensity of the longer lipid 51 to phase separate is possibly due to an 
increase in hydrogen bonding potentiated by the triethylene glycol spacer. For lipid 49, the 
saccharide groups were expected to sit close to the membrane surface and possibly interact 
with the charged choline part of the lipids. The addition of the hydrophilic spacer probably 
projected the lipid further from the membrane surface, where it became free to form 
hydrogen bonds with its neighbours, further stabilising the phase separated patches. 
 
3.4.5 Binding of ConA to vesicle-embedded mannosyl-lipids 
 
In DMPC vesicles at loadings of 1% mol/mol, lipids 49 and 51 predominantly displayed 
monomer fluorescence emission (E/M 0.06 and 0.09 respectively), as the lipids were evenly 
distributed through the ld membrane. The monomer emission being at 379 nm meant that 
significant overlap of the MUM fluorescence (375 nm) would render that assay impractical, 
as any change in MUM fluorescence would be masked by pyrene emission. However, it 
was noted that during the solution phase ConA titrations, significant fluorescence 
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quenching of the pyrene was taking place. Quenching of fluorescence occurs through two 
mechanisms; dynamic (a proximity/collisional effect) and static (directly due to binding).
82
 
Therefore, provided that quenching of fluorescence was at least partly caused by the 
binding event (static quenching), an assay could be developed to measure the affinity for 49 
and 51.  
 
3.4.6 Dynamic quenching parameter 
 
In order to measure the dynamic quenching constant a titration was performed using the 
non-ConA binding lipid backbone 23, as any quenching would be purely dynamic. When 
ConA was titrated into DMPC vesicles containing 1% mol/mol 23 (200 µM total lipid, 2 
µM 23) significant quenching of both monomer and excimer fluorescence was observed. 
Fluorescence measurements were taken 60s after each titre, minimising the effect of 
membrane disruption by ConA.
74
 Stern-Volmer plots were used to determine the quenching 
constant and the slope of the plots were linear suggesting purely dynamic or static 
quenching.
82
 As the lipid backbone 23 possesses no binding saccharide, the quenching 
constant obtained from the slope of the linear fits must correspond to the dynamic 
quenching constant (Kdyn). Kdyn was determined using monomer emission, as excimer 
formation was minimal. Excimer quenching also depends on monomer quenching as well 
as direct quenching of the excimer, therefore monomer quenching was simpler to analyse. 
Repeated titrations with lipid backbone 23 and the non-ConA binding galactose-capped 
lipid 47 in DMPC and 50/50 mol/mol DMPC/cholesterol gave average Kdyn (Table 3.2). 
 
Lipid 
Vesicle 
composition 
Average Kdyn 
(× 103 M-1) 
Lipid anchor 7 DMPC 3.1 ± 0.1 
Lipid anchor 7 DMPC/chol 3.8 ± 0.4 
Gal-lipid 47 DMPC 3.8 ± 0.3 
Gal-lipid 47 DMPC/chol 3.1 ± 0.4 
 
Table 3.2 Average values of Kdyn obtained through fluorescence quenching of lipid anchor 
7 and Gal-lipid 47 by ConA. 
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The similarity of the values of Kdyn for 7 and 47 suggested that the overall structure of a 
non-binding pyrene-containing lipid had little effect upon dynamic quenching. Therefore it 
could be used to determine if a static quenching contribution (Kstat) to the overall quenching 
occurred when ConA was titrated into vesicles containing mannose-lipids 49 and 51. If 
upwards curvature on a Stern-Volmer plot at higher ConA concentrations was observed, 
this would indicate a co-dependence of fluorescence quenching upon Kdyn and Kstat 
(Equation 3.6 – modified from Equation 3.2).82 Furthermore, if quenching of 49 or 51 was 
greater than the dynamic quenching observed for lipid anchor 23 and the Gal-lipid 47, the 
difference must correspond to the static quenching constant, as the two effects are additive 
at low concentrations of ConA (Equation 3.7), 
 
  
 
                                         
  
 
Equation 3.6 The co-dependence of fluorescence quenching by ConA upon Kdyn and Kstat.
82
 
 
As [ConA] → 0, the equation can be approximated as: 
 
  
 
                      
 
Equation 3.7 Simplified version of Equation 3.6 at low ConA concentrations.
82
 As Kdyn has 
been determined, Kstat can be determined from the initial slope of the Stern-Volmer plot.  
 
3.4.7 Static quenching of mannosyl-lipids in DMPC vesicles 
 
At 25 ºC, DMPC membranes are in the ld state, therefore do not cause the phase separation 
of lipids 49 and 51, as shown by their E/M ratios (0.06 and 0.09 respectively). Fluorescence 
quenching experiments were carried out on lipid 49 and 51 in order to determine the 
affinity of ConA for lipids dispersed evenly in the membrane. DMPC vesicles containing 
1% mol/mol lipid 49 or 51 were synthesised and diluted to 2 mM total lipid (2 mL, 20 μM 
49 or 51). Then using a constant analyte concentration method, 20 × 10 μL titres of ConA 
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solution (62.4 mg/mL = 2.4 mM (binding sites), 2 mM vesicles) were added and the 
fluorescence spectra recorded after each titre. Monomer fluorescence quenching was then 
analysed using a Stern-Volmer plot which, interestingly for both lipid 49 and 51, yielded a 
plot that sloped upwards towards the latter titres (see examples in Figure 3.14) - suggesting 
contributions from both static and dynamic quenching of the monomer fluorescence.
82
 The 
titration was repeated three times and the linear fit of the initial slopes gave a Ktotal of (5.4 ± 
0.2) × 10
3
 M
-1
 for lipid 49 and (5.1 ± 0.3) × 10
3
 M
-1
 for lipid 51. Subtraction of the 
monomer Kdyn for the lipid 23 ((3.1 ± 0.1) × 10
3
 M
-1
) yielded Kstat values of (2.3 ± 0.3) × 
10
3
 M
-1
 for lipid 49 and (2.0 ± 0.4) × 10
3
 M
-1
 for lipid 51.  
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Figure 3.14 Stern-Volmer plot of monomer quenching of lipid 49 (a, ●) and 51 (b, ●) in 
DMPC vesicles at 1% mol/mol loading. The open circles (○) represent dynamic quenching, 
calculated from lipid backbone 23. 
 
These values of Kstat are around 3-fold lower than the values obtained for the affinities of 
lipids 49 and 51 in solution, possibly due to some steric blocking by the membrane surface. 
Steric blocking and other effects of the membrane on protein binding have been 
demonstrated by various groups, including that of P. Cremer.
122
 Their system used lipids 
labelled with biotin and 2,4-dinitrophenyl (DNP), measuring the affinity of these lipids for 
anti-biotin anti-DNP respectively in solution and comparing them to their affinities when 
incorporated in glass-supported membranes. They found that binding to membrane-bound 
ligands was strongly inhibited by incorporation of the ligands into a membrane. For 
example, the dissociation constants for the DNP/anti-DNP system were increased by almost 
1000-fold when incorporated in a membrane vs. in solution, indicating weaker binding. 
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3.4.8 Static quenching at increased membrane loadings 
  
Although the values of affinities of ConA for lipids 49 and 51 were significantly reduced 
when incorporated into DMPC vesicles, it was hoped an increase in the amount of surface 
mannose lipid loading may result in an increased affinity due to multivalent chelation. This 
would be expressed by a larger value of Kstat in the Stern-Volmer relationship (Equation 
3.6). As static quenching encompasses monovalent, multivalent intermembrane and 
multivalent intramembrane binding modes, the elucidation of the contribution of each of 
these binding modes will be difficult but may be possible using the model relationship in 
Equation 3.9. This was derived from a model of inter vs. intra binding modes of membrane-
bound receptors in the Webb lab (Equation 3.8). After the initial binding event K1, 
subsequent binding events may be inter (K
inter
) or intramembrane (κ). As shown previously, 
κ is dependent upon the membrane loading (χ) – Figure 1.21.53 
 
  
      
          
 
Equation 3.8 Model equation demonstrating that observed binding events for multivalent 
species may be a combination of inter and intramembrane binding modes.
53
 
 
By extension to four binding sites the overall observed affinity (or in the case for quenching 
of pyrene-labelled glycolipids by ConA, Kstat) is equal to equation 3.9: 
 
            
             
             
          
 
 
 
Equation 3.9 The effect of multivalent binding on Kstat. K1 is the static quenching constant 
due to the initial binding event. An enhancement of the overall static quenching (Kstat) 
could arise through binding of one of the other three binding sites (denoted 2, 3 and 4), via 
the intramembrane binding mode (κ – dependent upon χ, the membrane loading). 
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Therefore increasing the membrane loading χ would reveal an intramembrane binding 
mode through an increase in observed affinity (Kstat). If no intramembrane binding is 
present, i.e. if κn was small, no enhancement of Kstat with increased χ would be observed. 
Increasing the membrane loading (χ) of lipids 49 and 51 from 1 to 2 and 5% mol/mol was 
achieved by reducing the amount of DMPC when synthesising vesicles. This would ensure 
that the concentration of lipid 49 or 51 would remain constant, allowing a direct 
comparison with 1% mol/mol loadings. Vesicles composed of DMPC containing 2 or 5% 
mol/mol lipid 49 or 51 were diluted (2 mL, 20 µM 49 or 51) and the fluorescence spectra 
measured. As before, 20 × 10 μL titres of ConA solution (62.4 mg/mL, 2.4 mM (binding 
sites), 20 µM 49 or 51 in vesicles) were then titrated into the vesicle solution (2 mL) and 
the fluorescence spectra taken 60 s after each titre. Stern-Volmer analysis was then 
performed upon the fluorescence data followed by subtraction of Kdyn, which yielded the 
results in Table 3.3. 
 
lipid loading 
(% mol/mol) 
Kstat 49 
(× 103 M-1) 
E/M 49 
Kstat 51 
(× 103 M-1) 
E/M 51 
1 2.3 ± 0.3 0.06 2.0 ± 0.4 0.079 
2 2.6 ± 0.2 0.12 2.8 ± 0.2 0.15 
5 3.0 ± 0.3 0.24 3.5 ± 0.3 0.58 
Increase (from 
1% to 5%) 23%  75%  
 
Table 3.3 Kstat with increased amounts of lipid 49 or 51 in DMPC membranes. The % 
increase in Kstat from 1 to 5% mol/mol loading and E/M ratios are also shown. 
 
The increase in Kstat with increasing membrane loading (χ) suggested that some 
intramembrane binding by ConA was occurring and chelation of ConA could arise via an 
intramembrane mode. Furthermore, the results demonstrated that, as predicted, the longer 
triethylene glycol linker of lipid 51 was more capable of facilitating this binding mode.  
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Figure 3.15 Plot of Kstat vs. membrane loading for 49 (■) and 51 (●) (a). Kstat vs. E/M for 
vesicles composed of DMPC with 1, 2 or 5% mol/mol loading 49 or 51 (b). 
 
Figure 3.15 demonstrates the larger increase in Kstat with the longer lipid 51. Correlating the 
E/M ratio of the two vesicle systems with the observed Kstat seemed to indicate that the 
higher the E/M ratio the higher the Kstat value. In other words, lipid clustering could explain 
the increase in the strength of the observed binding interaction. 
 
Increased excimer formation of 49 and 51 at 2 and 5 mol% loadings also indicated 
increased pyrene collisional frequency, possibly due to some transient clustering even in 
the absence of a lo or so phase. In addition to quenching of monomer fluorescence, 
quenching of this excimer fluorescence was observed. However, the decrease in emission at 
460 nm is not solely dependent upon the quenching of excimer, but also on the 
concentration of non-quenched excited state monomers. Therefore it was impractical to 
infer binding data from quenching of excimer fluorescence. In addition, the quenching of 
excimer and monomer caused a decrease in the E/M ratio, meaning that it was not possible 
to infer immediate changes in E/M caused by the ConA binding event alone.  
 
Even though the affinities appeared to be greater at larger loadings, the contribution of the 
intramembrane binding mode (κ) to monomer quenching was much lower than might be 
expected for a multivalent chelating system.
33,
 
97
 The largest increase was observed for lipid 
51 with only a 75 % increase in Kstat for a 5-fold increase in membrane loading. 
Nonetheless, it was hoped that inducing phase separation in the membrane may also offer 
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an enhancement of Kstat; restricting the lateral movement of lipids 49 or 51 by confining 
them in these domains may stabilise an intramembrane binding mode. 
 
3.4.9 Binding of ConA to mannosyl-lipids in cholesterol containing vesicles 
 
Cholesterol changes the structure of phospholipid membranes by interacting favourably 
with the hydrophilic and hydrophobic regions.
5
 In membranes composed of lipids which 
produce bilayers in the ld phase, the presence of cholesterol reduces the membrane fluidity 
and induces the lo phase.
8
 This behaviour is observed in DMPC/cholesterol mixtures in 
which perfluoroalkyl pyrene lipids are known to phase separate.
77
 It was envisaged that 
phase separated patches could display glycocluster effects by providing domains rich in 
binding headgroups. These patches may enhance binding strength in a manner analogous to 
the glycocluster effects seen with glycodendrimers,
33
 and manifest itself in an increased 
Kstat due to statistical rebinding. To investigate this, vesicles composed of a range of 
DMPC/cholesterol ratios containing 1% mol/mol 51 were synthesised – lipid 51 was 
chosen as it gave the greatest increase in Kstat as lipid loading increased. A gradual increase 
of cholesterol allowed the correlation of binding affinity with membrane phase and 
subsequent mannose lipid phase separation. Later lipid 49 in 50/50 DMPC/cholesterol was 
also tested. 
 
800 nm vesicles composed of DMPC/cholesterol ratios of 90/10, 80/20, 70/30, 60/40 and 
50/50 and containing 1% mol/mol lipid 51 were synthesised via extrusion and incubated 
overnight at 25 ºC to reach the equilibrium E/M values (Figure 3.13). The fluorescence 
spectrum of each composition was then recorded at 2 mM total lipid, 20 μM lipid 51. Using 
the same constant analyte method as employed previously, 20 × 10 μL titres of ConA 
solution (62.4 mg/mL, 2.4 mM (binding sites), 2 mM vesicles containing 20 µM 51) were 
then titrated into the vesicle solution and the fluorescence spectra taken 60 s after each titre. 
Stern-Volmer analysis was then performed on each experiment and Kdyn subtracted from 
the initial slope to give Kstat (Figure 3.16). 
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Cholesterol 
 (% mol/mol) 
Kstat  
(× 103 M-1) 
E/M 
 
0 2.0 ± 0.4 0.079 
10 2.4 ± 0.6 0.11 
20 3.2 ± 0.4 0.20 
30 2.8 ± 0.3 0.96 
40 2.3 ± 0.3 1.51 
50 2.7 ± 0.4 1.66 
 
 
Figure 3.16 Tabulated (a) and plotted (b) values of Kstat obtained for lipid 51 quenching. 
 
The absence of a large increase in Kstat with vesicles composed of 40 and 50% mol/mol 
cholesterol indicated that formation of highly concentrated lipids in phase separated 
domains did not offer a significant enhancement of ConA affinity through a glycocluster 
effect. However, it was noted that Kstat increased up to the onset of the lo phase. At around 
10% mol/mol cholesterol, islands of the lo phase exist in the ld matrix and as the mole 
fraction of cholesterol increases the size of the lo phase „islands‟ increase until the 
membrane is fully in the lo phase.
8, 123
 At these intermediate levels of cholesterol, the 
membrane may possess enough structure to drive phase separation but retain enough 
fluidity to permit binding via an intramembrane binding mode; a 62% increase in Kstat was 
observed at 20% mol/mol cholesterol compared to DMPC alone. 
 
Quenching of 49 and 51 in so phase DSPC vesicles was also measured and was comparable 
to that of 50:50 DMPC/chol, consistent with the above explanation. Table 3.4 contains a 
summary of all the Kstat values obtained. 
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   Lipid 49  Lipid 51  
Lipid Composition Lipid Phase 
Kstat  
(103 M-1) E/M Ratio 
Kstat  
(103 M-1) E/M Ratio 
In Solution n/a 5.4 ± 0.5* 3.7 6.9 ± 1.1* 65 
DMPC ld 2.3 ± 0.3 0.06 2.0 ± 0.4 0.079 
DMPC (2% mol/mol) ld 2.6 ± 0.2 0.12 2.8 ± 0.2 0.15 
DMPC (5% mol/mol) ld 3.0 ± 0.3 0.24 3.5 ± 0.3 0.58 
90/10 DMPC/chol ld + lo - 0.11 2.4 ± 0.6 0.11 
80/20 DMPC/chol ld + lo - 0.23 3.2 ± 0.4 0.20 
70/30 DMPC/chol lo - 0.42 2.8 ± 0.3 0.96 
60/40 DMPC/chol lo - 0.57 2.3 ± 0.3 1.51 
50/50 DMPC/chol lo 2.4 ± 0.1 0.65 2.7 ± 0.4 1.66 
DSPC so 2.6 ± 0.3 0.51 2.3 ± 0.2 0.74 
 
Table 3.4 Full Kstat and E/M data obtained from ConA binding studies. * Value of K from 
MUM competition experiments. Dashes indicate that the experiment was not performed. 
 
3.5 Aggregation of vesicles doped with mannosyl-lipids 
 
During the titrations it was noticed that for every lipid mixture considerable aggregation 
had occurred, with large flocculent aggregates clearly visible by the naked eye. With 
hindsight this is unsurprising, as ConA is well-known to cause agglutination of human 
cells, indeed the primary function of legume lectins is thought to be an antifeedant defence 
mechanism.
1
 However the formation of intermembrane links is a competing binding mode 
to intramembrane binding (Equation 3.8), and may have inhibited the intramembrane 
binding mode. In order to further investigate this intervesicle binding mode, UV-vis 
turbidity and fluorescence microscopy were employed. 
 
 
3.5.1 Turbidimetric assay of mannosyl-lipids in vesicles 
 
The turbidity of a solution is its „cloudiness‟ and changes in turbidity can be used to 
elucidate macromolecular changes in size in solution.
124
 The formation of vesicle 
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aggregates can cause increases in solution turbidity and can be measured using UV-vis 
spectroscopy as an increase in UV-vis absorbance at 700 nm, corresponding to an increase 
in light scattering caused by the formation of large vesicle aggregates. The data acquired 
can also be used to estimate binding affinity; plotting the change in turbidity (ΔAbs) vs. the 
log concentration of protein (log[ConA binding sites]) should yield an s-shaped curve and 
the inflection point corresponds to the effective concentration at which 50% aggregation 
occurs (EC50). Changes in turbidity can be used to give an estimation of Kd.
125, 126
 
 
Vesicles composed of 50/50 mol/mol DMPC/cholesterol doped with 1% mol/mol lipid 49 
or 51 were synthesised and diluted to 2 mM total lipid (2 mL). Using a constant analyte 
method, 10 μL titres of a concanavalin A solution (40.8 mg/mL, 1.57 mM FITC labelled-
Con A, 2 mM vesicles) were added and the absorption spectrum recorded 60s after each 
addition. FITC-Con A was used to visualise the aggregates post-titration using fluorescence 
microscopy. The absorption at 700 nm was used as the UV-vis indicator of turbidity. The 
change in absorbance at 700 nm (ΔAbs) was plotted vs. log[ConA binding sites] (Figure 
3.17). 
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Figure 3.17 Change in turbidity with increasing ConA concentration of 50/50 mol/mol 
DMPC/cholesterol vesicles doped with 1% mol/mol lipid 49 (a) or 51 (b). 
 
 
The EC50 values were approximately 80 μM and 40 μM for lipid 49 and 51 respectively. 
Again this demonstrated that lipid 51 was more capable of forming links with ConA, 
perhaps facilitated by its longer spacer presenting the saccharide further from the bilayer 
surface. These results are lower than the Kd for methyl mannose (125 μM), but should not 
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be taken for evidence of a higher binding affinity, as only a single lectin is required to 
crosslink two vesicles loaded with many mannosyl lipids, i.e. turbidity is not directly 
proportional to the extent of binding. Turbidity may also decrease at high [ConA] as the 
aggregates break down. Furthermore, changes in turbidity are not solely dependent upon 
aggregation; changes in refractive index can also cause changes in absorbance at 700 nm.
124
  
 
3.5.2 UV-vis turbidity timescale experiment 
 
To further characterise the vesicle aggregates formed with ConA binding and to reveal the 
time-dependence of this process, the turbidity after ConA addition was monitored over 
time. ConA (4 binding site equivalents, i.e. a 1:1 protein/mannosyl-lipid ratio) was added to 
DMPC vesicles doped with 1% mol/mol lipid 51 (2 mM total lipid) and the absorption at 
700 nm was recorded at regular intervals over 20 hours. Spectroscopic analysis suggested 
extensive aggregation occurred immediately after ConA addition (Figure 3.18, a).  
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Figure 3.18 Change in turbidity with time after addition of 4 binding site equivalents ConA 
to DMPC vesicles doped with 1% mol/mol 51. Aggregates increase in size (a) reaching a 
maximum size beyond which they are no longer suspended in solution (b). 
 
However, after several hours the vesicles had formed such large aggregates that they 
dropped out of solution, sticking to the sides of the cuvette and settling on the bottom, 
despite stirring. The plot of turbidity vs. time (Figure 3.18) appeared to show that the 
aggregation of vesicles increases slowly over time, reaching a maximum size after 5 hours, 
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and then becoming so large that they settle regardless of stirring (Figure 3.18, b). This then 
reduces the local concentration at the position in the cuvette where the instrument measures 
the absorbance, producing an apparent decline in turbidity. 
 
3.5.3 Fluorescence microscopy 
 
Fluorescence microscopy can be used to directly visualise and measure the size of vesicle 
aggregates.
52, 53
 Vesicles containing 1% mol/mol lipid 49 or 51 were synthesised, diluted to 
2 mM total lipid and pictures were taken through the microscope (at 100× zoom). Through 
the microscope, vesicles doped with lipid 49 or 51 appeared as little dark blue or light blue 
dots when viewed through the zoom lens: In lipid compositions where phase separation 
occurs, the vesicles appeared light blue due to stronger excimer formation (the emission is 
visible to the naked eye). In lipid compositions where no phase separation occurs (e.g. 
DMPC) the vesicles appeared dark blue and appeared dull as the wavelength of monomer 
fluorescence emission is on the edge of the visible spectrum.  
 
Prior to the addition of ConA, the vesicles were dispersed through the sample and no 
aggregates were present. After the addition of 4 binding site equivalents of FITC-ConA 
(Figure 3.19), the vesicles exhibited clear aggregation and the coexistence of pyrene and 
FITC fluorescence in these aggregates indicated that ConA was essential for this vesicle 
agglutination. In addition, aggregation occurred in both DMPC vesicles and 
DMPC/cholesterol vesicles, suggesting that domain formation is not important when it 
comes to agglutination of vesicles decorated with mannose on the surface. These 
observations further corroborated that with ConA, binding in an intervesicular mode was 
favoured over intravesicular binding. 
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Figure 3.19 Aggregation of FITC-labelled ConA through binding to 50/50 mol/mol 
DMPC/cholesterol vesicles doped with 1% mol/mol lipid 49 (a) and lipid 51 (b). 
 
3.6 Reorganisation of mannosyl-lipids with ConA 
 
The pyrene reporter group on the mannosy-lipids 49 and 51 gives insight the distribution of 
pyrene lipids in the membrane through changes in the fluorescence excimer to monomer 
ratio (E/M). Provided that the quenching of pyrene-lipids by ConA is instantaneous, 
subsequent slower changes in the E/M ratio could indicate changes in the lateral 
distribution of mannosyl-lipids. Therefore, clustering of pyrene-labelled lipids driven by an 
extravesicular ConA binding event would be expressed in an increase in the E/M ratio, and 
the converse, if extravesicular binding events caused dispersal of pyrene lipids the E/M 
ratio should drop, as the lipids are driven apart.  
 
3.6.1 Fluorescence timescale experiment 
 
ConA (4 binding site equivalents) was added to DMPC vesicles doped with 1% mol/mol 
mannosyl-lipid 51 (2 mM total lipid) and fluorescence spectra were recorded every minute 
for 10 minutes, then every 10 minutes for 2 hours, then every hour until 20 hours had 
passed. Initially after ConA addition the fluorescence dropped considerably due to 
fluorescence quenching. It was observed that monomer fluorescence was quenched slightly 
more effectively than excimer fluorescence, raising the E/M ratio slightly (0.078 to 0.093). 
Excimer and monomer fluorescence remained constant over the first 20 minutes (Figure 
3.20a), then both gradually dropped over time, appearing to reach a minimum after several 
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hours (Figure 3.20b). However, little change in the E/M ratio was observed, suggesting no 
significant rearrangement had taken place (Figure 3.20c).  
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Figure 3.20 Change in fluorescence (● = monomer fluorescence, ◌ = excimer 
fluorescence) over time after addition of 4 binding site equivalents of ConA to DMPC 
vesicles containing 1% mol/mol 51 (a, b).  Change in E/M with time (c). The drop in 
fluorescence intensity observed over the first 2 hours may be due to vesicle settling. 
 
Upon inspection of the fluorescence cuvette after the final time point, it was noted that 
substantial aggregation had taken place and these large aggregates had either adhered to the 
side of the cuvette or flocculated in the sample solution despite rapid stirring. The absence 
of a change in E/M despite the substantial changes in vesicle aggregate size suggested that 
intervesicular binding modes were dominant and that intervesicular binding did not lead to 
significant reorganisation of lipids in the membrane. Any changes in lipid distribution 
therefore cannot be ruled out, but appear to be too small to be confirmed. 
 
3.7 Conclusions 
 
The binding of the tetrameric soluble form of ConA to mannosyl-lipids 49 and 51 was 
studied in detail, both when the lipids were suspended in solution and incorporated into 
phospholipid vesicles. In buffered aqueous solution, mannosyl-lipids 49 and 51 self-
assembled into higher structures, indicated by high E/M ratios, similar CAC values to 
pyrene-lecithin lipids and the detection of objects with average diameters of around 60 nm 
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by DLS measurements. Both lipids were bound by ConA in aqueous suspension with 
binding constants of (5.4 ± 0.5) × 10
3
 M
-1
 and (6.9 ± 1.1) × 10
3
 M
-1
 for lipids 49 and 51 
respectively, which were determined using a competitive fluorescence quenching assay. 
ITC gave a less accurate binding affinity of (9 ± 3) × 10
3
 M
-1 
for 51, possibly due to weak 
binding and low heat flows. 
 
Mannosyl-lipids 49 and 51 incorporated into fluid-phase DMPC vesicles at 1% mol/mol 
were dispersed in this lipid matrix, giving low E/M ratios (0.06 and 0.079 respectively). 
The addition of ConA quenched the pyrene fluorescence in both a static and dynamic 
manner. A novel fluorescence quenching assay was developed to measure the static 
contribution (caused by the binding event) to the overall quenching, using a non-binding 
analogue to determine the dynamic contribution. Both lipids bound ConA weaker than 
when suspended in solution (K ≈ 2200 M-1), suggesting steric repulsion due to the 
membrane surface (Figure 3.21.i). Increasing the membrane loading to 2 and 5% mol/mol, 
by reducing the amount of phospholipid gave a slight increase in affinity with Kstat = (3.0 ± 
0.3) × 10
3
 M
-1
 and  (3.5 ± 0.3) × 10
3
 M
-1
 for lipids 49 and 51 respectively, suggesting some 
intravesicle chelation or statistical rebinding (Figure 3.21.a.iii). The larger increase in Kstat 
with a 5-fold increase in mannosyl-lipid 51 loading also suggested that the lipid with the 
flexible triethylene glycol spacer could better facilitate the intravesicle binding mode.  
 
As expected the addition of cholesterol to the lipid matrix drove clustering of the mannosyl-
lipids, giving E/M ratios up to 0.65 for lipid 49 and 1.66 for lipid 51 in 50/50 
DMPC/cholesterol. Only very small increases in affinity were observed with both lipids at 
this level of cholesterol. This implies that the extensively clustered mannosyl-lipids may 
not be able to offer multivalent chelation or a significant statistical rebinding effect (Figure 
3.21.b.iii). However, a considerable increase in Kstat was observed at 20% mol/mol 
cholesterol for lipid 51, suggesting intravesicular chelation may be possible at intermediate 
cholesterol levels.  
 
These modest increases in affinity compare poorly to other multivalent systems in the 
literature, where ConA is known to offer much greater increases in affinity due to both 
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chelation and statistical effects.
27, 33, 97
 Furthermore, monitoring the vesicular solution 
turbidity and fluorescence microscopy revealed extensive aggregation of vesicles of all 
compositions facilitated by ConA (Figure 3.21.ii). Given the absence of any large increases 
in affinity due to chelation or statistical effects, this suggests that the intervesicular binding 
mode is favoured over the intravesicular binding mode.  
 
 
 
Figure 3.21 Binding of ConA to mannosyl-lipids 49 and 51 in dispersed (a) and clustered 
(b) systems was inhibited by the membrane surface (i). Binding of ConA to dispersed lipids 
in the fluid-phase or heavily clustered in ordered-phase phospholipid mixtures occurred in a 
monovalent manner (i). In all cases this was followed by intervesicular ConA binding a 
mannosyl-lipid on a neighbouring vesicle through one of its remaining three binding sites 
(ii), leading to extensive aggregation. Mannosyl-lipid 51 in fluid phase DMPC at higher 
loadings and in the intermediate ld + lo phase may exhibit intravesicular binding through 1 
or 2 extra ConA CRDs (iii), enhancing Kstat. 
 
However, in a concurrent study reorganisation of a biotin analogue of lipid 51 (59, Figure 
3.22.a) was observed upon avidin introduction; the stronger binding affinity (>10
9
 M
-1
) and 
more favourable binding site geometry (two sets of two parallel binding sites separated by 
2.1 nm at opposite ends of the protein, Figure 3.22.b)
127
 drove the dispersal of clustered 
biotin lipids in lo membranes and clustering of dispersed biotin lipids in ld membranes.
128
 
Even so, steric crowding caused by lipid clustering caused avidin to be bound with half the 
affinity compared to dispersed lipids. This steric crowding effect is mirrored in the work of 
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Cremer et al, who observed that GM1 binding to cholera toxin is impeded by phase 
separation of the GM1 receptor in a planar bilayer.
72
  
 
 
 
Figure 3.22 Biotin-capped perfluoroalkyl pyrene lipid 59 (a).
128
 Crystal structure of avidin 
(b) and the arrangement of protein binding sites (c).
127
 
 
Both the group of Groves and Ohtoyo have observed changes in the lateral distribution of 
glycolipids upon lectin binding (CTB5 and WGA respectively).
75, 76
 Cholera toxin, WGA 
and avidin are proteins that present adjacent and directionally-aligned binding sites that are 
able to facilitate multivalent binding. In comparison the binding sites of ConA are very 
well-spaced and are aligned at the corners of its tetrahedral shape (Figure 3.2). Therefore it 
is reasonable to assume that intramembrane glycolipid binding and any subsequent 
glycolipid reorganisation can only be truly observed with lectins that present binding sites 
with the correct spatial configuration.  
 
Although glycolipid clustering had little effect on the binding of ConA, it was possible that 
it could have an effect on the rate of enzymatic glycosylation. In order to glycosylate a 
saccharide-capped lipid a transferase enzyme must first bind the membrane-bound substrate 
with its CRD. This initial binding event may be influenced by glycocluster effects in a 
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similar fashion to lectin binding. Other effects, such as steric blocking by the membrane 
surface, glycolipid flip-flop, or simply the chemical structure of the lipid may also impact 
the rate of glycosylation. To this end enzymatic galactosylation by bovine β-(1,4)-
galactosyltransferase and sialylation by Trypanosoma cruzi trans-sialidase of glycolipids 
capable of phase separation in phospholipid bilayers were investigated and are presented in 
the following chapters. 
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4 Enzymatic glycosylation of glycolipids at the vesicle membrane surface 
 
Ubiquitous on the outer leaflet of the cell‟s plasma membrane, glycolipids act as cellular 
markers to distinguish cell types. The binding of proteins to glycolipid oligosaccharide 
sequences is implicated in many normal cellular processes, so the formation and 
modification of these oligosaccharide sequences by enzymes is very important. 
Modification of oligosaccharides is known to occur in the Golgi and at the cell-surface.
1
 In 
addition, the recognition and modification of surface oligosaccharides is often utilised by 
invasive bacteria and virus particles in endocytosis and virus budding.
1
 Investigation of the 
biochemical mechanisms of glycolipid modification at the membrane surface is therefore of 
importance in glycobiological research. 
 
4.1 Glycolipids and gangliosides 
 
The most common type of glycolipids are the gangliosides.
1
 The gangliosides are a family 
of ceramide-linked glycolipids (or glycosphingolipids) that contain one or more sialic acid 
residues in their oligosaccharide sequence,
1
 for example GM3 (Figure 4.1). The name for N-
acetylneuraminic acid, sialic acid (after saliva) was first coined by Blix et al in the 50s after 
analysis of submaxilliary mucin.
129
 Oligosaccharide sequences containing sialic acid are 
important cell markers that are involved in cell adhesion processes along with cell surface 
selectins. This interaction is known to be implicated in immune response; the classic 
leukocyte „rolling‟ movement along blood vessel walls is caused by multivalent low-
affinity selectin-sialic acid interactions, facilitated by the clustering of selectins in lipid 
rafts.
130
 
 
 
Figure 4.1 Example of a ganglioside, GM3. 
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In addition gangliosides are implicated in the formation and stabilisation of lipid rafts.
11
 
The current view is that transmembrane raft proteins are „lubricated‟ by glycosphingolipids, 
in that they associate with actin-bound transmembrane raft proteins and may potentiate the 
formation of a raft domain. At this point they help stabilise the raft by interacting with the 
transmembrane and GPI-anchored proteins or aid the inclusion of more raft proteins by 
lubricating the domain (Figure 4.2).
11
  
 
Figure 4.2 Glycosphingolipids associate with raft proteins (a), after which they coalesce 
into rafts (b) and „lubricate‟ the assembly.11 
 
4.2 Ganglioside biosynthesis 
 
The oligosaccharide components of gangliosides are built up by successive addition of 
individual saccharides by glycosyltransferase enzymes to a ceramide lipid anchor.
1, 131
 Each 
transferase enzyme has a high specificity for the target saccharide sequence to which it 
transfers another saccharide. The transferred saccharide originates from a donor species – 
usually a uridine diphosphate (UDP)-linked monosaccharide – and is linked to a specific 
hydroxyl on the glycolipid. The primary site of glycosyltransferase activity is in the Golgi 
lumen. Golgi glycosyltransferases are type II membrane-bound proteins composed of four 
main parts (Figure 4.1),
131
 although soluble forms of the enzymes may be formed by 
proteolytic cleavage of the stem region.  
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Figure 4.3 Golgi glycosyltransferases are composed of a small cytosolic region, a 
transmembrane domain, a stem region and the catalytic domain.
131
 The enzyme shown is 
bovine galactosyltransferase (PDB ref. 1O0R).
132
 
 
Glycosyltransferase enzymes are thought to be sequentially arranged along the Golgi 
pathway; each enzyme is not uniformly spread along the pathway i.e. they are in the 
required order to build up specific oligosaccharide sequences. The influx and efflux of 
material is also at a steady state.
131
 This conveyor belt-like assembly allows the building up 
of complex oligosaccharides in a very specific manner. Post-synthesis the glycolipids are 
sorted and transferred to their site of action by transport vesicles in the trans-Golgi network. 
 
4.3 Galactosyltransferases 
 
As their name suggests, the galactosyltransferases (GalT) are a family of enzymes that 
catalyse the transfer of galactose from UDP-Gal (Scheme 4.1.c) to various acceptor species 
(commonly Glc or GlcNAc).
133
 Despite GalT-activity being prevalent in nature, there is 
little structural homology between prokaryotic and eukaryotic GalTs and the GalTs of 
prokaryotic cells share few conserved regions. However, the GalTs of eukaryotic cells do 
share homology between organisms and can be subdivided according to the stereochemistry 
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of the anomeric centre generated and the position galactosylated; for instance α-(1,3)-GalT 
transfers a galactose residue with an α-configuration to the 3-hydroxyl of the target 
saccharide. In mammalian species the GalT enzymes exist primarily in the Golgi in the 
membrane-bound form, but soluble forms can be found, particularly in the mammary 
glands. While the majority of GalTs are located in the Golgi, there is evidence that they are 
also present on the surface of some cells and there is also limited evidence of GalT being 
involved in the mammalian fertilisation process.
134
 
 
4.3.1 Bovine β-(1,4)-galactosyltransferase 
 
Bovine β-(1,4)-galactosyltransferase (β4GalT1) was the first mammalian GalT enzyme to 
be characterised and cloned.
133
 β4GalT1 catalyses the irreversible transfer of Gal to the 4-
position on terminal GlcNAc residues (Scheme 4.1.a), and is also well-known for its ability 
to transfer Gal to Glc and create lactose in the presence of α-lactalbumin (Scheme 4.1.b). 
The enzyme utilises UDP-Gal as the donor substrate, biosynthesised from UDP-Glc and 
catalysed by UDP-galactose 4‟ epimerase with a NADH cofactor.1 β4GalT associates with 
α-lactalbumin to create a heterodimer (lactose synthase), which induce a change in the 
acceptor site of the β4GalT1 domain and enhance its affinity for Glc. Like most GalT 
enzymes β4GalT1 is almost exclusively located in the Golgi, where it is membrane-bound. 
It is produced continuously, confirming it is necessary for cell-marker oligosaccharide 
synthesis and regular cellular function.
133
 In vivo, membrane-bound β4GalT1 forms 
homodimers linked through the transmembrane domain, a mechanism thought to aid Golgi 
retention of the enzyme.
135
 Soluble forms of β4GalT1 are also found in the mammary 
glands, where expression is upregulated during lactation and lactose produced in the 
presence of α-lactalbumin.  β4GalT1 is also an important enzyme in the biochemical 
synthesis of gangliosides; the second glycosylation step transforms glucosylceramide to 
lactosylceramide in the presence of β4GalT1 (Scheme 4.1.d).1 
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Scheme 4.1 β4GalT1 catalyses the formation of N-acetyllactosamine (LacNAc, a), and in 
the presence of α-lactalbumin, lactose (Lac, b), with UDP-Gal (c). The second 
glycosylation step in the synthesis of GM3 gangliosides is catalysed by GalT (d).
1
 
 
As well as being the first glycosyltransferase cloned, soluble bovine β4GalT1 was also the 
first mammalian glycosyltransferase to have its crystal structure solved.
136
 Since then, the 
full catalytic site and mechanism of Gal transfer have been elucidated. The enzymatic 
domain is essentially cone shaped with an invagination to accommodate the reactants. The 
mechanism entails first binding of UDP-Gal, aided by a manganese ion which complexes to 
the phosphates, followed by the acceptor (GlcNAc or Glc).
137
 The UDP-Gal is then cleaved  
to give a galactosyl cation that reacts with the acceptor. In the catalytic centre an Asp-252 
residue binds the Mn
2+
 ion, while residues Glu-317 and Asp-318 form hydrogen bonds to 
the two sugars, ensuring stereoselectivity by controlling orientation as well as aiding proton 
transfer.
137
 
 
The catalytic activity of β4GalT1 has been well studied by several groups. The soluble 
form of the enzyme can operate in a pH range of 5-10 and at temperatures ranging from 20-
55 °C, above which the enzyme becomes denatured.
138
 The optimum conditions naturally 
lie around pH 7 and 37 °C,
138
 although the enzyme has been used at ambient room 
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temperature as an effort to minimise rates of denaturation.
139
 β4GalT1 is usually used in 
sodium cacodylate (caco) or morpholino-based buffers such as 2-(N-
morpholino)ethanesulfonic acid (MES); the morpholino buffers have the advantage of 
being much less toxic and are thought to interfere less with β4GalT1 activity.140 Surfactant 
additives such as Triton X-100 (TX-100) can also help stabilise recombinant enzymes 
which are membrane-bound in nature by preventing aggregation.
141
 Manganese ions are 
essential for function and a small excess of MnCl2 is usually added to the reaction mixture.  
 
β4GalT is known to accept a wide-range of GlcNAc ligands, including a variety of 
oligosaccharide sequences. It has also been shown to galactosylate other soluble small 
molecules, such as ρ-nitrophenyl-GlcNAc,142, 143 umbelliferyl-GlcNAc,142, 144 and other 
hydrophobic GlcNAc conjugates.
142
 The group of Nishimura also used the enzyme in their 
synthesis of sialyl Lewis X (SLeX)-functionalised cyclodextrin glycoclusters, using the 
products to demonstrate inhibition of selectin binding to a SLeX-BSA surface.
145
 Although 
β4GalT will accept many conjugated GlcNAc systems, the efficiency of the enzyme can be 
affected by the aglycone part of the molecule; accessibility and possible secondary 
interactions may influence the enzyme rate.  
 
4.3.2 Bovine β-(1,4)-galactosyltransferase kinetics – Michaelis-Menten relationship 
 
A simple enzyme catalysed process can be defined as an enzyme (E) reversibly binding (k1, 
k-1) a substrate (S) to form an enzyme substrate complex (ES). Followed by irreversible 
conversion (kcat) to the product (P) and release from the enzyme:
146
 
 
 
The activity of enzymes can be modelled using this simple interpretation, which leads to 
Michaelis-Menten kinetics.
146
 The relationship assumes that the formation of the enzyme-
substrate complex is a reversible process and that the formation of product (kcat) is the rate 
determining step. The interpretation was elaborated by Briggs and Haldane who proposed 
the concentration of the ES complex is in a steady state, i.e. that the rates of formation and 
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dissociation of the ES complex are equal.
147
 This leads to the form of the Michaelis-Menten 
equation in Equation 4.2, which relates the observed rate of an enzyme catalysed reaction 
(initial velocity – V0) to the substrate concentration ([S] in M), maximum rate (Vmax, usually 
M
-1
s
-1
) and Michaelis constant (or apparent dissociation constant, Km in M). 
 
   
       
      
              
 
Where, 
   
        
  
              
 
The catalytic turnover is usually expressed in terms of kcat, which is the maximum number 
of molecules of substrate that the enzyme can convert to product per catalytic site per unit 
of time, usually expressed in s
-1
. kcat is related to Vmax and the concentration of enzyme 
catalytic sites ([E]) by Equation 4.4. The theoretical rate limit of an enzyme is where the 
turnover rate reaches the rate of small molecule diffusion in aqueous solution (around 10
8
 
M
-1
s
-1
).
5, 148
 
 
                    (4.4) 
 
For a single-substrate enzyme, kcat and Km can be determined experimentally by varying [S] 
and plotting it against the initial rate observed (V0). This gives an asymptotic curve where 
the initial rate reaches a maximum (Vmax) when the substrate saturates the enzyme. Km is 
defined as the substrate concentration at which V0 = ½ Vmax. The curve parameters can be 
easily solved by performing linear regression such as plotting the reciprocal of the observed 
initial rate (1/V0) vs. 1/[S] (Lineweaver-Burk plot), where the x-intercept = -1/Km and the y-
intercept = 1/Vmax. However, linear regression analysis using Lineweaver-Burk plots can 
weight the data towards the higher substrate concentrations used (when 1/[S] is low), or to 
lower concentrations if the substrate is poorly soluble (1/[S] high). Other linear regression 
methods such as Eadie-Hofstee (V0 vs. V0/[S]) and Hanes-Woolf ([S]/V0 vs. [S]) plots are 
also error prone as the axes in each case are not independent variables (exaggerating any 
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experimental errors). These effects can distort the Km and Vmax values obtained. Non-linear 
regression programs such as Origin can solve the saturation curve directly, giving more 
accurate values for Km and Vmax as well as providing calculated errors. 
 
For a multi-substrate enzyme - β4GalT1 is a two-substrate enzyme (GlcNAc acceptor and 
UDP-Gal donor) - the concentration of both substrates is altered and the rate of the 
enzymatically catalysed reaction can again be analysed by linear regression or non-linear 
regression. As the relationship is more complex than for a single substrate, it is more 
convenient to use a non-linear regression program. For multi-substrate transferase enzymes 
it may be impossible to perform a full analysis altering both substrate concentrations (due 
to assay limitations or material available), in which case if [S] is modified for only one 
substrate, regression analysis yields apparent Km and Vmax values.
149, 150
 Km and Vmax values 
determined by changing both substrate concentrations are known as true Km and Vmax.
149
 
 
For β4GalT1 the true Michaelis constant and kcat for unfunctionalised GlcNAc have been 
determined as Km = 10 mM and kcat = 3.6 s
-1
.
150
 Recent highly detailed crystal structures of 
β4GalT1 indicated that the enzyme has an extended binding site capable of accommodating 
oligosaccharide acceptors.
132
 This is demonstrated by enhanced binding affinities (Km) and 
increased kcat for chitobiose (GlcNAc-β-(1,4)-GlcNAc) and chitotriose (GlcNAc-β-(1,4)-
GlcNAc-β-(1,4)-GlcNAc); Km = 1.5 mM and kcat = 4.8 for both species.
150
 Other non-
carbohydrate GlcNAc conjugates have shown increased affinity, such as the hydrophobic 
GlcNAc compounds of Palcic et al (Figure 4.4).
142
 The methyl octanoate (66) and 
umbelliferyl (67) acceptors offered Km values of 0.134 and 0.168 mM respectively, an 
enhancement of Km up to 75-fold compared with unmodified GlcNAc, possibly due to 
secondary binding interactions with the hydrophobic aglycone.  
 
 
 
Figure 4.4 Hydrophobic GlcNAc ligands for β4GalT1 by Palcic et al.142 
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4.3.3 β4GalT1-catalysed reactions on supported GlcNAc ligands 
 
Many examples of β4GalT1 catalysing the galactosylation of solid-supported GlcNAc 
residues exist, including GlcNAc on gold nanoparticles in suspension
151
 and Sepharose 
beads,
152
 or coated surfaces. Of these platforms self-assembled monolayers (SAMs) are the 
most widely used, due to their capacity to allow quick screening of many enzyme-substrate 
pairs. Park et al fabricated carbohydrate chips by spotting maleimide-linked sugars onto an 
SH-functionalised surface.
153
 The group confirmed enzyme conversion by using fluorescent 
lectins; only converted sugars bound to the fluorescent lectin. Self-assembled monolayers 
of glycated thiols on gold (glycoarrays) have also been used as a platform for studying 
β4GalT1-catalysed galactosylation, exploiting the availability of label-free mass 
spectrometry techniques, such as MALDI, which can be performed directly on gold chips. 
Zhi et al recently demonstrated the galactosylation of GlcNAc-capped SAMs, using 
MALDI to detect conversion to LacNAc and observing full conversion after overnight 
incubation with the enzyme.
154
 In this case to separate the GlcNAc groups, a „dilutor‟ 
alkanethiol was added in a 50:50 ratio with the substrate GlcNAc-alkanethiol.  
 
Much like the inhibition of lectin binding by clustered receptors,
72
 Mrksich and co-workers 
observed inhibition of β4GalT1 activity at high densities of GlcNAc-alkanethiols on gold 
supports.
155
 During the addition of 
14
C-labelled galactose to the surface, it became clear that 
at loadings up to 70% mol/mol GlcNAc there was a steady increase in β4GalT1 activity 
(Figure 4.5). However, at higher loadings, the measured amount of 
14
C at the surface was 
reduced, suggesting that accessibility for the enzyme becomes an issue if the surface 
acceptor species are too crowded.  
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Figure 4.5 Relationship between mol fraction of GlcNAc-alkanethiol and amount of 
14
C 
enzymatically transferred by Mrksich and co-workers (a).
155
 Low densities of receptors 
may be more accessible (a, i) than high densities (b, i) for binding to the enzyme and steric 
crowding may inhibit binding (b, ii). 
 
4.4 β4GalT1-catalysed galactosylation of membrane-embedded GlcNAc-lipids 
 
The work of Palcic et al and Ramasamy et al clearly demonstrates that changing the nature 
of the aglycan affects the rate and profile of enzymatic reactions catalysed by β4GalT1. It is 
therefore likely that surface-bound GlcNAc residues will also display different Km and kcat 
values compared to soluble GlcNAc. However the kinetic parameters of β4GalT1-catalysed 
reactions to surface-bound or membrane-bound substrates have not yet been fully 
investigated, as most surface-based analytical platforms are used solely for screening 
enzyme specificity. In addition there is a lack of thorough investigations into the effects of 
ligand clustering - with regards to how it influences Km or kcat - when studying enzymatic 
glycosylation by β4GalT1 with interfacial systems.  
 
Given that Mrksich and co-workers observe maximum enzyme efficiency with dispersed 
substrates and that other researchers have observed optimal conversions at non-saturating 
a) 
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surface coverage,
155
 it might be expected that the clustering of substrate lipids in a 
phospholipid membrane would give a decrease in rate due to crowding of the substrate. 
However, secondary enzyme-substrate interactions outside the active site or statistical 
rebinding could cause a rate increase by enhancing Km. The GlcNAc-functionalised lipid 53 
would give access to both situations as the degree of perfluoroalkyl lipid clustering can be 
controlled by the membrane phase, for example allowing the investigation of β4GalT1-
catalysed galactosylation of artificial lipid rafts. In general glycosylation of 
inhomogeneously distributed glycolipids has not been well studied in vitro or in vivo, 
despite lipid rafts being known to play major roles in many other cellular processes.
12
 It 
was therefore proposed that GlcNAc-lipid 53 would be used to investigate the kinetic 
parameters of β4GalT1-catalysed galactosylation at the membrane interface, allowing any 
changes in rate caused by glycolipid clustering to be assessed. 
 
4.4.1 GlcNAc-lipid behaviour in solution and vesicles 
 
Using similar methodology to that employed with mannosyl-lipids 49 and 51, the behaviour 
of GlcNAc-lipid 53 in buffered solution was assessed. GlcNAc-lipid 53 was suspended in 
50 mM MES buffer at 20 μM by sonication of a thin lipid film. As with mannosyl-lipids 49 
and 51, GlcNAc-lipid 53 self-assembled in aqueous buffer and exhibited a high E/M ratio 
of 20.9. The suspension was then diluted and the fluorescence spectra measured with each 
dilution and the E/M ratios were plotted vs. log[53] (Figure 4.6).  
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Figure 4.6 CAC - E/M of lipid 53 vs. log[lipid 53]. 
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The point at which excimer fluorescence became steady gave a CAC of 15.4 nM. The value 
was similar to that of the mannosyl-lipid with the aminoethyl linker (49) and again 
suggested the lipid should be fully incorporated into the hydrophobic bilayer. 
 
GlcNAc-lipid 53 was then incorporated into phospholipid vesicles (at 1% mol/mol loading) 
composed of DMPC, 50:50 mol/mol DMPC/cholesterol (DMPC/chol) or DPPC, which are 
respectively in the ld, lo and so phase between 23 – 41 °C.
8, 156
 As expected, clustering of 
lipid 53 at 37 °C was observed in DMPC/cholesterol (E/M = 1.5) and DPPC (E/M = 1.3), 
but not in DMPC (E/M = 0.15). The initial loading of GlcNAc-lipid 53 in DMPC vesicles 
was also increased to 2 and 10% mol/mol which gave E/M values of 0.18 and 1.5 at 37 °C; 
the increase in excimer formation observed at such loadings is possibly due to an increased 
collisional frequency between pyrene lipids. The initial loading of lipid 53 in DMPC/chol 
and DPPC was also increased to 10% mol/mol, which gave increased clustering as 
evidenced by the high E/M ratios (3.5 for DMPC/chol, 4.7 for DPPC at 37 °C).  
 
To verify that GlcNAc-lipid 53 was fully incorporated into the membrane at 10% mol/mol 
initial loadings, UV-vis spectra were recorded after elution down a GPC column and 
compared to reference molar extinction coefficients of lipid 53 at 20 μM in 1:1 
CHCl3/MeOH. This revealed actual loadings of 8.7% mol/mol in DMPC, 6.4% mol/mol in 
DMPC/chol and 8.5% mol/mol in DPPC, even though the target loading was 10% mol/mol. 
These values are in agreement with Orr et al who observed similar loadings with synthetic 
glycolipids in egg yolk lecithin vesicles (loadings above 14% mol/mol could not be 
attained),
157
  reflecting the difficulty of incorporating some synthetic lipids into vesicles at 
high loadings. 
 
To visualise the lipid clustering directly, GUVs composed of the GlcNAc-lipid in DMPC, 
DMPC/chol and DPPC with a target incorporation of 10% mol/mol 53 were synthesised 
using electroformation.
19
 Fluorescence microscopy was used to visualise GUVs containing 
53. GlcNAc-lipid 53 gave artificial lipid raft formation in both DMPC/chol and DPPC, but 
not DMPC, which is in agreement with the E/M ratios observed with these compositions. In 
DMPC only dull blue monomer fluorescence was observed around the perimeter of the 
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GUVs, but with DMPC/chol and DPPC the GUV domains were clearly observed, with 
sizes up to 50 μm observed in DMPC/chol with diameters of 100 μm. Interestingly, domain 
and bilayer morphology differed between these mixtures. Domains in DMPC/chol vesicles 
were on average slightly larger than those in DPPC (~10-20 μm), where many of the GUVs 
appeared to exhibit a ripple phase with some domains lying in the invaginated areas of the 
ripple. This behaviour is perhaps similar to that observed with DPPC/cholesterol vesicles, 
where cholesterol is known to stabilize the ripple phase,
156
 a state where the normally flat 
bilayer adopts a „corrugated‟ structure.158 
  
 
 
Figure 4.7 Epi-fluorescence microscopy of GUVs 8.7% mol/mol 53 in DMPC (a), 6.4% 
mol/mol 53 in DMPC/chol (b) and 8.5% mol/mol 53 in DPPC (c). Scale bar = 20 μm. 
 
As the GlcNAc-lipid 53 was incorporated during vesicle synthesis it should be distributed 
on both leaflets of the membrane. A study of the quenching of N-(7-nitrobenz-2-oxa-l,3-
diazole-4-yl) (NBD)-labeled lipids embedded in LUVs with the membrane impermeable 
oxidant dithionate, showed that around 56% of the NBD-lipid was incorporated in the outer 
leaflet.
159
 Similarly, Sillence et al studied the oxidation of glycolipids in LUVs by 
membrane impermeable carboxy-TEMPO indicated that approximately 50% of the 
glycolipids were incorporated in the outer leaflet, albeit at lower membrane loadings (0.5% 
mol/mol)
160
 than used for 53. These studies suggest that at any instant only around 50% of 
GlcNAc-lipids 53 are accessible for β4GalT1. Therefore, it was important to establish the 
flip-flop rate of 53 to see how it could affect the rate of enzymatic conversion. 
 
a) b) c) 
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GlcNAc-lipid 53 in ethanol (40µL, 1 mM) was added to vesicles composed of DMPC or 
DMPC/chol (2 mL, 2 mM total lipid) in buffer (50 mM MES, pH 7 at 37 °C) to give a 
loading of 1% mol/mol. Fluorescence spectra were taken at regular intervals over 20 hours. 
Immediately after addition the E/M ratios dropped from 20.9 to 0.55 for DMPC and from 
20.9 to 2.60 for DMPC/chol as the lipids inserted and dispersed in the fluid phase 
membranes. In each case the E/M ratio subsequently dropped slowly, reaching 0.09 for 
DMPC and 1.55 for DMPC/chol after 20 hours (Figure 4.8). The half-life of the slow 
decline corresponded to flip-flop half-lives of t1/2 = 1 hour in DMPC and t1/2 = 4 hours in 
DMPC/chol; the more rigid lo phase retarded the rate of flip-flop. Consequently all the 
GlcNAc-lipids in each system should be available for galactosylation during an overnight 
enzymatic reaction. 
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Figure 4.8 Transverse diffusion of GlcNAc-lipid 53 in DMPC (a) and DMPC/chol (b) 
vesicles, showing the decline in E/M over several hours. 
 
4.4.2 β4GalT1-catalysed glycosylation of GlcNAc-lipids – initial studies 
 
800 nm vesicles composed of DMPC, DMPC/chol and DPPC with target loadings of 10% 
mol/mol GlcNAc-lipid 53 were synthesised by the extrusion method (2 mM phospholipid, 
200 μM 53, 50 mM MES, pH 7 at 37 °C) and incubated overnight at 37 ºC to reach the 
equilibrium E/M values. GlcNAc-lipid 53 in vesicle membranes was then galactosylated 
according to the general β4GalT1 reaction protocol outlined in Section 7.3.18; vesicle 
solution (100 μL) was then mixed with β4GalT1 (30 μL, 11.65 μM, 1% v/v Triton X-100, 
50 mM MES, pH 7 at 37 °C), UDP-Gal (30 μL, 10 mM in H2O) and MnCl2 (1 μL, 1 M in 
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H2O) in a mini Eppendorf tube and incubated overnight at 37 °C. This gave concentrations 
of 124.2 μM 53, 1.86 mM UDP-Gal, 6.21 mM MnCl2 and 2.17 μM β4GalT1. The 
concentration of β4GalT1 was estimated using its molecular weight,161 and molar extinction 
coefficient.
162
 This would ensure that there was always an excess of MnCl2 and UDP-Gal 
donor species in the reaction mixture.  
 
GlcNAc-lipid 53 was also galactosylated as a suspension in buffer (in the absence of 
vesicles) to give a solution phase comparison to the vesicle-bound experiments: GlcNAc-
lipid 53 was suspended in buffer by sonication of a thin film of lipid 53 (200 μM 53, 50 
mM MES, pH 7 at 37 °C). The suspension was galactosylated using the general β4GalT1 
reaction protocol outlined in Section 7.3.18. 
 
Upon inspection of the reaction vials the following morning, it was clear that the vesicles 
had lysed – the normally opaque solutions were fully transparent. Nevertheless the reaction 
solutions were analysed using MALDI-ToF MS to determine whether galactosylation had 
taken place. An aliquot of the reaction solution (1 μL) was spotted onto a polished steel 
MTP-384 MALDI plate followed by sinapinic acid (1 μL, 10 mg/mL in 5:4:1 
MeCN/H2O/MeOH) and allowed to dry at room temperature. Analysis of the MALDI-ToF 
spectra revealed full conversion of the GlcNAc-lipid 53 in all mixtures, demonstrated by a 
change in mass from 1003 m/z (53 + Na
+
) to 1165 m/z (LacNAc-lipid 68 + Na
+
) (Figure 
4.9). 
 
The cause of vesicle lysis was found to be the surfactant Triton X-100 (TX-100) in the 
enzyme buffer (50 mM MES, 1% v/v TX-100). TX-100 is a non-ionic surfactant and is 
well-known for its ability to permeabilize vesicles and cell membranes. Fluorescence 
spectroscopy of the reaction solutions confirmed vesicle lysis had taken place - the E/M 
ratio of 53 in DMPC at 10% mol/mol loading had dropped from 1.5 to 0.05). Despite lysis, 
MALDI-ToF analysis showed that lipid 53 was a suitable substrate for β4GalT1 and that 
galactosylation at the membrane could be investigated, provided that high concentrations of 
TX-100 were avoided.  
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Figure 4.9 β4GalT1-catalysed galactosylation of GlcNAc-lipid 53 in solubilised DMPC 
vesicles before galactosylation (a) and after overnight incubation with β4GalT1 (b). 
Reaction scheme showing conversion of GlcNAc-lipid 53 into LacNAc lipid 68 (c). The 
peak at 1356 m/z is a dimer of DMPC. 
 
4.4.3 β4GalT1-catalysed glycosylation of GlcNAc-lipids – TX-100 lysis of vesicles 
 
TX-100 has been reported to stabilise enzymes that are particularly prone to 
denaturation. TX-100 prevents enzyme aggregation, aids folding and can also stimulate 
the activity of normally membrane-associated species.
141
 TX-100 induces membrane 
permeabilisation or full rupture of phospholipid vesicles, which occurs in a three stage 
process:
163
 at low concentrations TX-100 molecules adsorb onto or insert into the 
membrane; as the local concentration of surfactant increases to a critical point (the 
CMC) the bilayer becomes partially solubilised (and permeable); at higher 
concentrations the membrane is fully solubilised in mixed micellar structures.  
 
In order to ascertain vesicle stability with TX-100, a 5-(6)-carboxyfluorescein (CF) 
assay was used. CF is a self-quenching dye which is very sensitive to changes in local 
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concentration and can be encapsulated in phospholipid vesicles to monitor the 
permeability of the membrane.
163
 800 nm vesicles composed of DPPC with a target 
loading of 10% mol/mol lipid 53 were synthesised in a CF-containing buffer (MES 50 
mM, 10 mM CF). A dilute TX-100 solution (0.5% v/v TX-100, 50 mM MES, pH 7 at 
37 °C) was then titrated into the vesicular suspension and the fluorescence spectra of 
both the pyrene (excitation at 346 nm) and fluorescein (excitation at 491 nm) were 
recorded; CF release from vesicles would give an indication of membrane permeability 
and a large drop in pyrene E/M ratio would signify full membrane solubilisation. The 
E/M ratio was then plotted vs. log[TX-100] (Figure 4.10) and %CF release plotted vs. 
log[TX-100] (Figure 4.11.b).  
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Figure 4.10 E/M vs. log[TX-100] showing lysis of vesicles with TX-100 composed of 
DMPC (a), DMPC/chol (b) and DPPC (c) with a target loading of 10% mol/mol lipid 53. 
 
Vesicular stability was observed with 0.01% v/v TX-100 (0.16 mM). In the reaction 
mixture the amount of β4GalT1 solution added is 30 μL in a total volume of 161 μL, 
therefore the amount of TX-100 chosen for the β4GalT1 buffer was 0.05% v/v (0.856 
mM). This gave a molar ratio of TX-100 to phospholipid of 0.16:1.24 mM TX-
100/phospholipid for 10% mol/mol 53 vesicles, 0.16:6.8 mM TX-100/phospholipid for 
2% mol/mol 53 vesicles or 0.16:12.4 mM TX-100/phospholipid for 1% mol/mol 53 
vesicles. For subsequent experiments, the β4GalT1 buffer was exchanged to 0.05% v/v 
TX-100 (using HiTrap™ columns from GE Healthcare, see Section 7.3.17 for full 
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details) and 10% v/v glycerol as anti-freeze. It should also be noted that no enzymatic 
activity was observed when the enzyme was stored in buffer with 0% v/v TX-100. 
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Figure 4.11 CF release from vesicles composed of DPPC with a target loading of 10% 
mol/mol 53 caused by TX-100-induced lysis; fluorescence spectra showing increase in 
fluorescence at 491 nm (a) and plot of % release with increasing TX-100 (b). 
 
4.4.4 β4GalT1-catalysed glycosylation of GlcNAc-lipids – 10% mol/mol target loading 
 
Vesicles with target loadings of 10% mol/mol GlcNAc-lipid 53 were synthesised and 
galactosylated with β4GalT1 using the general procedure described in Section 4.4.2 (see 
Section 7.3.18 for full details), but with the reduced TX-100 concentration (0.05% v/v) in 
the enzyme buffer. Vesicles with target loadings of 10% mol/mol GlcNAc-lipid 53 (actual 
loadings were 8.7% mol/mol in DMPC, 6.4% mol/mol in DMPC/chol and 8.5% mol/mol in 
DPPC, see Section 4.4.1) initially chosen as they gave the cleanest MALDI-ToF spectra; in 
the absence of purification after β4GalT1 reactions detector saturation by the phospholipid 
hampered detection of the GlcNAc-lipid 53 at 1% mol/mol loadings. After overnight 
incubation, lipid 53 was found by MALDI to have been partially converted to the LacNAc 
product 68 in all three lipid mixtures (Figure 4.12, a). However, the vesicles were now also 
stable under the reaction conditions, as the E/M ratios of each mixture after overnight 
galactosylation (DMPC E/M = 1.4, DMPC/chol E/M = 3.7 and DPPC E/M = 4.5 at 37 °C) 
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were consistent with that of the pre-β4GalT1 values (DMPC E/M = 1.5, DMPC/chol E/M = 
3.5 and DPPC E/M = 4.7 at 37 °C). 
 
The distinctive UV-visible spectrum of pyrene (λmax = 346 nm) allowed monitoring of the 
reaction by HPLC, as the characteristic pyrene UV-vis trace would be easy to differentiate 
from the rest of the material in the β4GalT1 reaction mixture. Furthermore a shift in the 
pyrene UV-vis trace to a shorter retention time on a reverse-phase column would be 
observed should glycosylation have taken place, as the product lipid 68 is more hydrophilic 
than GlcNAc-lipid 53. HPLC analysis could also give an accurate measurement of the 
extent of the reaction through comparison of the area of the product and starting material 
peaks. The rates of reaction should be available from HPLC analysis performed at set time 
intervals.  
 
 
  
Figure 4.12 Example MALDI-ToF spectrum showing conversion of GlcNAc-lipid 53 
(1003 m/z, sodium adduct) to LacNAc-lipid 68 (1165 m/z, sodium adduct) in DPPC 
vesicles at 10% mol/mol loading (a) (peak at 1468 m/z corresponds to a DPPC dimer + 
Na
+
). Conversion of 53 to 68 was confirmed using HPLC (b). 
 
Aliquots of the galactosylated vesicle samples (5 μL) were injected onto a C18-
functionalised silica HPLC column without prior purification of the vesicle mixtures, and 
eluted with a mixture of THF/H2O. As anticipated, the retention time of the LacNAc 
product 68 was shorter than GlcNAc 53 (Figure 4.12, b). Integration of the peaks revealed 
only partial conversion of GlcNAc-lipid 53 to 68; around 20-40% conversion was observed 
for all the vesicle mixtures after overnight treatment with β4GalT1. LC/MS was used to 
1003.254 1165.281
1468.130
0
500
1000
1500
2000
In
te
n
s
. 
[a
.u
.]
1000 1100 1200 1300 1400 1500
m/z
(a) (b) 
53 
68 
4. Enzymatic Galactosylation 
 
136 
 
correlate these retention times to changes in mass; co-elution of the UV-vis peaks with 
detected mass peaks at 1003 m/z and 1165 m/z confirmed the identity of the two peaks. 
 
Interestingly, after overnight galactosylation the conversion of GlcNAc-lipid 53 in 
DMPC/chol vesicles reached 40%, but for DMPC only 20% conversion was observed, 
indicating that lipid clustering may have influenced the reaction. To investigate this effect 
further, HPLC measurements were performed on aliquots of the samples (5 μL) every half 
hour for 8 hours. The percent conversion was calculated for each point and plotted vs. time 
for each of the lipid compositions (Figure 4.13). After 8 hours the amount of lipid 53 
galactosylated in DMPC/chol and DPPC was approximately double that of the lipid in 
DMPC vesicles. As the lo phase DMPC/chol and so phase DPPC lipid mixtures induced 
more clustering of lipid 53 compared to the ld phase DMPC (E/M = 1.5, 3.5 and 4.7 at 
8.7%, 6.4% and 8.5% mol/mol loading in DMPC, DMPC/chol and DPPC respectively), it 
appeared that the enzymatic reaction was enhanced significantly by the presence of 
artificial lipid rafts on the vesicle surface. 
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Figure 4.13 Conversion of GlcNAc-lipid 53 to LacNAc-lipid 68 in DMPC (●), DMPC/chol 
(●) and DPPC (●) at a target loading of 10% mol/mol with time after 3 repeats (a). 
Representative HPLC trace of enzymatic galactosylation of 53 in DPPC vesicles (b). 
  
The enzyme and UDP-Gal could also be separated from the vesicles after enzymatic 
galactosylation using centrifugation. Vesicular reaction mixtures were spun at 13,000 rpm 
for 5 minutes in a desktop centrifuge, causing the vesicles to settle. The supernatant was 
(a) (b) 
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then removed, fresh buffer was added and the vesicles resuspended via vortex mixing. The 
process was then repeated and the UV spectra taken of each aliquot of removed supernatant 
and the absorption at 280 nm plotted in Figure 4.14 - both UDP-Gal and β4GalT1 absorb in 
this region. This indicated that the neither β4GalT1 nor UDP-Gal irreversibly associated 
with or inserted into the membrane. 
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Figure 4.14 Plot showing removal of β4GalT1 and UDP-Gal from enzymatic reaction 
solutions containing DMPC vesicles (●) and DMPC/chol vesicles (●). 
 
As the saccharide label of these enzymatically transformed vesicles was now different, they 
became susceptible to lectins that selectively bind LacNAc residues. After enzymatic 
transformation and removal of β4GalT1 via centrifugation, vesicle samples composed of 
DMPC/chol with a target loading of 10% mol/mol GlcNAc-lipid 53 (actual load 6.4% 
mol/mol) were mixed with FITC-labelled WGA (GlcNAc-specific) or FITC-labelled 
Erythrina cristagalli lectin (ECL, LacNAc-specific). The two lectins were also mixed with 
DMPC/chol vesicles prior to enzymatic transformation. As expected WGA caused 
aggregation of both samples (Figure 4.15, c, d), as the vesicles still retained some unreacted 
GlcNAc after enzymatic treatment, but ECL only caused aggregation of vesicles that had 
been galactosylated with β4GalT1 (Figure 4.15, e, f). 
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Figure 4.15 Epifluorescence micrographs of DMPC/chol vesicles with a target loading of 
10% mol/mol 53 before (a) and after (b) β4GalT1 treatment. Incubation with FITC-WGA 
agglutinated both vesicles with (d) and without (c) prior incubation with β4GalT1. FITC-
ECL only agglutinated β4GalT1-treated vesicles (f), not non-β4GalT1 vesicles (e). Images 
show merged FITC and pyrene fluorescence. Scale bar represents 20 μm. 
 
4.4.5 β4GalT1-catalysed glycosylation of GlcNAc-lipids – lower lipid loadings 
 
From the galactosylation experiments at substrate lipid 53 loadings of ~10% mol/mol it 
appeared that the greater the clustering of lipid 53 the greater the rate of reaction. The 
difference in E/M of lipid 53 in the ld phase DMPC compared to DMPC/chol (lo) and DPPC 
(so) at 1% mol/mol is much greater than that at 10% mol/mol, so it was envisaged that any 
enhancements due to lipid clustering would be further emphasised at the lower loading. In 
DMPC, lipid 53 exhibited a high E/M ratio at 10% mol/mol target loading (E/M = 1.5), due 
to an increased pyrene collisional frequency caused by the high surface density of 53. 
Therefore reducing the loading in DMPC vesicles also enabled a comparison of enzyme 
rate with different substrate surface density (10% mol/mol 53 in DMPC vs. 1% or 2% 
mol/mol 53 in DMPC), as well as a comparison between laterally dispersed and clustered 
GlcNAc-lipids (1% mol/mol 53 in DMPC vs. 1% mol/mol 53 in DMPC/chol). 
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Vesicles composed of DMPC with a loading of 1 or 2% mol/mol GlcNAc-lipid 53 were 
synthesised by increasing the amount of phospholipid to 10 mM and 20 mM total lipid, 
whilst maintaining the concentration of GlcNAc-lipid 53 (200 μM). The samples were then 
galactosylated with β4GalT1 using the same procedure as in Section 4.4.4 (see Section 
7.3.18 for full details). As before, HPLC measurements taken every half hour for 8 hours. 
The amount of 68 produced and rate of lipid conversion was drastically reduced compared 
to the 10% loading experiments, indicating that the conversion rate is higher as substrate 
surface density increases (Figure 4.16, a).  
 
To further investigate the effects of lipid clustering on the β4GalT1-catalysed reaction, 
vesicles composed of DMPC/chol or DPPC with a loading of 1% mol/mol GlcNAc-lipid 53 
were synthesised and galactosylated with β4GalT1 using the same procedure as in Section 
4.4.4 (see Section 7.3.18 for full details). HPLC measurements were taken every half hour 
for 8 hours which again revealed that lipid clustering enhanced the enzymatic reaction; the 
conversion of 53 in DMPC/chol (E/M = 1.5) was almost 9-fold that of 53 in DMPC (E/M = 
0.15) after 8 hours (Figure 4.16, b). The vesicles were also stable under the reaction 
conditions; after galactosylation the E/M ratio of 53 in DMPC, DMPC/chol and DPPC 
(E/M = 0.14, 1.4 and 1.3 respectively) were similar to the E/M values prior to 
galactosylation (E/M = 0.15, 1.5 and 1.3 for DMPC, DMPC/chol and DPPC respectively).    
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Figure 4.16 Conversion of GlcNAc-lipid 53 to LacNAc-lipid 68 in DMPC at 1% mol/mol 
(●), 2% mol/mol (●) and 10% mol/mol (●) with time (a). Conversion of GlcNAc-lipid 53 
to LacNAc-lipid 68 in DMPC (●), DMPC/chol (●) and DPPC (●) at 1% mol/mol (b). 
(a) (b) 
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The fact that the extent of enhancement due to lipid clustering was more pronounced at 1% 
than 10% mol/mol, probably reflected the greater difference in lipid clustering (E/M); at 
1% mol/mol DMPC/chol E/M = 1.5 and at 1% mol/mol DMPC E/M = 0.15, whereas at 
10% mol/mol in DMPC/chol E/M = 3.5 and at 10% mol/mol in DMPC E/M = 1.5. 
 
4.4.6 β4GalT1-catalysed glycosylation of GlcNAc lipids – non-specific effects 
 
As β4GalT1 is known to possess an oligosaccharide binding site, it was envisaged that 
multiple GlcNAc-lipids 53 in a clustered area could have bound at or around the active site. 
However, other non-specific „raft effects‟, such as secondary interactions between the 
enzyme and GlcNAc-lipids not bound by the active site or β4GalT1 associating with the 
membrane surface, could have also been responsible for the increase in rate. 
 
To investigate the possibility of non-specific effects a series of experiments were designed. 
First the association of β4GalT1 to the membrane surface was assessed; the β4GalT1-
catalysed galactosylation of soluble substrates is known to be enhanced in the presence of 
phospholipid vesicles.
164
 β4GalT1 was labelled using NHS-fluorescein (see Section 7.3.20 
for full details), which gave access to Förster resonance energy transfer (FRET)-based 
assays. FRET involves transfer of energy from an excited fluorophore (donor) to a different 
non-excited fluorophore (acceptor) in close proximity, resulting in emission from the 
initially non-excited acceptor (Table 3.1).
82
 The technique can be used to measure distance 
or provide information about the relative positions of the donor and acceptor in a system. 
The labelled enzyme (30 μL, 0.05% v/v TX-100, 50 mM MES, pH 7 at 37 °C, 3 fluorescein 
molecules per protein) was mixed with DPPC vesicles (100 μL, 20 mM total lipid, 50 mM 
MES, pH 7 at 37 °C) labelled with 0.1% mol/mol of the acceptor lipid dye, rhodamine 
dihexadecanoyl phosphoethanolamine (Rh-DHPE), UDP-Gal (30 μL, 10 mM in H2O) and 
MnCl2 (1 μL, 1 M in H2O). The labelled enzyme was also mixed with DPPC vesicles 
containing 10% mol/mol GlcNAc-lipid 53. Little FRET was observed from the fluorescein 
to the rhodamine and very little from the GlcNAc-lipid 53 excimer to the fluorescein. This 
indicated that β4GalT1 may not have associated with the phospholipid membrane and only 
weakly associated with the GlcNAc-lipid 53 as expected. It should be noted that the 
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enzyme retained its function after labelling – MALDI and HPLC analysis revealed partial 
conversion of GlcNAc-lipid 53 in DPPC after overnight incubation. 
 
To investigate the possibility of enzyme enhancement through non-specific activation by 
clustered lipids which are not substrates for the enzyme, DMPC/chol vesicles with „mixed 
rafts‟ with a target loading of 1% mol/mol GlcNAc-lipid 53 and 9% mol/mol Gal-lipid 47 
were prepared (20 mM total lipid, 200 μM 53, 1.8 mM 47). The incorporation was 
measured at 72% using the UV method, so the actual concentration of the two lipids were 
0.72% mol/mol GlcNAc-lipid 53 and 6.48% mol/mol Gal-lipid 47, which gave 140 μM 53, 
1.3 mM 47. It was envisaged that if the rate observed was similar to 10% mol/mol 53 in 
DMPC/chol vesicles a non-specific „raft effect‟ was present. The vesicles displayed similar 
phase separation to lipid 53 alone in DMPC/chol at 6.4% mol/mol, with an E/M of 3.8 
indicating clustering of the two lipids into mixed rafts. The incorporation was measured at 
72% using the UV method. As before the vesicles were mixed with the β4GalT1 reaction 
mixture and HPLC measurements were taken every half hour for 8 hours (Figure 4.17, a). 
The retention time of the Gal-lipid 47 was slightly longer than that of the GlcNAc-lipid 53 
so the two peaks were resolvable under HPLC conditions (Figure 4.17, b). 
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Figure 4.17 GlcNAc-lipid 53 to LacNAc-lipid 68 conversion in DMPC/chol vesicles with 
target loadings of 1% mol/mol (●), 10% mol/mol (●) and 1% mol/mol with 9% mol/mol 
Gal-lipid 47 (●) with time (a). Example of an HPLC trace of an overnight reaction on 
„mixed raft‟ vesicles with β4GalT1 (b). 
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Initially the enzymatic transformation occurred at the same rate as for 53 in DMPC/chol at 
1% mol/mol loading and then trailed-off up to 8 hours. This suggested that no non-specific 
binding to artificial lipid rafts (independent of lipid identity) by β4GalT1 was taking place 
and instead the enzyme was possibly sterically hindered by Gal-lipid 47 masking GlcNAc-
lipids 53 in the mixed raft. 
 
4.4.7 β4GalT1-catalysed glycosylation of GlcNAc lipids – kinetic investigation 
 
In the absence of any non-specific effects due to the interaction of β4GalT1 with 
phospholipids or lipid clusters, it was thought that kinetic analysis of the β4GalT1-
catalysed transformation of GlcNAc-lipid 53 would improve the understanding of cluster-
mediated enhancement. Ramasamy et al had found an extended β4GalT1 oligosaccharide 
binding site and enhanced rates (kcat) and binding (Km) of both chitobiose/chitotriose and 
short natural oligosaccharide sequences over monomeric GlcNAc.
150
 The enhancement of 
enzymatic conversion of GlcNAc-lipid 53 in rafts may therefore be a manifestation of an 
increased Km and/or kcat due to association of >1 GlcNAc-lipid 53 with the extended 
binding site. 
 
Enzymatic reactions were performed as outlined in Section 7.3.18 on vesicles composed of 
DMPC and DMPC/chol doped with 1% mol/mol 53, but with varying dilutions of vesicles 
(30 – 250 μM 53, 3 – 25 mM total lipid) and analysed using HPLC. DMPC and 
DMPC/chol mixtures with 1% mol/mol 53 gave the largest difference in E/M (0.15 and 1.5 
respectively) so allowed a direct comparison between the transformation of when the 
GlcNAc-lipid 53 is in domains or dispersed over the vesicle surface. The initial rate was 
calculated by plotting the concentration of product 68 formed vs. time and taking the linear 
fit of the first two data points. The initial rate data was fitted to both linear and non-linear 
regression Michaelis-Menten models to determine the apparent Km, Vmax (as concentration 
of product 68 formed per second) and kcat (s
-1
), shown in Table 4.1. 
 
As a solution phase control, p-nitrophenyl GlcNAc (PNP-GlcNAc) was transformed with 
β4GalT1 under the same conditions used for lipid 53 in vesicles (see Section 7.3.18 for 
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details). The p-nitrophenyl group allowed the monitoring of reaction rate again via HPLC 
(λmax = 300 nm, see Appendix). The soluble substrate reacted much faster than the vesicle-
embedded species; after 60 minutes the reaction approached 40% conversion, whereas it 
took over 8 hours to reach the same level of conversion for even the most active vesicle 
mixtures. The reaction was performed with PNP-GlcNAc concentrations of 15-600 μM 
(above this concentration the acceptor concentration approaches the donor concentration, 
reducing enzyme rate). The initial rate analysed using non-linear regression in Origin to 
give apparent Km, Vmax and kcat shown in Table 4.1.  
 
Substrate E/M Km / mM Vmax / Ms
-1 kcat / s
-1 
GlcNAc* n/a 10 - 3.6 
PNP-GlcNAc n/a 1.02 ± 0.22 (2.27 ± 0.39)×10-7 0.11 
GlcNAc-lipid 53 in 
DMPC 0.15 0.92 ± 0.13 (4.62 ± 0.54)×10-9 0.0021 
GlcNAc lipid 53 in 
DMPC/chol 1.5 0.18 ± 0.13 (4.08 ± 0.16) ×10-9 0.0019 
 
Table 4.1 Apparent Km, Vmax and kcat obtained from modification of GlcNAc-lipid 53 
concentration (non-linear regression of HPLC data). *Data taken from Ramasamy et al.
150
 
 
4.5 Conclusions 
 
The β4GalT1-catalysed galactosylation of the GlcNAc-functionalised lipid 53 was 
investigated at the vesicle membrane surface. This enzyme was an ideal candidate to study 
as there is a wealth of structural, mechanistic and kinetic information available about the 
enzyme acting upon a multitude of soluble GlcNAc forms. The enzyme is known to be 
inhibited by high substrate surface densities on microarray systems, but a detailed kinetic 
study into the effects of substrate crowding or indeed β4GalT1 simply acting on GlcNAc 
substrates bound to a surface is not present in the literature.  
 
GlcNAc-lipid 53 behaved similarly to mannosyl-lipids 49 and 51 in aqueous buffer; lipid 
53 self-assembled into higher structures, displaying a high E/M ratio (E/M = 20.9 at 20 
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μM) and a CAC value of 15.4 nM. As expected, when incorporated into phospholipid 
vesicles composed of DMPC (ld) at loadings of 1% mol/mol, lipid 53 was laterally 
dispersed in the membrane with a low E/M of 0.15.  In DMPC/chol (lo) and DPPC (so) 
vesicles GlcNAc-lipid 53 exhibited phase separation into clusters in the ordered 
membranes, with E/M ratios of 1.5 and 1.3 respectively. At higher loadings GlcNAc-lipid 
53 exhibited higher E/Ms in DMPC (0.18 and 1.5 at 2% and 8.7% mol/mol) due to 
increased pyrene collisional frequency brought about by a higher surface density. At higher 
loadings more extensive phase separation of GlcNAc-lipid 53 was observed in DMPC/chol 
(6.4% mol/mol, E/M = 3.5) and DPPC (8.5% mol/mol, E/M = 4.7). However full 
incorporation of 53 did not take place when aiming for a target of 10% mol/mol. Clustering 
of lipid 53 in GUVs was visualised directly using epifluorescence microscopy: Phase 
separated domains were observed in DMPC/chol and DPPC up to 50 μm in size, with 
slightly smaller domains observed in DPPC (10-20 μm). The rate of flip-flop was estimated 
at 1 hour in DMPC and 4 hours in DMPC/chol.  
 
Initial studies with buffered β4GalT1 containing 1% v/v TX-100 demonstrated that 
GlcNAc-lipid 53 was an adequate substrate when incorporated in phospholipid vesicles 
composed of DMPC, DMPC/chol and DPPC (at 8.7%, 6.4% and 8.5% mol/mol loading 
respectively), achieving 100% conversion to the LacNAc-lipid 68. However vesicle lysis 
was observed at this level of TX-100. Reducing the amount of TX-100 in the enzyme 
buffer to 0.05% v/v enabled vesicle stability whilst retaining catalytic activity, which may 
or may not have been lessened by the reduction in TX-100. A maximum of around 40% 
conversion was observed with vesicles composed of DMPC, DMPC/chol and DPPC with 
8.7%, 6.4% and 8.5% mol/mol loading 53 respectively, GlcNAc-lipid 53, after overnight 
incubation with β4GalT1 with 0.05% TX-100. Given that the flip-flop rate of 53 is in the 
order of a few hours, this low level of conversion may reflect denaturing of the enzyme 
over the course of the reaction or the availability of lipid 53 on the outer leaflet of the 
vesicle; as GlcNAc-lipid 53 is galactosylated it becomes more hydrophilic, therefore less 
likely to flip-flop to the inner leaflet. As only around 50% of the glycolipids exist in each 
leaflet, a reduced flip-flop rate would likely result in an asymmetric distribution of lipids 
across the membrane, with a higher concentration of LacNAc-lipids on the outer leaflet. 
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The rate of β4GalT1-catalysed galactosylation of vesicles at target loadings of 1 and 10% 
mol/mol loading of lipid 53 was measured using HPLC methodology. For each vesicle 
composition the rate of conversion was substantially reduced compared to the soluble 
substrate PNP-GlcNAc, most likely due to steric hindrance caused by the membrane 
surface. Comparing the rate of enzymatic conversion between lipid 53 in DMPC and 53 in 
DMPC/chol vesicles it was obvious that substrate clustering heavily influenced the enzyme 
rate. The rate of conversion was enhanced almost 10-fold when lipid 53 was clustered in 
DMPC/chol over being dispersed in DMPC at 1% mol/mol loading (Figure 4.18, a). 
Enzyme rate was also increased at the higher loadings (8.7%, 6.4% and 8.5% mol/mol 
loading in DMPC, DMPC/chol and DPPC respectively) (Figure 4.18, b), reflecting an 
enhancement brought about by increased surface density, an effect also observed by 
Mrksich and co-workers with GlcNAc-functionalised SAMs (Figure 4.5).
155
  
 
 
 
Figure 4.18 Conversion of 53 to 68 by β4GalT1. Comparison of rate in vesicles composed 
of DMPC (○) vs. DMPC/chol (●). b) Comparison of rate in vesicles composed of DMPC (1 
% mol/mol 53, ○, or 8.5 % mol/mol 53, □) and DMPC/chol (6.4 % mol/mol 53, ■). 
Increasing surface density by changing the loading enhanced enzyme rate, which was 
further enhanced by clustering of lipid 53 into rafts. 
 
Cluster-mediated enhancement was investigated with a series of experiments: 
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Kinetic assays were performed, varying the concentration of GlcNAc-lipid 53 and UDP-
Gal to give apparent Km, Vmax and kcat values. The Km values for UDP-Gal were 5-fold 
greater than the solution phase value, while Km for vesicle-bound GlcNAc-lipid 53 were at 
least 10-fold less than for GlcNAc in solution. A possible explanation is that interactions 
between the enzyme and the vesicle surface may have aided binding to membrane phase 
GlcNAc-lipid 53 while inhibiting binding to the solution phase UDP-Gal. 
 
Comparing the apparent kcat values in Table 4.1 it is clear that vesicle-embedded 53 was a 
poorer substrate for β4GalT1 than the soluble forms of GlcNAc, with around 50-fold fewer 
molecules converted to product per unit time compared to PNP-GlcNAc. This is possibly 
due to steric constraints at the membrane interface, an effect also observed with lectin 
binding (Chapter 3), and possibly caused by the substrate being withdrawn into the 
membrane (Figure 4.19). Furthermore the bound GlcNAc-lipid 53 gave the same kcat values 
with β4GalT1 regardless of it existing in clusters or dispersed through the membrane. 
However this is not reflected in the Km values, which indicate that the enzyme bound the 
dispersed GlcNAc-lipids with a similar affinity to the PNP-GlcNAc substrate, but 
clustering of the GlcNAc-lipids raised the affinity of 53 for β4GalT1 by 5-fold.  
 
This decrease in both Km and kcat of membrane-bound GlcNAc-lipid 53 compared to 
soluble GlcNAc are consistent with the observations of Ohno et al, who compared 
galactose oxidase activity on analogous substrates in solution and membrane phases. They 
ascribed the decrease in kcat to poor accessibility of the substrate when it is membrane 
embedded. This and other rate limiting factors such as low flip-flop rates for glycolipids 
with hydrophilic headgroups are likely to be the cause of the reduction in catalytic 
efficiency (kcat). 
 
It is possible that GlcNAc-lipid clustering in DPPC or DMPC/chol, or increased surface 
density in DMPC at 8.5% mol/mol, helped alleviate this reduction in kcat by providing an 
extended platform for β4GalT1 react upon. In this case, even though the GlcNAc-lipids 
may be somewhat withdrawn into the membrane, the substrates would not be crowded out 
by the phospholipids (Figure 4.19, b), allowing binding to take place. This is possibly the 
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cause of clustering of GlcNAc-lipids providing a 5-fold reduction in Km. In addition to 
increased accessibility, this reduction in Km could also reflect the association of β4GalT1 to 
multiple GlcNAc lipids through its oligosaccharide binding site. However, a statistical 
rebinding mechanism is also possible, where β4GalT1 converts a GlcNAc lipid 53 to 
LacNAc 68, is released, quickly acquires a UDP-Gal molecule then rebinds another 
GlcNAc-lipid 53 for conversion. 
 
 
 
Figure 4.19 Binding of β4GalT1 to membrane bound GlcNAc-lipid 53 dispersed (a) or 
clustered in rafts (b). Clustering of GlcNAc-lipids enhances enzymatic conversion by 
reducing the Km (i). In all cases kcat was reduced compared to solution as the GlcNAc 
headgroup was withdrawn into the membrane (ii).  
 
The identity of saccharide headgroups in the clusters was crucial for enzyme enhancement 
as galactosylation of „mixed rafts‟ of clustered GlcNAc 53 and Gal 47 lipids at 1 and 9% 
mol/mol loading respectively in DMPC/chol vesicles gave similar initial rates to GlcNAc-
lipid 53 in DMPC/chol alone at 1% mol/mol. This is consistent with studies by Pâquet et al, 
who found that GlcNAc/GlcNAc “antenna” oligosaccharides had lower Km and higher kcat 
values for β4GalT1 than mixed Gal/GlcNAc analogues.165  
 
4.5.1 Possible mechanism and future work 
 
Overall, confining the GlcNAc substrate to the membrane surface slowed the rate of 
enzymatic conversion (cf. kcat for 53 in vesicles vs. kcat for PNP-GlcNAc). In addition the 
Km decreased with membrane-bound 53 compared to PNP-GlcNAc, indicating faster 
association of β4GalT1 with GlcNAc substrates that are membrane-bound or decreased off-
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rates after galactosylation. This therefore is consistent with a mechanism that involves 
some association of the enzyme with the membrane surface, which would enhance Km 
through secondary interactions and decrease kcat as a result of this and slow off-rates caused 
by membrane-protein interactions. To confirm this further investigation would be needed: 
First the kinetic parameters (Km and kcat) of GlcNAc-lipid 53 suspended in buffer could be 
assessed. This would give the Km and kcat for 53 in the absence of any phospholipid 
membranes for a direct comparison to membrane-bound species. Secondly a more robust 
test of β4GalT1 association to the membrane would be needed, possibly by using FRET-
based titrations or ITC, which both could be used to measure the association constant of 
any β4GalT1-membrane interaction. 
 
The mechanism of the artificial raft enhancement of the rate of β4GalT1-catalysed 
galactosylation of 53 is unclear. The kcat for the conversion of 53 to 68 is very similar with 
1% mol/mol loading 53 in DMPC and DMPC/chol vesicles (kcat = 0.0021 and 0.0019 s
-1
 
respectively), whereas Km is increased almost 5-fold for 1% mol/mol 53 in DMPC/chol 
compared to 1% mol/mol 53 DMPC. Therefore any enhancement in the overall rate by the 
presentation of 53 in clusters is purely due to the difference in how the β4GalT1 protein 
binds to the GlcNAc-lipid 53. There are two plausible mechanisms which explain this 
behaviour: Statistical rebinding and the binding of multiple GlcNAc residues in a cluster by 
β4GalT1 through its oligosaccharide binding site. It is unlikely to involve a statistical 
rebinding mechanism, as after galactosylation β4GalT1 must first dissociate from the 
newly-formed LacNAc-lipid 68, then shed the UDP residue, bind another UDP-Gal from 
the bulk solution and then re-bind to another GlcNAc-lipid 53 on the same vesicle. To 
further investigate these mechanisms Km and kcat could be determined for 53 in „mixed 
rafts‟ composed of 53 and the lipid backbone 23 at various ratios of 53 to 23. Unlike for 
mixed rafts of GlcNAc-lipid 53 and Gal-lipid 47, no steric blocking by a non-substrate lipid 
would take place, allowing the GlcNAc-lipid 53 density in domains to be easily controlled.  
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5 Enzymatic sialylation of glycolipids at the vesicle membrane surface 
 
The following work presented was done in conjunction with 4
th
 year MChem student Susan 
Williamson in the Webb lab. *Indicates work done by the MChem student. 
 
Sialic acid containing oligosaccharides are commonly found at the termini of 
oligosaccharide sequences on glycoproteins or at the cell surface, where their primary 
function is as a cell marker.
1
 As they are often the sites of cellular attachment for viruses, 
bacteria and other foreign bodies, studying enzymatic sialylation is of importance in 
biochemical research. Lipid-linked oligosaccharides containing sialic acid are known as 
gangliosides and are built-up by transferase enzymes in the Golgi and at the membrane 
surface.
1
 Following enzymatic galactosylation of membrane-bound GlcNAc-lipids 53 by 
β4GalT1, it was thought that more complex oligosaccharide sequences such as the GM3 
epitope (Neu5Acα(2-3)Galβ(1-4)Glc) could be created at the membrane surface using 
successive enzymatic glycosylation. Sialic acid-displaying vesicle membranes would 
provide a more functional biomimetic surface and open up the possibility of studying 
interactions with Siglec-expressing cells and other sialic acid-binding organisms.
98
 
 
5.1 Trypanosoma cruzi 
 
Trypanosoma cruzi (T. cruzi) is a parasitic trypanosome endemic in Latin America that is 
the cause of Chagas disease, a condition that results in cardiomyopathy and digestive 
megasyndromes at the chronic stage of infection.
166, 167
 Around 40% of acute infections 
lead to cardiomyopathy, weakening of the heart muscle tissue, and is the primary cause of 
fatality. Around 8 million people in Latin America are affected.
167
 The parasite vector is the 
reduviid family of blood sucking insects, which are infested with the parasite. When the 
reduviid bug takes a blood meal it may defecate on the skin near the wound site, subsequent 
scratching of the bite causes the parasite to enter the bloodstream through the wound. At 
this stage T. cruzi exists in a trypomastigote form (long and worm-like) and has flagella to 
enable motility.
168
 Parasitic invasion of host cells occurs by means of sialic acid-
functionalised proteins binding to cell-surface antibodies on the host cell, after which the 
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parasite is endocytosed. T. cruzi then converts to the amastigote form (spherical), 
reproduces by mitosis until the host cell is full and converts back to trypomastigotes, 
resulting in release as the cell ruptures.
168
 The full life cycle is shown in Figure 5.1.
169
  
 
5.1.1 Trypanosoma cruzi trans-sialidase 
 
Although sialic acid is involved in the cell invasion process, T. cruzi is unable to synthesise 
its own, instead employing a membrane-bound trans-sialidase to transfer sialic acid from 
host cell glycoconjugates.
169
 The enzyme is an example of a trans-glycosidase, a reversible 
enzyme that removes the terminal saccharide of a particular oligosaccharide sequence and 
transfers it to a similar sequence. As the enzyme does not require an activated substrate, 
such as a UDP conjugate, the reaction is reversible. In a practical sense, trans-sialylation of 
a substrate is in equilibrium and the exact equilibrium position is controlled by the relative 
concentrations of the sialic acid „donor‟ and acceptor. Trypanosoma cruzi trans-sialidase 
(TcTS) has a high specificity for Galβ(1-4)Glc (Lac) and Galβ(1-4)GlcNAc (LacNAc) 
sequences, catalysing the formation of Neu5Acα(2-3)Galβ(1-4)Glc (or GlcNAc).170, 171 
 
 
 
Figure 5.1 Life-cycle of T. cruzi displaying each stage in the vector and host. The relative 
TcTS activity is shown, indicating increased activity during the infective stages.
169
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The catalytic domain of TcTS is a relatively small protein sequence (60-90 kDa), but larger 
aggregates (>400 kDa) are known to occur during the amastigote stage.
172
 The catalytic site 
is a wide flexible cleft close to the surface of the protein (Figure 5.2) and flexibility is 
reduced upon substrate binding.
173
 Upon binding into the active site the terminal sialic acid 
becomes strained into a boat conformation (Figure 5.2, b, i), allowing protonation by Asp59 
in the active site followed by nucleophilic attack by Tyr342 (Figure 5.2, b, ii), resulting in 
cleavage of the sialic acid from the oligosaccharide (Figure 5.2, b, iii). Transfer of enzyme-
bound sialic acid to lactose is effectively the reverse process of cleavage; Glu230 in the 
active site aids both steps by acting as a general base. 
 
  
 
Figure 5.2 T. cruzi trans-sialidase (TcTS) in complex with sialyl-lactose (a).
173
 Mechanism 
of sialic acid cleavage catalysed by TcTS (b)  first involving ring strain of the sialic acid 
residue (i) nucleophilic attack by Tyr342 (ii), then loss of the oligosaccharide (ROH, iii).
173
 
 
As TcTS is essential for T. cruzi to produce the sialyl-lactose containing cell markers 
required for the invasive process, the large majority of research is focused on inhibition of 
the enzyme.
174-176
 However the enzyme has also found use in chemoenzymatic 
oligosaccharide synthesis both in solution and at interfaces,
4
 as chemical sialylation is a 
b) a) 
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notoriously difficult process. As well as the sialylation of unfunctionalised substrates TcTS 
has been used to sialylate saccharide conjugated systems such as the glycopeptides 
presented by Campo et al (Scheme 5.1).
177
 The group used TcTS to attach sialic acid onto 
LacNAc-functionalised peptides, achieving up to 80% yield when using fetuin as a sialic 
acid donor. Fetuin is a heavily glycated protein, displaying many sialyl-lactose-terminated 
oligosaccharides on the proten surface.
178
 The group also observed sialylation of cyclic 
substrates, dubbed pseudo-oligosaccharides, that had been constructed using „click‟ 
chemistry.
179
 The group managed to achieve yields around 50-65% using 
methylumbelliferyl-sialic acid (MUNANA) as the sialic acid donor, which is known to be a 
good alternative to sialyl-lactose.
180, 181
 
 
 
 
Scheme 5.1 TcTS-catalysed sialylation of glycopeptides made by Campo et al.
177
 
 
Recent work in the Flitsch lab has focused on the enzymatic synthesis of carbohydrate 
arrays, building up oligosaccharides on SAM surfaces using transferase and 
transglycosidase enzymes.
4
 They have appended sialic acid onto LacNAc immobilised on 
SAMs and monitored the conversion using MALDI-ToF MS. The sensitivity of sialates 
towards MALDI conditions is known to be a problem when analysing the products formed, 
with degradation of analytes often observed, but the group has overcome this problem by 
methylating the carboxyl group of the sialic acid. This revealed conversions estimated at 
around 50% based on the MS peak intensity. Binding of fluorescently-stained Chinese 
hamster ovary (CHO) cells - expressing Siglecs at their cell surface - to the sialyl-lactose 
SAMs was also observed, demonstrating the biocompatibility of such surfaces. 
These examples highlight the broad substrate specificity of the enzyme with regards to the 
aglycone part of the substrate; flexibility in the enzymatic site allows a wide variety of 
species to dock and may allow catalysis of vesicle embedded lacto-lipids. 
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5.2 TcTS-mediated sialylation of vesicle-embedded lactose lipids 
 
It was envisaged that TcTS could be used to sialylate lactose or LacNAc sequences at the 
vesicle membrane interface to generate complex glycolipids. Furthermore, perfluoroalkyl 
lipid vesicle systems could be used to study the effects of lipid clustering upon the degree 
and rate of enzymatic transformation, in a similar way to β4GalT1-activity (Chapter 4). 
With these goals in mind lactose-lipid 55 was chosen, as Lactose is the natural substrate for 
TcTS and compound 55 was the more easily synthesised of the Lac-glycolipids (55 and 
57). If enzymatic sialylation was successful, TcTS could then be used in conjunction with 
β4GalT1 to build ganglioside sequences (such as GM3) in a biomimetic way at the 
membrane interface, solely using glycosyltransferase and transglycosidase enzymes. 
 
 
 
Scheme 5.2 TcTS-catalysed sialylation of Lac glycolipid 55. 
 
5.2.1 Lac-lipid behaviour in solution and in vesicles 
 
As with glycolipids 49, 51 and 53, the behaviour of Lac-lipid 55 in buffered solution was 
assessed. Lac-lipid 55 was suspended in phosphate bufer (20 μM 55, 100 mM phosphate 
buffer, pH 7.4 at 37 °C) by sonication of a thin lipid film. As for glycolipids 49, 51 and 53, 
Lac-lipid 55 self-assembled in aqueous buffer to give a high E/M ratio of 19.5. Plotting the 
E/M ratios after dilution vs. log[55] (Figure 5.3) gave a CAC of 49.5 nM. This value was 
similar to the other glycolipids, though around 3-fold higher than that of the other 
aminoethyl linked lipids, possibly due to increased aqueous solubility afforded by the 
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additional sugar in the headgroup. This also again suggested that the Lac-lipid 55 should be 
fully incorporated into the hydrophobic bilayer. 
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Figure 5.3 CAC determination: plot of E/M vs. log[lipid 55]. 
 
800 nm vesicles composed of DMPC, DMPC/chol or DPPC containing a target loading 1% 
or 10% mol/mol Lac-lipid 55 (200 μM 55, 2 or 20 mM total lipid, 100 mM phosphate 
buffer, pH 7.4) were synthesised using the extrusion method. As expected Lac-lipid 55 
exhibited little phase separation in DMPC membranes at 1% mol/mol loading (E/M = 
0.14). At 10% mol/mol in DMPC, Lac-lipid 55 exhibited an E/M of 0.96 as a result of 
higher surface density. In DMPC/chol (E/M = 1.3 and 4.1 at 1% and 10% mol/mol 
respectively) and DPPC (E/M = 1.0 and 2.6 at 1% and 10% mol/mol respectively) 
clustering of Lac-lipid 55 was observed. The exact loading at 10% mol/mol target loading 
was not confirmed, but the high E/M ratios indicated good incorporation.  
 
To establish the flip-flop rate of Lac-lipid 55 insertion experiments were performed using 
the same methodology GlcNAc-lipid 53. Using the same protocol Lac-lipid 55 was inserted 
into blank vesicles in phosphate buffer composed of DMPC, DMPC/chol or DPPC to give a 
loading of 1% mol/mol. Immediately after addition the E/M ratios dropped from 20.9 to 0.5 
in DMPC, 1.5 in DMPC/chol and 1.3 in DPPC as the lipids inserted and dispersed in the 
fluid phase membrane (Figure 5.5). The rate of the slower second decline corresponded to 
flip-flop half-lives of approximately t1/2 = 1.5 hours in DMPC, t1/2 = 7 hours in DMPC/chol 
and t1/2 = 5 hours in DPPC as the more rigid phases slowed the rate of flip-flop. The half-
lives are also longer for 55 than the monosaccharide lipids 49, 51 and 53, likely due to the 
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extra hydrophilicity caused by the extra OH groups hindering the transfer of the lipid 
through the hydrophobic core of the bilayer. Such lengthy flip-flop half-lives may also 
hinder the complete sialylation of Lac-lipids in DMPC/chol and DPPC membranes over 
shorter reaction times, but should allow for complete sialylation during an overnight 
enzymatic reaction. 
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Figure 5.4 Transverse diffusion of Lac-lipid 55 in DMPC (a), DMPC/chol (b) and DPPC 
(c) vesicles showing the decline in E/M over several hours. 
 
GUVs were again employed to visualise the clustering of Lac-lipid 55 directly (Figure 5.4). 
At 10% mol/mol loading, clustering was observed in GUVs composed of DMPC/chol 
DPPC, but not DMPC, in agreement with the E/M values of the LUVs. 
 
   
 
Figure 5.5 Epi-fluorescence microscopy of GUVs. 10% mol/mol 55 in DMPC (a), 
DMPC/chol (b) and DPPC (c). Scale bar = 40 μm.* 
 
 
 
 
a) b) c) 
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5.2.2 TcTS-mediated sialylation of Lac-lipids 
 
800 nm vesicles composed of DMPC, DMPC/chol and DPPC containing a target loading of 
10% mol/mol Lac-lipid 55 (200 μM 55, 2 mM total lipid, 100 mM phosphate buffer, pH 7.4 
at 37 °C) were synthesised by the extrusion method. Undiluted vesicle solution (100 μL) 
was then incubated with fetuin and TcTS solution and overnight at 37 °C. Either 1 mg 
fetuin (equivalent to 1.25 mM sialic acid)
182
 and 1 μL TcTS (est. 3.91 μM, 100 mM 
phosphate buffer, pH 7.4 at 37 °C) or 5 mg fetuin (equivalent to 6.0 mM sialic acid)
182
 and 
5 μL TcTS (est. 3.91 μM, 100 mM phosphate buffer, pH 7.4 at 37 °C) was used. The 
vesicles were stable under the reaction conditions (the vesicle solutions remained cloudy), 
which was likely aided by the lack of any co-solvent or surfactant in the enzyme buffer. 
MALDI-ToF MS and HPLC were performed on the non-purified vesicle mixtures using the 
same procedure outlined in Section 4.4.4 (see Section 7.3.18 for full details), which 
indicated partial sialylation of the Lac-lipid 55.  
 
MALDI-ToF analysis was hampered by the sensitivity of the product to the harsh ionising 
conditions of the MALDI laser.
4
 Initially 2,4,6-trihydroxyacetophenone (THAP) was used 
as the matrix in reflector-positive mode. However, no peak corresponding to the sialylated 
product was observed, with only the mono-sodium adduct of the stating lactose lipid 55 
(m/z 1124) and phospholipid monomers/dimers appearing. However under the linear-
positive mode (i.e. reflector mode off) a small peak at m/z 1437 corresponding to the di-
sodium sialylated product was observed, albeit with low signal to noise ratios (Figure 5.6). 
The small peak may have been interpreted as poor conversion – comparing peak heights 
gave around 7-9% conversion after overnight reaction – but as sialic acid residues are 
renowned to be unstable in MALDI-ToF conditions, the peak height may not reflect the 
true starting material/product ratios. 
 
Methylation of sialic acid-containing oligosaccharide sequences is known to stabilize these 
compounds under MALDI conditions,
4
 so the vesicle reaction mixtures were treated with 
MeI according to the method described by Powel and Harvey.
183
 Briefly, MeI (5 μL) was 
added to the vesicle mixtures (100 μL) after sialylation and vortex mixed. After 2 hours the 
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MeI was evaporated by warming the mixtures in a fume hood. The resulting solution was 
again analysed using MALDI-ToF in reflector positive and negative modes. This MALDI 
analysis and HPLC showed no peaks corresponding to methyl ester product or indeed 
starting material. Possibly the reactive MeI caused the degradation of the glycolipids. 
 
 
Figure 5.6 MALDI-ToF MS spectrum of Lac-lipid 55 in DMPC/chol vesicles (10% 
mol/mol loading) after fetuin (5 mg) and TcTS (5 μL) treatment. Peaks displayed are 55 
(+Na
+
, m/z 1124), DMPC dimer (+Na
+
, m/z 1377) and product 71 (+2Na
+
, m/z 1437).  
 
HPLC analysis of the non-methylated reaction mixture gave clearer results than MALDI 
analysis, with a good resolution of pyrene-containing peaks. Sialylation of the Lac-lipid 55 
resulted in a much more hydrophilic compound with a retention time of around 4.5 minutes 
compared to around 18 minutes for the starting Lac-lipid 55 (Figure 5.7).  
 
 
Figure 5.7 3D projection of HPLC trace displaying Lac-lipid 55 (18 mins) and sialylated 
product 71 (4.5 mins) in DPPC vesicles after fetuin (5 mg) and TcTS (5 μL) treatment.  
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As for enzymatic galactosylation of 53 by β4GalT1, the fraction of 55 converted to 71 was 
determined using the peak areas of the starting Lac-lipid 55 and sialylated product 71 
(Table 5.1). Low yields of around 8% sialylation were observed when using 1 mg fetuin 
(equivalent to 1.25 mM sialic acid) and 1 μL of TcTS (3.91 μM, 100 mM phosphate buffer, 
pH 7.4 at 37 °C), which was in agreement with the MALDI spectra. The yield increased to 
20-35% when using 5 mg fetuin (equivalent to 6.0 mM sialic acid) and 5 μL of TcTS 
solution (3.91 μM, 100 mM phosphate buffer, pH 7.4 at 37 °C). In both cases there was an 
excess of sialic acid available for transfer from fetuin; Lee et al estimated that 126 nmol 
sialic acid is available per mg of fetuin, corresponding to around 75% of the protein‟s total 
sialic acid.
182
 Therefore in the reaction mixture there was 1.25 mM and 6 mM sialic acid 
available with 1 mg and 5 mg fetuin respectively, around a 6-fold or 32-fold excess 
compared to 154 μM Lac-lipid 55 in the reaction mixture. It was likely that having a greater 
excess of sialic acid drove the reaction equilibrium towards the product. Nevertheless these 
initial reactions indicated that Lac-lipid 55 was an adequate substrate for TcTS. 
 
Vesicle composition E/M Fetuin (mg) TcTS (μL) % sialylation after 18 hours 
DMPC (10%) 0.96 1 1 8.5 
  5 5 34.8 
DMPC/chol (10%) 4.1 1 1 7.4 
  5 5 21.4 
DPPC (10%) 2.6 1 1 7.6 
  5 5 30.4 
 
Table 5.1 Percent sialylation of Lac-lipid 55 after reaction with TcTS and fetuin at 37 °C. 
The amount of TcTS and fetuin used is indicated.* 
 
Interestingly the extent of sialylation of Lac-lipid 55 differed little between the vesicle 
mixtures when using 1 mg of fetuin and 1 μL of TcTS solution. However at 5 mg of fetuin 
and 5 μL of TcTS solution more Lac-lipid was sialylated in DMPC vesicles, where little 
lipid clustering is observed, compared to the mixtures where Lac-lipid 55 exhibits phase 
separation.  
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5.3 Conclusions and future work 
 
Enzymatic sialylation of membrane-embedded lactose lipids, capable of phase separation in 
ordered phase membranes was catalysed by the trans-sialidase from Trypanosoma cruzi. 
The lactose lipid used for the study was aminoethyl linked Lac-lipid 55, which behaved 
similarly to the Man, Gal and GlcNAc lipids in aqueous solution and in vesicles. Lac-lipid 
55 self-assembled in phosphate buffer, with a CAC = 49.5 nM and E/M = 19.5 at 20 μM. 
Flip-flop half-lives were found to be slightly longer that the monosaccharide lipids 49, 51 
and 53, which may suggest the more hydrophilic disaccharide head-group retarded the rate 
of transfer through the hydrophobic centre of the membrane. 
 
Lac-lipid 55 also behaved as expected in phospholipid vesicles, displaying lateral clusters 
in ordered phase membranes at target loadings of 1% and 10% mol/mol, as evidenced by 
high E/M values (Table 5.1). Clustering was not observed in ld-phase DMPC membranes at 
1% mol/mol, but a higher E/M was observed at 10% mol/mol loading, possibly due to the 
increased pyrene-pyrene collisional frequency brought about by the higher surface density. 
Further evidence of Lac-lipid clustering was gained using GUVs; phase separated domains 
were observed in GUVs composed of DMPC/chol and DPPC but not DMPC. 
 
An initial investigation into the sialylation of Lac-lipid 55 embedded in phospholipid 
membranes was performed. Vesicles composed of DMPC, DMPC/chol and DPPC 
containing  a target loading of 10% mol/mol Lac-lipid 55 were sialylated using 1 mg fetuin 
(equivalent to 1.25 mM sialic acid)
182
 and 1 μL TcTS (est. 3.91 μM, 100 mM phosphate 
buffer, pH 7.4 at 37 °C) or 5 mg fetuin (equivalent to 6.0 mM sialic acid)
182
 and 5 μL TcTS 
(est. 3.91 μM, 100 mM phosphate buffer, pH 7.4 at 37 °C). The extent of sialylation was 
dependent upon the excess of sialic acid available for transfer, with a 6-fold (1 mg fetuin) 
and 32-fold (5 mg fetuin) excess of sialic acid producing conversions in the range of 8% 
and 25-35% respectively. This maybe reflects the reversible nature of the trans-sialidase-
catalysed process with higher donor concentrations pushing the equilibrium towards 
sialylated-acceptor (Figure 5.8, ii). In future experiments it may be prudent to use 
MUNANA as a sialic acid donor, as the methyl-umbelliferyl side product is not a substrate 
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for TcTS, removing it from the equilibrium.
180, 181
 Therefore, with excesses of donor it may 
be possible to drive the equilibrium position fully to sialylated product 71. 
 
 
 
Figure 5.8 Higher concentrations (ii) of the fetuin donor help push the equilibrium towards 
the product lipid over lower concentrations (i). 
 
It should be stressed that the extent of conversion of lipid 55 to 71 after 18 hours is not an 
indicator of the rate of enzymatic sialylation. It also may not be the final equilibrium value 
for the reaction. In order to draw solid conclusions as to whether clustering of lipid 55 has 
an effect on the initial rate or final equilibrium position, further experiments would be 
needed in the form of [71] formed vs. time, similar to that for the β4GalT1-catalysed 
galacosylation of GlcNAc-lipid 53. The initial rate of product formation for reversible 
enzyme catalysed reactions can still be determined even though the reaction is reversible; 
during the first stages of the reaction [Product] = 0, so the initial rate is purely the 
formation of product, with little of the reverse reaction.
149
 The final equilibrium 
concentrations of 55 and 71 could also be used to calculate the equilibrium constant for the 
reaction according to Equation 5.1.
149
 The final equilibrium position and initial rate could 
be compared between 55 clustered and dispersed in the membrane, giving an indication of 
the effect of clustering on the enzyme activity. 
 
   
            
            
                 
 
Unlike β4GalT1 displaying enhanced rates for GlcNAc oligosaccharides, TcTS does not 
demonstrate higher activity for Lac-terminated oligosaccharide sequences over Lac.
170, 184
 
Therefore, clustering of Lac-lipid 55 may not enhance enzyme rate in a mechanism where 
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multiple Lac headgroups are bound at the active site, but may increase activity through a 
statistical rebinding effect.  
 
HPLC proved to be the most reliable method of analysis, but unambiguous identification of 
the product was difficult, because MALDI-ToF and methylation of the sialyl-lactose 
product in the reaction mixture to give a stronger signal was unsuccessful. For future 
studies it will be necessary to confirm the identity of the product peak and methylation 
could be performed upon sialyl-lactose lipids purified using semi-preparative or preparative 
HPLC and characterised by NMR and MALDI.  
 
The product 71 from the TcTS-catalysed transformation has a Neu5Acα(2-3)Galβ(1-4)Glc 
group, which is an oligosaccharide epitope (GM3) that is involved in many biological 
processes, including flu binding.
1, 2
 This makes it an ideal target for the model vesicle 
system described. Furthermore, the ability to induce clustering of the perfluoroalkyl-based 
lipids opens up the possibility of studying the effects of target lipid clustering on vesicle 
binding and targeting of cells that display Siglecs at their surfaces. 
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6.1 Conclusions 
 
The main goal of the project was to create vesicle systems that displayed an artificial 
glycocalyx at the membrane surface. Elaborating previous work in the Webb group into 
fluorinated lipids capable of lateral phase separation in ordered-phase membranes,
77
 lipids 
47, 49, 51, 53, 55 and 57 were synthesised. As anticipated, lateral phase separation of these 
glycolipids in the bilayer was observed in lo-phase DMPC/chol mixtures and so-phase 
DPPC and DSPC, as evidenced by high E/M ratios. These glycolipids possessed Gal (47), 
Man (49, 51), GlcNAc (53) and Lac (55, 57) headgroups to allow the study of a variety of 
biological processes involving carbohydrates at the membrane surface in a biomimetic 
environment. Two such processes were studied in detail: The effect of lateral phase 
separation of mannosyl-lipids 49 and 51 on the binding of concanavalin A (ConA) and the 
effect of lateral phase separation of GlcNAc-lipid 53 on the rate of β4GalT1-catalysed 
galactosylation. 
 
ConA caused the fluorescence quenching of pyrene containing mannosyl-lipids 49 and 51, 
which had both negative and positive connotations. It hindered the accurate study of the 
effect of ConA binding upon lipid clustering (an effect studied by Sasaki and co-workers)
74
, 
as quenching of monomer and excimer fluorescence was not equal, which affected the E/M 
value. However accurate determination of ConA affinity for membrane-bound lipids 49 and 
51 was possible using fluorescence quenching assays, which allowed for a comparison 
between clustered and dispersed mannosyl-lipids. It was found that ConA affinity for 
membrane-bound lipids 49 and 51 was diminished around 3-fold compared to binding to 49 
and 51 in solution. This perhaps reflected steric blocking from the surface. At 1% mol/mol 
49 or 51 lipid clustering had little effect upon the observed affinity of the ConA-mannosyl-
lipid interaction. This suggested that a cluster glycoside effect (chelation or statistical 
rebinding) was not in operation, possibly inhibited due to steric blocking by the congestion 
of mannosyl-lipids in clustered domains. Nonetheless, increasing the membrane loading to 
5% mol/mol in DMPC increased ConA affinity by up to 75%, which indicated the presence 
of either an intramembrane chelation (of 2-3 ConA CRDs per vesicle) or statistical 
rebinding mode. In hindsight, this modest increase in affinity for a 5-fold increase in 
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membrane loading is not surprising given the geometric arrangement of ConA binding 
sites; a multivalent ligand would have to span the 6.5 nm distance between the binding 
sites. Furthermore, as the binding sites are arranged at the corners of a tetrahedron, after the 
first mannosyl-lipid is bound, the second binding site is angled at 109° to the first, i.e. 
pointing away from the membrane surface. This results in intermembrane binding (to a 
mannosyl-lipid in an adjacent vesicle) being favoured over intramembrane binding (to 
another mannosyl-lipid on the same vesicle) regardless of lipid clustering, and is evidenced 
by the extensive aggregation observed. Perhaps an affinity enhancement through a 
chelation binding mode could be observed between vesicle-bound glycolipids and lectins 
which provide adjacent and directionally-aligned binding sites. 
 
In a similar way to ConA binding to membrane-bound mannosyl-lipids, galactosylation of 
membrane-bound GlcNAc-lipid 53 by β4GalT1 was inhibited, likely due to steric blocking 
by the membrane. However, unlike ConA binding to membrane-bound mannosyl-lipids, the 
rate of galactosylation of GlcNAc-lipid 53 by β4GalT1 was found to be influenced by both 
surface density and lipid clustering. Surface density was increased by raising the membrane 
loading of 53 from 1% to 8.5% mol/mol in DMPC, whilst keeping the bulk concentration 
of 53 constant, which gave an increase in rate of approximately 10-fold. A similar 
enhancement in rate was observed for lipid clustering; 53 in DMPC/chol at 1% mol/mol 
loading (E/M = 1.5) was galactosylated around 9-fold faster than 53 in DMPC at 1% 
mol/mol (E/M = 0.15). Michaelis-Menten analysis on the galactosylation of 53 in DMPC 
and DMPC/chol membranes at 1% mol/mol revealed that lipid 53 clustering increased the 
rate by enhancing Km (kcat was the same between these mixtures). Therefore, any 
enhancement in rate caused by 53 clustering is purely due to how β4GalT1 bound the lipid. 
A mechanism whereby β4GalT1 binds to multiple clustered GlcNAc lipids through its 
oligosaccharide binding site is proposed, but further experiments are needed to confirm 
this. 
 
A preliminary investigation of TcTS-catalysed sialylation of membrane-bound Lac-lipid 55 
was made. Initial results suggest that clustering of 55 may enhance the rate or influence the 
final equilibrium value; percent sialylation after 18 hours was slightly higher for 55 
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dispersed in DMPC vesicles compared to clustered 55 in DMPC/chol. This may indicate 
that clustering inhibits TcTS-catalysed sialylation, but as this is only a single time point 
further experiments are needed to confirm this.  
 
It is interesting to note how each protein presented herein has responded to glycolipid 
clustering. Perhaps the appearance (or lack) of an enhancement of protein action upon 
glycolipid clusters is a reflection of their natural functions. For instance, soluble plant 
lectins are thought to be a defence against predators that act by agglutinating cells; their 
multivalent arrangement of binding sites maximise these intercellular links. As a 
consequence intracellular binding modes may be disfavoured. This behaviour is reflected in 
the binding of ConA to vesicle-bound mannosyl-lipid 49 and 51 and could imply that 
glycolipids located in lipid rafts may not necessarily be preorganised for multivalent 
intracellular binding. Furthermore, clustering of glycolipids may be a mechanism of 
enhancing enzyme rate in vivo. 
 
6.2 Future work 
 
Further experimentation is required to elucidate the exact mechanism of the influence of 
GlcNAc clustering on the rate of galactosylation of GlcNAc-lipid 53 by β4GalT1. The 
affinity of any interaction of β4GalT1 with the phospholipid membrane should be measured 
and the Michaelis-Menten kinetic parameters could also be determined for other membrane 
loadings, „mixed rafts‟ and the free lipid 53 in solution. The sialylation of Lac-lipid 55 or 
triethylene glycol-linked Lac-lipid 57 by TcTS also requires further study. Firstly the 
identity of the product peak 71 should be confirmed, possibly by purification from vesicles 
by semi-preparative-HPLC followed by NMR or MALDI-ToF analysis; methylation of the 
isolated product should be easier in the absence of enzyme, fetuin and buffer. Secondly the 
rate and final percent conversion of the TcTS-catalysed sialylation should be measured with 
a series of HPLC-based rate experiments. The Michaelis-Menten kinetic parameters could 
also be determined for a robust comparison of TcTS-catalysed sialylation of clustered and 
dispersed membrane-bound Lac-lipids. 
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The experimental procedures presented in this thesis represent the development and 
application of a vesicle-based system for the biomimetic study of the effects of raft 
formation upon lectin binding and enzymatic glycosylation. To assess whether the effects 
of glycolipid clustering presented herein are general phenomena observed with lectin 
binding or enzymatic glycosylation, or are exclusive to ConA and β4GalT1, further 
experimentation with more lectin/enzyme-glycolipid pairs is necessary. HPLC 
methodology (as employed for the study of β4GalT1-catalysed galactosylation) in 
particular could be easily applied to other enzyme-glycolipid pairs, such as 
fucosyltransferases, sialyltransferases and mannosyltransferases.
185, 186
  
 
Vesicles are well-known for their drug delivery potential in nanomedicine research, 
however effective and selective targeting remains a challenge.
16
 Recent work joint between 
the Webb and Gough group demonstrated that biotin-functionalised vesicles are stable in 
vitro under cell culture conditions.
187
 The vesicles were found to bind to fibroblast 
membranes; the attachment was mediated by biotin interactions with the cell surface 
receptors. The release of contents of gel-embedded vesicles using a non-invasive magnetic 
trigger has also been reported.
188
 Using vesicle platforms labelled with oligosaccharide 
headgroups, built by successive enzymatic glycosylations, specific cell types could be 
targeted by these systems. 
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7.1 General methods and materials 
 
Unless otherwise stated, all reagents and solvents were obtained from standard commercial 
suppliers (Sigma-Aldrich, Fluka, TCI or Acros). Anhydrous DMF (99.8% purity) and THF 
(99.8% purity) were obtained from Sigma-Aldrich. Anhydrous CH2Cl2 was obtained by 
distillation over CaH. Anhydrous THF was obtained by distillation over 
sodium/benzophenone ketyl. Anhydrous chloroform was obtained by drying over activated 
(by oven heating) 4Ǻ molecular sieves. Spectrophotometric grade chloroform (>99.8% 
purity with amylenes as stabiliser) was obtained from Sigma-Aldrich for UV-vis and 
fluorescence spectroscopy. DSPC and DPPC were purchased from Avanti Polar Lipids Inc. 
DMPC was purchased from Fluka. PD-10 gel permeation chromatography (GPC) columns 
and HiTrap Ni
2+
-affinity columns were purchased from GE Healthcare. Vivaspin 500 
ultrafiltration vials were obtained from Sartorius Stedin Biotech. UDP-Gal was bought 
from Carbosynth Ltd as the disodium salt. NHS-fluorescein was obtained from Thermo 
Scientific. Fetuin from fetal calf serum was obtained from Sigma-Aldrich. 
 
ConA was obtained from Merck (Calbiochem). FITC-conjugated ConA was obtained from 
Sigma-Aldrich. FITC-conjugated lectins ECL and WGA were both kind donations from 
GALAB Technologies. Bovine β-(1,4)-galactosyltransferase (β4GalT1) was expressed by 
Josef Voglmeir (University of Life Science, Vienna) from bovine CDNA cloned by 
Dubravko Rendic (University of Life Science, Vienna) in E. coli. Trypanosoma cruzi trans-
sialidase (TcTS) was expressed by Sara Kaloo (University of Manchester) in E. coli. 
 
NMR spectra were recorded using Bruker DPX 300, 400 and 500 instruments in deuterated 
solvents (CDCl3, CD3OD, acetone-d6 or DMF-d7), calibrated to the tetramethysilane (δ = 0 
ppm) or the NMR solvent trace,
189
 and assigned with the aid of 
1
H, 
13
C, COSY, DEPT 135 
and HMQC. Coupling constants are in Hertz (Hz) and multiplicities indicated with the 
appropriate abbreviations: singlet (s), doublet (d), triplet (t), double doublet (dd) double 
double doublet (ddd) and multiplet (m). Mass spectra (ES and HRMS) were taken using 
Micromass Prospec and Micromass Platform spectrometers. MALDI-ToF mass spectra 
were taken using a Bruker Ultraflex II ToF/ToF instrument. IR spectra were taken with a 
7. Experimental Procedures 
 
170 
 
Bruker Alpha-P. Optical rotations were taken using an AA-100 polarimeter from Optical 
Activity Ltd.  
 
For the purposes of structural assignment/nomenclature saccharides were numbered 
according to Figure 7.1. 
 
 
 
Figure 7.1 Nomenclature for mono and disaccharide carbon skeletons. 
 
LUVs were synthesised by extrusion through LipsoFast polycarbonate membranes. GUVs 
were synthesised using an Agilent 33210A 10 MHz function arbitrary waveform generator. 
UV-vis spectroscopy was carried out using a Jasco V-660 Spectrophotometer measuring a 
200-800 nm range at 400 nm/min. Fluorescence spectra were taken using a Perkin Elmer 
LS55 Luminescence Spectrometer with an attached Julabo F25 waterbath. Fluorescence 
microscopy was carried out using a Ziess Axio Imager A1 and pictures taken using a Canon 
Powershot G6 digital camera. Isothermal titration calorimetry was carried out using a 
Microcal VP-ITC calorimeter. DLS measurements were taken using a Wyatt technologies 
DynaPro Dynamic Light Scattering system. Analytical HPLC data were obtained using an 
Agilent 1200 series LC system with an attached G1315B diode-array detector (DAD). 
LC/MS measurements were made using an Agilent 110 series LC system with an attached 
G1315B DAD and G1956B LC/MSD SL unit. HPLC and LC/MS experiments were carried 
out using a Phenomenex Luna C18 column (250 × 2 mm, 5 μm) or a Machery-Nagel 
Nucleosil 100-5 C18 column (250 4.6 mm, 5 μm) with HPLC grade solvents from Fisher 
Scientific. 
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7.2 Synthesis 
 
7.2.1 General synthetic methods 
 
7.2.1.1 Hydrogenation of CBz-protected aminoethyl-linked sugars – General method 1 
 
CBz-protected aminoethyl sugar was dissolved in ethanol and 10% palladium hydroxide on 
carbon (0.1 eq.) was added. A rubber stopper was used to plug the flask. The mixture was 
stirred under N2 for 5 minutes, then flushed using a balloon of H2 and stirred under H2 for 
30-60 minutes. The H2 balloon was removed and the reaction was filtered over Celite, 
washing with EtOH. The EtOH was then evaporated under vacuum to yield the free 
aminoethyl sugar. 
 
7.2.1.2 Coupling of aminoethyl-linked sugar to perfluoroalkyl pyrene backbone 23 – 
General method 2 
190
  
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ylmethoxy)-decyloxy)-acetic 
acid (23, 1 eq.), dicyclohexylcarbodiimide (DCC, 1.3 eq.) and N-hydroxysuccinimide 
(NHS, 1.3 eq.) were dissolved in dry CH2Cl2 under N2. The solution was left to stir for 3 
hours at room temperature, after which time a milky white precipitate had formed. The 
reaction mixture was filtered through cotton wool to remove the dicyclohexylcarbourea 
DCU precipitate and aminoethyl-linked sugar or aminotriethylene glycol-linked sugar (1.2-
2.0 eq.) was added in dry CH2Cl2 (1 mL). The mixture was stirred under N2 overnight. The 
mixture was filtered again and the CH2Cl2 was evaporated under reduced pressure. The 
crude mixture was then purified using flash column chromatography (first 19:1 
CHCl3/MeOH on silica, then 3:2:1 ethyl acetate/chloroform/cyclohexane on silica followed 
by MeOH flush to recover the product (see section 2.2.3 for details)) to yield the desired 
acetyl protected glycolipid. 
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7.2.1.3 Deacetylation of acetyl-protected glycolipids – General method 3 93  
 
Acetyl-protected glycolipid was dissolved in methanol (2 mL). NaOMe/MeOH solution 
(15% w/v, 0.2 mL) was then added slowly to the stirring lipid solution, and the mixture 
stirred for 30 minutes. Ion-exchange resin (Amberlite IR-120) was then added until the 
solution reached pH 7. The resin was then filtered off through cotton wool and the ethanol 
removed under reduced pressure to yield the deprotected glycolipid. 
 
7.2.2 Synthesis and analytical data of compounds 
 
Where referenced, synthetic procedures are modified from literature protocols. 
 
Bromomethylpyrene (20)
191
 
 
Pyrene methanol (700 mg, 3.01 mmol, 1 eq.) and pyridine (120 µL, 1.51 mmol, 0.5 eq.) 
were dissolved in chloroform (10 mL). Phosphorous tribromide (0.28 mL, 3.01 mmol, 1 
eq.) was dissolved in chloroform (2 mL) and slowly added dropwise over 20 minutes to the 
stirring pyrene methanol solution, then stirred for a further 4 hours. The reaction was then 
quenched with sat. NaHCO3 (5 mL) and the organic phase was washed a further three times 
with sat. NaHCO3 (3 × 10 mL). The organic phase was then dried over anhydrous MgSO4 
and the solvent removed under reduced pressure to yield a yellow powder (845.9 mg, 95%); 
TLC Rf 0.27 (1:2 ethyl acetate/cyclohexane); 
1
H NMR (400 MHz, CDCl3, 25 °C) : δH 5.24 
(2H, s, ArCH2Br), 7.98 – 8.09 (5H, m, 5 × ArH), 8.19–8.24 (3H, m, 3 × ArH), 8.35 (1H, d, 
3
J (H,H) = 8 Hz, ArH); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 32.7 (ArCH2Br), 123.2 
(CH), 125.0 (C), 125.2 (CH), 125.5 (C), 126.0 (2 × CH), 126.6 (CH), 127.7 (CH), 128.0 
(CH), 128.4 (CH), 128.6 (CH), 129.4 (C), 130.9 (C), 131.1 (C), 131.6 (C), 132.3 (C); MS 
(ES
+
)  m/z 215.1 [M-Br]
+
 (100%), 216.1 [M-Br+H]
2+
 (27%). 
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 (2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ylmethoxy)-decanol (22)
77
 
 
Sodium hydride (solid) (91.5 mg, 3.813 mmol, 1.5 eq.) was dissolved in dry DMF (5 
mL) in a 3-necked round bottom flask. The solution was stirred under nitrogen for 5 
minutes. 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-1,10-diol (2.16 g, 5 mmol, 3 eq) 
in dry DMF (5 mL) was then added to the stirring solution and the mixture was stirred 
for a further 10 minutes, then the mixture was then cooled to 0 ºC. Bromomethylpyrene 
20 (460 mg, 1.556 mmol, 1 eq.) in dry DMF (5 mL) was then added dropwise and the 
solution stirred over 24 hours. The DMF was then evaporated using a high vacuum 
rotary evaporator and the crude product dissolved in ethyl acetate (30 mL), washed 
twice with water (2 × 10 mL), followed by saturated brine solution (10 mL). The 
organic layers were combined, dried over magnesium sulphate and the solvent removed. 
The product was then purified using column chromatography (2:7 ethyl 
acetate/cyclohexane on silica) to yield a yellow solid (744 mg, 71%); TLC Rf 0.35 (1:2 
ethyl acetate/cyclohexane); 
1
H NMR (400 MHz, acetone-d6, 25 °C) : δH 4.17 (2H, t, 
3
J 
(H,F) = 14.0 Hz, CF2CH2OAr), 4.37 (2H, t, 
3
J (H,F) = 14.0 Hz, CF2CH2OH), 5.23 (1H, 
t, 
3
J (H,H) = 7.0 Hz, CH2OH), 5.52 (2H, s, CH2Ar), 8.11-8.47 (9H, m, 9 × ArH); 
13
C 
NMR (100 MHz, acetone-d6, 25 °C) : δC 61.0 (t, 
2
J (C,F) = 25.5 Hz, CF2CH2OH), 67.9 
(t, 
2
J (C,F) = 25.2 Hz, CF2CH2OAr), 73.7 (CH2Ar), 105-123 (weak m, 8 × CF2) 124.6 
(CH), 125.1 (C), 125.8 (C), 125.9 (CH), 126.7 (2 × CH), 127.5 (CH), 128.6 (CH), 128.7 
(CH), 129.0 (CH), 129.1 (CH), 130.8 (C), 131.5 (C), 132.1 (C), 132.6 (C), 132.9 (C); 
MS (ES
-
) m/z 721.4 [M+64] (100%), 676.2 [M-H]
-
 (12%); IR υ (cm-1) 1142, 1201, 
1367, 1739, 2970, 3032, 3359; Anal. Calc. for C27H16F16O2 C 47.94, H 2.37, found C 
43.15, H 1.97. 
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(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ylmethoxy)-decyloxy)-acetic 
acid (23)
52
 
 
(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ylmethoxy)-decanol 22 (300 
mg, 0.446 mmol, 1 eq.) in dry THF (2 mL) was added dropwise to a slurry of sodium 
hydride (50 mg, 2.083 mmol, 5 eq.) in dry THF (3 mL) and the mixture then stirred for 10 
minutes. Bromoacetic acid (133 mg, 0.957 mmol, 2 eq.) in dry THF (3 mL) was added 
dropwise and the mixture stirred for 72 hours. HCl (1 M) was then added cautiously until 
the NaH was quenched and the THF was removed using a rotary evaporator. The product 
was then extracted from the acidic solution by washing with ethyl acetate (3 × 10 mL). The 
organic layers were combined, washed again with HCl (1 M, 10 mL), dried over anhydrous 
magnesium sulphate and evaporated under vacuum to yield a yellow solid (302 mg, 92%); 
TLC Rf 0.26 (acetone); 
1
H NMR (400 MHz, acetone-d6, 25 °C) : δH 4.15 (2H, t, 
3
J (H,F) = 
14.0 Hz, CF2CH2), 4.17 (2H, t, 
3
J (H,F) = 14.0 Hz, CF2CH2), 4.19 (2H, s, OCH2CO2H), 
5.26 (2H, s, CH2Ar), 8.00-8.20 (9H, m, 9 × ArH); 
13
C NMR (100 MHz, acetone-d6, 25 °C) 
: δC 67.9 (t,
 2
J (C,F) = 25.4 Hz, CF2CH2), 68.6 (t,
 2
J (C,F) = 25.4 Hz, CF2CH2), 69.5 
(CH2Ar), 73.7 (OCH2CO2H), 106-122 (weak, 8 × CF2, m) 124.6 (CH), 125.7 (C), 125.8 
(CH), 125.9 (C), 126.7 (2 × CH), 127.5 (CH), 128.6 (2 × CH), 128.9 (CH), 129.1 (CH), 
130.7 (C), 131.4 (C), 132.1 (C), 132.5 (C), 132.9 (C), 171.5 (CO); MS (ES
-
) m/z 734.3 [M]
-
 
(29%), 733.3 [M-H]
-
 (100%); IR υ (cm-1) 1126, 1142, 1203, 1366, 1726, 2579, 2970-3027; 
Anal. Calc. for C29H18F16O4 C 47.42, H 2.45, found C 47.35, H 2.08. 
 
2,3,4,6-tetra-O-acetyl-1-(2-benzyloxycarbonylamino-ethoxy)-galactose (31)
192
 
 
Pentaacetyl galactose 30 (500 mg, 1.28 mmol) and N-Z-ethanolamine (300 mg, 1.54 mmol, 
1.2 eq.) were dissolved in dry dichloromethane (15 mL). The solution was cooled to 0 °C, 
stirred under N2 and BF3.Et2O (0.5 mL, 4.81 mmol, 3.1 eq.) was added dropwise. The 
reaction was stirred overnight. The reaction was then quenched with Et3N (1 mL) and the 
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solvent evaporated. The crude mixture was then acetylated using Ac2O (3 mL) and pyridine 
(9 mL) for 1 hour and the solution was evaporated. The product was purified using column 
chromatography (4:6 ethyl acetate/40-60 °C petroleum ether on silica) to yield a clear oil 
(399 mg, 59%); TLC Rf 0.53 (4:6 ethyl acetate/40-60 °C petroleum ether); 
1
H NMR (500 
MHz, CDCl3, 25 °C) : δH 1.90 (3H, s, Ac CH3), 1.93 (3H, s, Ac CH3), 1.95 (3H, s, Ac 
CH3), 2.07 (3H, s, Ac CH3), 3.32 (2H, m, CH2NHCBz), 3.62 (1H, ddd, 
3
J (H,H) = 3.6, 7.1 
10.2 Hz, OCHaHbCH2), 3.80-3.82 (2H, m, OCHaHbCH2 and CH-5), 4.03-4.07 (2H, m, CH2-
6), 4.38 (1H, d, 
3
J (H,H) = 7.9 Hz, CH-1), 4.93 (1H, dd, 
3
J (H,H) = 3.4, 10.5 Hz, CH-3), 
5.02 (2H, s, Ar-CH2), 5.10 (1H, dd, 
3
J (H,H) = 8.0, 10.4 Hz, CH-2), 5.19 (1H, t, 
3
J (H,H) = 
5.4 Hz, NHCBz), 5.31 (1H, dd, 
3
J (H,H) = 0.7, 3.4 Hz, CH-4), 7.25 (5H, m, Ar-H); 
13
C 
NMR (126 MHz, CDCl3, 25 °C) : δC 20.5-20.7 (4 × Ac CH3), 40.8 (CH2NH), 61.3 (CH2-6), 
66.7 (Ar-CH2), 67.0 (CH-4), 68.8 (CH-2), 69.4 (CH2CH2NH), 70.7 (2 × CH (CH-3, CH-
5)), 101.5 (CH-1), 128.2-128.5 (5 × Ar CH), 136.5 (Ar C), 156.3 (Ar CO), 169.6-170.4 (4 × 
Ac CO); MS (ES
+
) m/z 549.6 [M+Na+H]
2+
 (28%), 526.6 [M+H]
+
 (100%); HRMS (ES
+
) 
m/z calculated for [C24H31NO12Na]
+
 expected 548.1738, found 548.1747; IR υ (cm
-1
) 1042, 
1214, 1366, 1709, 1745, 2943, 3378. 
 
2,3,4,6-tetra-O-acetyl-1-(2-amino-ethoxy)-galactose (24)
193
 
 
 2,3,4,6-Tetraacetyl-2-(2-benzyloxycarbonylamino-ethoxy)-galactose (31, 100 mg, 0.19 
mmol) was deprotected using the general method for CBz removal (general method 1) to 
yield a clear oil (73 mg, 99%); TLC Rf 0.0 (4:6 ethyl acetate/40-60 °C petroleum ether); 
1
H 
NMR (500 MHz, CDCl3, 25 °C) : δH 1.96 (3H, s, Ac CH3), 2.02 (3H, s, Ac CH3), 2.04 (3H, 
s, Ac CH3), 2.13 (3H, s, Ac CH3), 2.79-2.82 (1H, m, CHaHbNH2), 2.84-2.91 (1H, m, 
CHaHbNH2), 3.14-3.17 (2H, bs, NH2), 3.58 (1H, ddd, 
3
J (H,H) = 3.8, 7.2, 10.0 Hz, 
OCHaHbCH2), 3.86-3.91 (2H, m, OCHaHbCH2 and H-5), 4.08-4.17 (2H, m, CH2-6), 4.48 
(1H, d, 
3
J (H,H) = 8.0 Hz, H-1), 5.00 (1H, dd 
3
J (H,H) = 3.4, 10.5 Hz, H-3), 5.18 (1H, dd, 
3
J (H,H) = 8.0, 10.4 Hz, CH-2), 5.37 (1H, dd, 
3
J (H,H) = 0.7, 3.3 Hz, H-4); 
13
C NMR (126 
MHz, CDCl3, 25 °C) : δC 20.5-20.8 (4 × Ac CH3), 41.5 (CH2NH2), 61.3 (CH2-6), 67.0 (CH-
4), 68.8 (CH-2), 70.5 (2 × CH (CH-3, CH-5)), 72.1 (CH2CH2NH2), 101.5 (CH-1), 169.6-
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170.4 (4 × CO); MS (ES
+
) m/z 392.1 [M+H]
+
 (100%); HRMS (ES
+
) m/z calculated for 
[C16H26NO10]
+
 expected 392.1556, found 392.1567; IR υ (cm
-1
) 1054, 1225, 1371, 1740, 
2343, 2853, 2924. 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-galactopyranosyl-ethyl)-acetamide (46) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-galactopyranosyl-ethyl)-acetamide (46) was synthesized according 
to the general method for DCC/NHS coupling (general method 2) using 1.4 equivalents of 
2,3,4,6-tetra-O-acetyl-1-(2-amino-ethoxy)-galactose (24) to yield a light-yellow solid (52 
mg, 78%); TLC Rf 0.25 (3:2:1 ethyl acetate/chloroform/cyclohexane); 
1
H NMR (400 MHz, 
CDCl3, 25 °C) : δH 1.98 (3H, s, Ac CH3), 2.03 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 2.13 
(3H, s, Ac CH3), 3.47-3.50 (2H, m, CH2NH), 3.69 (1H, ddd, 
3
J (H,H) = 3.6, 7.1, 10.6 Hz, 
OCHaHbCH2), 3.86-3.91 (2 H, m, OCHaHbCH2 and H-5), 4.01 (2H, t, 
3
J (H,F) = 14.0 Hz, 
CH2CF2), 4.06 (2H, t, 
3
J (H,F) = 14.2 Hz, CH2CF2), 4.09–4.15 (4H, m, CH2CONH, CH2-6), 
4.47 (1H, d, 
3
J (H,H) = 7.9 Hz, CH-1), 5.00 (1H, dd, 
3
J (H,H) = 3.4, 10.5 Hz, CH-3), 5.19 
(1H, dd, 
3
J (H,H) = 7.9, 10.5 Hz, CH-2), 5.39 (3H, m, Ar-CH2, CH-4), 6.75 (1H, t,
 3
J (H,H) 
= 5.6 Hz, CONH), 7.97-8.34 (9H, m, 9 × Ar H); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 
20.6-20.7 (4 × Ac CH3), 38.8 (CH2NH2), 61.3 (CH2-6), 66.5 (t, 
2
J (C,F) = 25.8, CH2CF2), 
67.0 (CH-4), 68.3 (t, 
2
J (C,F) = 25.3, CH2CF2), 68.4 (CH2CH2NH), 68.8 (CH-2), 70.9 (CH-
3), 71.0 (CH-5), 72.0 (CH2CONH), 73.2 (Ar-CH2), 101.3 (CH-1), 123.1 (CH), 124.6 (CH), 
124.7 (C), 125.0 (C), 125.6 (2 × CH), 126.2 (CH), 127.4 (CH), 127.6 (CH), 128.2 (CH), 
128.3 (CH), 129.2 (C), 129.6 (C), 130.8 (C), 131.3 (C), 131.9 (C), 168.2 (CONH), 169.6-
170.5 (4 × Ac CO); MS (ES
+
) m/z 1130.1 [M+Na]
+ 
(12%), 1108.4 [M+H]
+ 
(8%), 916.0 
(30%), 894.0 (14%), 471.3 (12%), 449.3 (10%), 331.0 (41%), 266.2 (67%), 215.2 
[pyreneCH2]
+
 (100%); HRMS (ES
+
) m/z calculated for [C45H41F16NO13Na]
+
 expected 
1130.2215, found 1130.2249; IR υ (cm-1) 1345, 1399, 1522 (CO), 1686 (CO), 1729 (CO), 
2837, 2922, 3333 (NH). 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
galactopyranosyl-ethyl)-acetamide (47) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-galactopyranosyl-ethyl)-acetamide (46, 12 mg) was deprotected 
using the general method for deacetylation (general method 3) to yield a light yellow solid 
(9 mg, 75%); TLC Rf 0.2 (9:1 chloroform/methanol); 
1
H NMR (400 MHz, CD3OD, 25 °C) 
: δH  3.43-3.91 (7H, m, CH2CH2NH, CH2CH2NH, CH-5,6a,6b), 4.07-4.28 (5H, m, sugar 
CH-1,2,3,4, CH2CONH), 4.37 (2H, t, 
3
J (H,F) = 14.7 Hz, CH2CF2), 4.40 (2H, t, 
3
J (H,F) = 
14.3 Hz CH2CF2), 5.55 (2H, s, CH2-Ar), 7.45 (1H, t, 
3
J (H,H) = 5.8 Hz, NH), 8.11-8.50 (9 
H, m, 9 × Ar H); 
13
C NMR (100 MHz, CD3OD, 25 °C) : δC 40.4 (CH2NH), 63.1 (sugar 
CH2), 68.2 (t, 
2
J (C,F) = 25.6, CH2CF2), 69.5 (t, 
2
J (C,F) = 25.8, CH2CF2), 69.8 
(CH2CH2NH), 73.2 (CH2CONH), 74.1 (Ar-CH2), 74.1 (CH), 74.7 (CH), 75.1 (CH), 75.4 
(CH), 105.1 (CH-1), 125.0 (CH), 126.1 (C), 126.2 (CH), 126.3 (C), 127.0 (CH), 127.1 
(CH), 127.9 (CH), 129.0 (CH), 129.1 (CH), 129.3 (CH), 129.5 (CH), 131.1 (C), 131.9 (C), 
132.5 (C), 132.9 (C), 133.3 (C), 167.9 (CONH); MS (ES
+
) m/z 962.0 [M+Na]
+ 
(13%), 
963.0 [M+Na+H]
2+ 
(8%), 940.1 [M+H]
+ 
(5%), 748.0 [M-pyreneCH2+Na]
+
 (32%), 726 [M-
pyreneCH2+H]
+
 (10%), 563.9 (37%), 266.2 (76%), 215.0 [pyreneCH2]
+
 (100%); HRMS 
(ES
+
) m/z calculated for [C37H33F16NO9Na]
+
 expected 962.1798, found 962.1803; IR υ (cm
-
1
) 1073, 1144, 1204, 1216, 1227, 1366, 1654 (CO), 2946-3027, 3325 (NH). 
 
Mannose pentaacetate (72)
194
 
 
D-(+)-Mannose (32, 5 g, 27.78 mmol, 1 eq.) was dissolved in pyridine (35 mL) and stirred. 
Acetic anhydride (13 mL, 0.138 mol) was then added and the solution was stirred 
overnight. The pyridine and acetic anhydride were then removed under reduced pressure, 
redissolved in ethyl acetate (50 mL) and washed with sat. CuSO4 solution (3 × 20 mL) to 
remove any remaining pyridine. The organic layer was then washed with water (3 × 20 mL) 
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and once with saturated brine (20 mL) then dried over anhydrous MgSO4. The ethyl acetate 
was then removed under vacuum to yield a viscous clear oil (10.57 g, 27.10 mmol, 97% as 
a mixture of anomers, 1 : 0.47 α/β ratio); TLC Rf 0.45 (1:1 ethyl acetate/40-60 °C 
petroleum ether); 
1
H NMR (400 MHz, CDCl3, 25 °C) α-anomer: δH 2.00 (3H, s, Ac CH3), 
2.04 (3H, s, Ac CH3), 2.08 (3H, s, Ac CH3), 2.16 (3H, s, Ac CH3), 2.17 (3H, s, Ac CH3), 
4.04 (1H, ddd, 
3
J (H,H) = 2.5, 4.8, 9.4 Hz, H-5), 4.08 (1H, dd, 
3
J (H,H) = 2.5, 12.4 Hz, H-
6a), 4.26 (1H, dd, 
3
J (H,H) = 4.8, 12.4 Hz, H-6b), 5.21 (1H, dd, 
3
J (H,H) = 1.9, 2.5 Hz, H-
2), 5.32-5.34 (2H, m, H-3, H-4), 6.07 (1H, d, 
3
J (H,H) = 1.8 Hz, H-1); β-anomer: δH 1.99 
(3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 2.08 (3H, s, Ac CH3), 2.09 (3H, s, Ac CH3), 2.20 
(3H, s, Ac CH3), 3.80 (1H, ddd, 
3
J (H,H) = 2.4, 5.3, 9.8 Hz, H-5), 4.12 (1H, dd, 
3
J (H,H) = 
2.3, 12.4 Hz, H-6a), 4.29 (1H, dd, 
3
J (H,H) = 5.3, 12.4 Hz,
 
H-6b), 5.12 (1H, dd, 
3
J (H,H) = 
3.3, 10.0 Hz, H-3), 5.28 (1H, dd, 
3
J (H,H) = 10.0, 10.0 Hz, H-4), 5.47 (1H, dd, 
3
J (H,H) = 
1.1, 3.3 Hz, H-2), 5.85 (1H, d, 
3
J (H,H) = 1.2 Hz, H-1); 
13
C NMR (100 MHz, CDCl3, 25 
°C) α-anomer: δC 20.7-21.0 (5 × Ac CH3), 62.2 (CH2-6), 65.6 (CH-4), 68.4 (CH-2), 68.8 
(CH-3), 70.7 (CH-5), 90.7 (CH-1), 168.2-170.7 (5 × Ac CO); β-anomer: δC 20.6-21.0 (5 × 
Ac CH3), 62.1 (CH2-6), 65.4 (CH-4), 68.3 (CH-2), 70.7 (CH-3), 73.3 (CH-5), 90.5 (CH-1), 
168.5-170.8 (5 × Ac CO); MS (ES
+
) m/z 413.4 [M+Na]
+
 (100%); HRMS (ES
+
) m/z 
calculated for [C16H22O11Na]
+
 expected 413.1054, found 413.1049; IR cm
-1
 1149, 1208, 
1368, 1633, 1737, 2987, 3033, 3472. 
 
Mannose tetraacetate (33)
195
  
 
Mannose pentaacetate 72 (3.5 g, 8.99 mmol, 1 eq.) was dissolved in dry THF (30 mL) in a 
three necked round bottom flask and stirred under nitrogen for 5 minutes. Benzylamine 
(1.47 g, 1.5 mL, 13.7 mmol, 1.5 eq.) was then added and the reaction was stirred under 
nitrogen overnight. The THF was then removed under vacuum. The brown slurry was then 
dissolved in CCl2H2, washed with HCl (1 M), sat. NaHCO3 and sat. NaCl. The organic 
layers were combined, dried over anhydrous magnesium sulphate and evaporated to yield a 
brown oil. The product was then purified using flash column chromatography (1:1 ethyl 
acetate/40-60 °C petroleum ether on silica) to yield a brown oil (2.29 g, 73 %, mixture of 
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anomers, 9 : 1 α/β ratio); TLC α-anomer: Rf 0.38, β-anomer: Rf 0.58, (1:1 ethyl acetate/40-
60 °C petroleum ether); 
1
H NMR (400 MHz, CDCl3, 25 °C) α-anomer: δH 1.96 (3H, s, Ac 
CH3), 2.01 (3H, s, Ac CH3), 2.06 (3H, s, Ac CH3), 2.12 (3H, s, Ac CH3), 4.08 (1H, dd, 
3
J 
(H,H) = 2.3, 12.2 Hz, H-6a), 4.19 (1H, ddd, 
3
J (H,H) = 2.3, 5.1, 9.8 Hz, H-5), 4.21 (1H, dd, 
3
J (H,H) = 4.8, 12.2 Hz, H-6b), 4.40 (1H, d, 
3
J (H,H) = 4.4 Hz, OH-1), 5.18 (1H, dd, 
3
J 
(H,H) = 1.9, 4.4 Hz, H-1), 5.20 (1H, dd, 
3
J (H,H) = 1.9, 3.2 Hz, H-2), 5.25 (1H, dd, 
3
J 
(H,H) = 9.8, 9.9 Hz, H-4), 5.36 (1H, dd, 
3
J (H,H) = 3.2, 10.0 Hz, H-3); β-anomer: δH 1.95 
(3H, s, Ac CH3), 2.00 (3H, s, Ac CH3), 2.05 (3H, s, Ac CH3), 2.17 (3H, s, Ac CH3), 3.68 
(1H, ddd, 
3
J (H,H) = 2.4, 5.4, 9.9 Hz, H-5), 4.10 (1H, dd, 
3
J (H,H) = 2.4, 12.2 Hz, H-6a), 
4.20 (1H, dd, 
3
J (H,H) = 5.5, 12.2 Hz, H-6b), 4.38 (1H, d, 
3
J (H,H) = 8.8 Hz, OH-1), 4.96 
(1H, dd, 
3
J (H,H) = 1.0, 9.0 Hz, H-1), 5.03 (1H, dd, 
3
J (H,H) = 3.3, 10.1 Hz, H-3), 5.20 
(1H, dd, 
3
J (H,H) = 10.0, 10.1 Hz, H-4), 5.38 (1H, dd, 
3
J (H,H) = 1.0, 3.4 Hz, H-2); 
13
C 
NMR (100 MHz, CDCl3, 25 °C) α-anomer: δC 21.0-21.2 (4 × Ac CH3), 62.8 (CH2-6), 66.4 
(CH-4), 68.5 (CH-5), 69.1 (CH-3), 70.4 (CH-2), 92.2 (CH-1), 170.2-171.3 (4 × CO); β-
anomer: δC 20.8-21.3 (4 × Ac CH3), 62.7 (CH2-6), 65.8 (CH-4), 70.2 (CH-2), 71.4 (CH-3), 
72.6 (CH-5), 93.1 (CH-1), 170.1-171.8 (4 × CO); MS (ES
+
) m/z 371.1 [M+Na]
+
 (100%); 
HRMS (ES
+
) m/z calculated for [C14H20O10Na]
+
 expected 371.0949, found 371.0940; IR 
cm
-1
 1052, 1228, 1371, 1745, 2955, 3363. 
 
2,3,4,6-tetra-O-acetyl-D-mannopyranosyl trichloroacetimidate (34)
196
  
 
2,3,4,6-tetra-O-acetyl-D-mannopyranose (33, 2.29 g, 6.58 mmol, 1 eq.) was dissolved in 
dry CH2Cl2 (20 mL) in a three necked round bottom flask and stirred under nitrogen at 4 °C 
for five minutes. Oven-dried potassium carbonate (1.54 g, 11.9 mmol, 1.7 eq.) was then 
added, followed by trichloroacetonitrile (2.76 g, 1.91 mL, 19.1 mmol, 2.9 eq.). The reaction 
was allowed to warm to room temperature and stirred under nitrogen. After 6 hours no 
more starting material was observed on TLC (1:1 ethyl acetate/40- 60 °C petroleum ether) 
so the reaction was stopped. The solution was filtered and the CH2Cl2 was removed under 
vacuum to yield a brown oil. The product was purified using flash column chromatography 
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(3:7-1:1 ethyl acetate/40-60 °C petroleum ether on silica) to yield a brown oil (1.43 g, 44 
%, α-anomer); TLC Rf 0.27, (3:7 ethyl acetate/40-60 °C petroleum ether); 
1
H NMR (400 
MHz, CDCl3, 25 °C) : δH  1.99 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 2.06 (3H, s, Ac 
CH3), 2.18 (3H, s, Ac CH3), 4.13 (1H, dd, 
3
J (H,H) = 2.8, 12.3 Hz, H-6a), 4.19 (1H, ddd, 
3
J 
(H,H) = 2.8, 5.1, 9.8 Hz, H-5), 4.26 (1H, dd, 
3
J (H,H) = 5.0, 12.4 Hz, H-6b), 5.37 (1H, dd, 
3
J (H,H) = 1.9, 9.7 Hz, H-3), 5.38 (1H, dd, 
3
J (H,H) = 9.8, 9.8 Hz, H-4), 5.45 (1H, dd, 
3
J 
(H,H) = 1.9, 2.4 Hz, H-2), 6.25 (1H, d, 
3
J (H,H) = 2.3 Hz, H-1), 8.79 (1H, s, C=NH); 
13
C 
NMR (100 MHz, CDCl3, 25 °C) : δC 20.8-21.0 (4 × Ac CH3), 62.3 (CH2), 65.7 (CH-4), 
68.1 (CH-2), 69.1 (CH-3), 71.5 (CH-5), 90.8 (CCl3), 94.8 (CH-1), 160.0 (C=NH), 169.9-
170.8 (4 × Ac CO); MS (ES
+
) m/z 514.2 [M+Na]
+
 (8%), 371.2 [M-OC(NH)CCl3+OH+Na]
+
 
(23%), 331.2 [M-OC(NH)CCl3]
+
 (100%); HRMS (ES
+
) m/z calculated for 
[C16H20Cl3NO11] expected 491.0153, found 371.0883 ([M-C(NH)CCl3+H+Na]
+
), 331.0919 
([M-OC(NH)CCl3]
+
). 
 
.2,3,4,6-Tetra-O-acetyl-1-(2-benzyloxycarbonylamino-ethoxy)-mannose (35)
196
 
 
 2,3,4,6-Tetra-O-acetyl-D-mannopyranosyl trichloroacetimidate (34, 500 mg, 1.02 
mmol, 1 eq.) and N-Z-ethanolamine (396 mg, 2.03 mmol, 2 eq.) were dissolved in dry 
THF (10 mL) in a round bottom flask in the presence of activated molecular sieves. The 
mixture was stirred at –30 °C and trimethylsilyl trifluoromethanesulfonate (50 µL, 
0.276 mmol, 0.271 eq.) in THF (5 mL) was added slowly. The reaction was allowed to 
warm to room temperature and stirred for a further 5 hours, at which point mass 
spectroscopy showed no starting material. The molecular sieves were removed by 
filtration, and the solvent removed from the filtrate under reduced pressure. The residue 
was purified using flash column chromatography (3:7-1:1 ethyl acetate/40-60 °C 
petroleum ether on silica). The product was obtained as a clear oil (328 mg, 62%); TLC 
Rf 0.23, (4:6 ethyl acetate/40-60 °C petroleum ether); 
1
H NMR (400 MHz, CDCl3, 25 
°C) : δH 1.99 (3H, s, Ac CH3), 2.03 (3H, s, Ac CH3), 2.08 (3H, s, Ac CH3), 2.15 (3H, s, 
Ac CH3), 3.41-3.47 (3H, m, CH2NHCBz, NH), 3.56 (1H, ddd, 
3
J (H,H) = 3.7, 5.6, 10.1 
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Hz, OCHaHb), 3.77 (1H, 
3
J (H,H) = 3.8, 5.5, 9.7 Hz, OCHaHb), 3.96 (1H, 
3
J (H,H) = 
1.7, 5.5, 11.8 Hz, H-5), 4.07 (1H, dd, 
3
J (H,H) = 1.5, 12.1 Hz, H-6a), 4.26 (1H, dd, 
3
J 
(H,H) = 5.6, 12.2 Hz, H-6b), 4.82 (1H, d, 
3
J (H,H) = 1.2 Hz, H-1), 5.11 (2H, s, 
OCH2Ar), 5.24 (1H, dd, 
3
J (H,H) = 1.2, 3.1 Hz, H-2), 5.27 (1H, dd, 
3
J (H,H) = 9.9, 11.5 
Hz, H-4), 5.31 (1H, dd, 
3
J (H,H) = 3.2, 9.9 Hz, H-3), 7.31-7.35 (5H, m, 5 × Ar H); 
13
C 
NMR (100 MHz, CDCl3, 25 °C) : δC 21.0-21.4 (4 × Ac CH3), 41.0 (CH2NH), 62.8 
(CH2-6), 66.4 (CH-4), 67.2 (Ar-CH2), 68.7 (CH2CH2NH), 69.1 (CH-5), 69.3 (CH-3), 
69.7 (CH-2), 98.1 (CH-1), 128.6-128.9 (5 × Ar CH), 136.8 (Ar Cq), 156.8 (Ar CO), 
170.0-171.0 (4 × Ac CO); MS (ES
+
) m/z 548.6 [M+Na]
+
 (100%), 526.6 [M+Na+H]
+
 
(92%); HRMS (ES
+
) m/z calculated for [C24H32NO12]
+
 expected 526.1925, found 
526.1912, calculated for [C24H31NO12Na]
+
 expected 548.1744, found 548.1725; IR cm
-1
 
1045, 1081, 1135, 1214, 1368, 1742, 2939, 3391. 
 
2,3,4,6-Tetra-O-acetyl-1-(2-aminoethoxy)-mannose (25) 
 
2,3,4,6-Tetra-O-acetyl-1-(2-benzyloxycarbonylaminoethoxy)-mannose (35, 80 mg) was 
deprotected using the general method for CBz removal to yield a clear oil (45 mg, 75%); 
TLC Rf 0.1 (4:6 ethyl acetate/40-60 °C petroleum ether); 
1
H NMR (400 MHz, CDCl3, 25 
°C) : δH 1.99 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 2.10 (3H, s, Ac CH3), 2.16 (3H, s, Ac 
CH3), 2.93 (2H, bs, CH2NH2), 3.50 (1H, ddd, 
3
J (H,H) = 5.0, 5.1, 10.2 Hz, OCHaHb), 3.74 
(1H, ddd, 
3
J (H,H) = 5.0, 5.1, 9.9 Hz, OCHaHb), 4.00 (1H, ddd, 
3
J (H,H) = 3.0, 5.5, 10.1 
Hz, H-5), 4.11 (1H, dd, 
3
J (H,H) = 2.8, 12.2 Hz, H-6a), 4.28 (1H, dd,
 3
J (H,H) = 5.3, 12.2 
Hz, H-6b), 4.85 (1H, d, 
3
J (H,H) = 1.8 Hz, H-1), 5.25 (1H, dd, 
3
J (H,H) = 1.7, 3.2 Hz, H-2), 
5.29 (1H, dd,
 3
J (H,H) = 9.8, 9.9 Hz, H-4), 5.35 (1H, dd, 
3
J (H,H) = 3.2, 10.0 Hz, H-3); 
13
C 
NMR (100 MHz, CDCl3, 25 °C) : δC 20.6-20.9 (4 × Ac CH3), 41.4 (CH2NH2), 62.5 (CH2-
6), 66.2 (CH-4), 68.6 (CH-5), 69.1 (CH-3), 69.6 (CH-2), 70.6 (CH2CH2NH2), 97.8 (CH-1), 
169.7-170.6 (4 × Ac CO); MS (ES
+
) m/z 422.1 (63%), 392.4 [M+H]
+
 (97%), 170.1 (100%); 
HRMS (ES
+
) m/z calculated for [C16H26NO10]
+
 expected 392.1556, found 392.1551; IR 
cm
-1
 1053, 1224, 1371, 1747, 2853, 2924, 3362. 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethyl)-acetamide (48) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethyl)-acetamide (48) was synthesized 
according to the general method for DCC/NHS coupling (general method 2) using 1.4 
equivalents of 2,3,4,6-Tetra-O-acetyl-1-(2-aminoethoxy)-mannose (25) to yield a light-
yellow solid (47 mg, 71%); TLC Rf 0.27 (3:2:1 ethyl acetate/chloroform/cyclohexane);
 
1
H NMR (500 MHz, CDCl3, 25 °C) : δH 1.98 (3H, s, Ac CH3), 2.02 (3H, s, Ac CH3), 
2.09 (3H, s, Ac CH3), 2.14 (3H, s, Ac CH3), 3.55-3.59 (3H, m, CH2NHCO, 
OCHaHbCH2), 3.78 (1H, ddd, 
3
J (H,H) = 4.0, 4.7, 9.9 Hz, OCHaHbCH2), 3.95 (1H, ddd, 
3
J (H,H) = 2.4, 5.7, 8.4 Hz, H-5), 4.02 (2H, t, 
3
J (H,F) = 14.1 Hz, CH2CF2), 4.05 (2H, t, 
3
J (H,F) = 13.8 Hz, CH2CF2), 4.11 (1H, dd, 
3
J (H,H) = 2.2, 12.4, H-6a), 4.17 (2H, s, 
OCH2CONH), 4.25 (1H, dd, 
3
J (H,H) = 5.9, 12.2 Hz, H-6b), 4.83 (1H, d, 
3
J (H,H) = 1.3 
Hz, H-1), 5.24 (1H, dd,
 3
J (H,H) = 1.7, 3.2 Hz, H-2), 5.27 (1H, dd,
 3
J (H,H) = 9.7, 10.1 
Hz, H-4), 5.31 (1H, dd,
 3
J (H,H) = 3.2, 10.1 Hz, H-3), 5.41 (2H, s, CH2Ar), 6.81 (1H, t, 
3
J = 5.6, NH), 7.99 - 8.36 (9H, m, 9 × Ar CH); 
13
C NMR (125 MHz, CDCl3, 25 °C) : δC 
19.5 – 19.8 (4 × Ac CH3), 37.4 (CH2NH), 61.5 (CH2-6), 65.1 (CH-4), 65.4 (t, 
2
J (C,F) = 
25.9 Hz, CH2CF2), 66.0 (CH-2), 67.1 (t, 
2
J (C,F) = 25.4 Hz, CH2CF2), 67.7 (CH-5), 
67.8 (CH-3), 69.6 (CH2CH2NH), 70.8 (CH2CONH), 72.0 (Ar-CH2), 96.7 (CH-1), 120.0 
(CH), 123.5 (CH), 123.6 (C), 123.9 (C), 124.5 (CH), 125.1 (CH), 126.3 (2 × CH), 126.8 
(CH), 127.1 (CH), 127.5 (CH), 128.1 (C), 128.5 (C), 129.7 (C), 130.2 (C), 130.8 (C), 
167.1 (CONH), 168.7-169.6 (4 × Ac CO); MS (ES
+
) m/z 1130.1 [M+Na]
+ 
(9%), 1108.4 
[M+H]
+ 
(4%), 449.5 (30%), 420.2 (76%), 392.2 (41%), 215.2 [pyreneCH2]
+
 (100%); 
HRMS (ES
+
) m/z calculated for [C45H41F16NO13Na]
+
 1130.2215, found 1130.2247; IR υ 
(cm
-1
) 1047, 1086, 1138, 1209, 1369, 1532, 1682, 1746, 2942, 3378. 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-
D-mannopyranosyl-ethyl)-acetamide (49) 
 
 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethyl)-acetamide (48, 47 mg, 0.043 mmol) was 
deprotected using the general method for deacetylation (general method 3) to yield a light 
yellow solid (37 mg, 93%); TLC Rf 0.2 (9:1 chloroform/methanol); 
1
H NMR (400 MHz, 
acetone-d6, 25 °C) : δH 3.49-3.86 (14H, m, CH2CH2NH, CH2CH2NH, sugar CH-
2,3,4,5,6a,6b, sugar OH-2,3,4,6), 4.22 (2H, s, CH2CONH), 4.35 (2H, t, 
3
J (H,F) = 14.5 Hz, 
CH2CF2), 4.37 (2H, t, 
3
J (H,F) = 15.0 Hz, CH2CF2), 4.81 (1H, d, 
3
J = 1.3 Hz, H-1), 5.55 
(2H, s, CH2Ar), 7.40 (1H, t, 
3
J = 5.7 Hz, NH),  8.11-8.51 (9H, m, 9 × Ar H); 
13
C NMR 
(100 MHz, acetone-d6, 25 °C) : δC 40.0 (OCH2), 63.1 (sugar CH2), 67.4 (t, 
2
J = 24.8 Hz, 
CH2), 69.1 (t, 
2
J = 24.7 Hz, CH2), 69.8 (CH), 70.8 (CH2), 72.4 (CH), 73.0 (CH2), 73.3 
(CH), 74.1 (Ar-CH2), 74.9 (CH), 101.8 (CH-1), 125.0 (CH), 126.3 (CH), 126.4 (C), 126.5 
(C), 127.1 (2 × CH), 127.9 (CH), 129.0 (CH). 129.1 (CH), 129.4 (CH), 129.5 (CH), 131.8 
(C), 131.9 (C), 132.3 (C), 132.5 (C), 132.9 (C), 168.7 (CO); MS (ES
+
) m/z 962.7 [M+Na]
+ 
(44%), 940.0 [M+H]
+ 
(3%), 747.7 [M-pyreneCH2+Na]
+
 (16%), 453.9 (50%), 412.9 (100%), 
215.0 [pyreneCH2]
+
 (72%); HRMS (ES
+
) m/z calculated for [C37H33F16NO9Na]
+
 expected 
962.1798, found 962.1788, 963.1846, 964.1879; Anal. Calc. for C37H33F16NO12 C 47.29, H 
3.54, N 1.49, found C 42.71, H 3.36, N 1.35; IR υ (cm-1) 1028, 1259, 1664, 2851, 2919, 
3329. 
 
Monotosylated triethylene glycol (37)
197
 
 
Triethylene glycol (36, 10 g, 66.591 mmol) and tosyl chloride (15 g, 78.7 mmol, 1.2 eq.) 
were dissolved in CH2Cl2 (100 mL).The mixture was cooled to 0 °C and silver oxide (20 g, 
86.3 mmol, 1.08 eq.) was added followed by potassium iodide (1.90 g, 11.4 mmol, 0.143 
eq.). The reaction was stirred for 30 minutes and filtered through a small plug of silica, 
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washing through with ethyl acetate. The solvent was removed under vacuum and purified 
using column chromatography (ethyl acetate on silica) to yield a clear viscous oil (10.290 g, 
51 %); TLC Rf 0.45 (ethyl acetate);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 2.45 (4H, s, 
OH + tosyl CH3), 3.57 (2H, t, 
3
J (H,H) = 4.8, TEG CH2), 3.61 (4H, s, 2 × TEG CH2), 3.71 
(4H, m, 2 × TEG CH2), 4.17 (2H, t, 
3
J (H,H) = 4.8, TEG CH2), 7.35 (2H, d, 
3
J (H,H) = 8.0, 
2 × tosyl Ar-H (meta to sulphate)), 7.80 (2H, d, 
3
J (H,H) = 8.3, 2 × tosyl Ar-H (ortho to 
sulphate)); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 21.6 (tosyl CH3), 61.7 (TEG CH2OH), 
68.8 (TEG CH2), 69.3 (TEG CH2), 70.3 (TEG CH2), 70.8 (TEG CH2), 72.6 (TEG 
CH2CH2OH), 127.8 (Ar CH), 128.0 (Ar CH), 129.8, (Ar CH), 130.0 (Ar CH), 132.7 (Ar 
Cq-CH3), 145.0 (Ar C-S); MS (ES
+
) m/z 305.1 [M+H]
+
 (100 %), 306.1 [M+2H]
+
 (17 %); 
HRMS (ES
+
) m/z calculated for [C13H21O6S]
+
, expected 305.1053, found 305.1083; IR υ 
(cm
-1
) 1095, 1120, 1173, 1362, 1738, 1730, 2873, 3420. 
 
Monophthalimido triethylene glycol (73) 
 
Monotosylated triethylene glycol (37, 943 mg, 3.099 mmol) was dissolved in toluene (20 
mL). Potassium phthalimide (689 mg, 3.720 mmol 1.2 eq.) and tributylhexadecyl 
phosphonium bromide (157 mg, 0.309 mmol, 0.1 eq.) were added and the solution was 
heated at 100 °C for 7 days under reflux. The reaction was then cooled, filtered through 
cotton wool and the toluene removed under vacuum. The product was purified using 
column chromatography (ethyl acetate on silica) to yield a clear viscous oil (321 mg, 37 
%); TLC Rf 0.25 (ethyl acetate);
 1
H NMR (300 MHz, CDCl3, 25 °C) : δH 2.56 (1H, s, OH), 
3.55 (2H, t, 
3
J = 5.6, TEG CH2), 3.61 (4H, s, 2 x TEG CH2), 3.67 (4H, m, 2 x TEG CH2), 
4.26 (2H, t, 
3
J = 4.7, TEG CH2), 7.47 (1H, dd, 
3
J = 3.4, 5.8, Ar-H), 7.65 (2H, m, 2 x Ar-H), 
7.77 (1H, dd, 
3
J = 3.2, 5.4, Ar-H); 
13
C NMR (75 MHz, CDCl3, 25 °C) : δC 37.2 (TEG CH2-
N), 61.7 (TEG CH2OH), 67.9 (TEG CH2), 70.3 (TEG CH2), 70.7 (TEG CH2), 72.5 (TEG 
CH2CH2OH), 123.2 (Ar CH), 129.0 (Ar CH), 131.1 (Ar CH), 132.0 (Ar Cq), 132.4 (Ar Cq), 
134.0 (Ar CH); MS (ES
+
) m/z 280.1 [M+H]
+
 (100 %), 281.1 [M+2H]
2+
 (16 %); HRMS 
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(ES
+
) m/z calculated for [C14H18NO5]
+
, expected 280.1185, found 280.1164; IR υ (cm
-1
) 
1065, 1111, 1230, 1365, 1662, 1712, 2870, 2911, 3370. 
 
Monoazido triethylene glycol (38)
198
 
 
Monotosylated triethylene glycol (37, 1 g, 3.286 mmol) was dissolved in dry DMF (25 
mL). Sodium azide (1.07 g, 16.462 mmol, 5 eq.) was added and the mixture heated at 70 °C 
overnight under nitrogen. Water (50 mL) was added and the reaction mixture cooled. The 
product was then extracted using ethyl acetate (3 × 30 mL), which was then washed with 
water (3 × 25 mL) and dried over anhydrous sodium sulphate. The ethyl acetate was then 
removed under vacuum and the crude mixture purified using column chromatography 
(ethyl acetate on silica) to yield a clear liquid (280 mg, 58 %); TLC Rf 0.41 (ethyl acetate);
 
1
H NMR (300 MHz, CDCl3, 25 °C) : δH 3.06 (1H, s, OH), 3.31 (2H, t, 
3
J = 3.8, TEG 
CH2N3), 3.51 (2H, t, 
3
J = 3.7, TEG CH2CH2OH), 3.59 (6H, m, 3 × TEG CH2), 3.63 (2H, t, 
3
J = 3.2, TEG CH2OH); 
13
C NMR (75 MHz, CDCl3, 25 °C) : δC 50.5 (CH2N3), 61.5 
(CH2OH), 69.9 (CH2), 70.3 (CH2), 70.5 (CH2), 72.5 (CH2CH2OH); MS (ES
+
) m/z 176.1 
[M+H]
+
 (100 %), 198.1 [M+Na]
+
 (44 %), 217.1 [M+CH3CN+H]
+
 (93 %), 235.1 
[M+CH3CN+Na]
+
 (51 %); HRMS (ES
+
) m/z calculated for [C6H13N3O3Na]
+
, expected 
198.0855, found 198.0849; IR υ (cm-1) 1064, 1116, 1217, 1351, 1739, 2094, 2869, 2921, 
3443. 
 
2,3,4,6-tetra-O-acetyl-1-(9-azido-triethylene glycol)-mannose (39)
199
  
 
2,3,4,6-Tetra-O-acetyl-D-mannopyranosyl trichloroacetimidate (34, 100 mg, 0.203 
mmol) and monoazido triethylene glycol (38, 42 mg, 0.240 mmol, 1.2 eq.) were 
dissolved in dry CH2Cl2 (5 mL). 4 Å molecular sieves were added, then the mixture 
placed under an inert atmosphere and cooled to 0 °C. Boron trifluoride diethyl etherate 
(15 µL, 0.122 mmol, 0.6 eq.) was added dropwise and the reaction was stirred for 1.5 
hours at room temperature. Triethylamine was added dropwise until the BF3 was 
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quenched, the mixture was filtered and the solvent was removed under from the filtrate 
under reduced pressure. The residue was purified using column chromatography (4:6 
ethyl acetate/40-60 °C petroleum ether on silica) to yield a viscous clear oil (74 mg, 72 
%); TLC Rf 0.43 (1:1 ethyl acetate/40-60 °C petroleum ether);
 1
H NMR (400 MHz, 
CDCl3, 25 °C) : δH 1.92 (3H, s, Ac CH3), 1.98 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 
2.09 (3H, s, Ac CH3), 3.34 (2H, t, 
3
J (H,H) = 5.0 Hz, TEG CH2N3), 3.62 (9H, m, 4 × 
TEG CH2 + TEG C(1)Ha), 3.75 (1H, dt, 
3
J (H,H) = 5.2, 8.7 Hz, TEG C(1)Hb), 4.01 (1H, 
m, H-5), 4.04 (1H, dd, 
3
J =  2.2, 12.4 Hz, H-6a), 4.23 (1H, dd, 
3
J (H,H) = 5.2, 12.5 Hz, 
H-6b), 4.81 (1H, d, 
3
J (H,H) = 1.6 Hz, H-1), 5.19 (1H, dd, 
3
J (H,H) = 1.8, 3.4 Hz, H-2), 
5.23 (1H, dd, 
3
J (H,H) = 9.9, 10.6 Hz, H-4), 5.29 (1H, dd, 
3
J (H,H) = 3.3, 10.1 Hz, H-
3); 
13
C NMR (101 MHz, CDCl3, 25 °C) : δC 20.7-20.9 (4 × Ac CH3), 50.6 (CH2N3), 
62.4 (CH2-6), 66.1 (CH-4), 67.4 (TEG CH2), 68.4 (CH-5), 69.1 (CH-3), 69.5 (CH-2), 
70.0 (TEG CH2), 70.1 (TEG CH2), 70.6 (TEG CH2), 70.7 (TEG CH2), 97.7 (CH-1), 
169.8-170.8 (4 × Ac CO); MS (ES
+
) m/z 506.1 [M+H]
+
 (10 %), 528.1 [M+Na]
+
 (100%), 
529.1 [M+H+Na]
+
 (23%); HRMS (ES
+
) m/z calculated for [C20H31N3O12Na]
+
, expected 
528.1800, found 528.1805; IR υ (cm-1) 1046, 1082, 1134, 1219, 1368, 1743, 2096, 
2359, 2857, 2924. 
 
2,3,4,6-tetra-O-acetyl-1-(9-amino-triethylene glycol)-mannose (28)
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2,3,4,6-Tetra-O-acetyl-1-(9-azido-triethylene glycol)-mannose (39, 75 mg, 0.149 mmol) 
was dissolved in ethanol (5 mL). 10 % Palladium on charcoal (2 mg) was added and the 
mixture was placed under nitrogen. The mixture was evacuated and placed under a 
hydrogen atmosphere, then stirred for 2 hours at room temperature. The mixture was then 
filtered through Celite and the solvent evaporated to yield a clear oil (63 mg, 89%); TLC Rf 
0.0 (1:1 ethyl acetate/40-60 °C petroleum ether);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 
1.93 (3H, s, Ac CH3), 1.98 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 2.09 (3H, s, Ac CH3), 
3.39 (2H, m, CH2NH2), 3.49 (2H, t, 
3
J (H,H) = 4.85 Hz, TEG CH2CH2NH2), 3.59 (9H, m, 4 
× TEG CH2 + TEG C(1)Ha), 3.75 (1H, dt, 
3
J (H,H) = 4.3, 8.4 Hz, TEG C(1)Hb), 4.00 (1H, m, 
H-5), 4.04 (1H, dd, 
3
J (H,H) = 3.2, 11.1 Hz, H-6a), 4.22 (1H, dd, 
3
J (H,H) = 4.9, 12.2 Hz, 
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H-6b), 4.81 (1H, d, 
3
J (H,H) = 1.5 Hz, H-1), 5.19 (1H, dd, 
3
J (H,H) = 1.68, 2.94 Hz, H-2), 
5.22 (1H, dd, 
3
J (H,H) = 8.2, 8.8 Hz, H-4), 5.27 (1H, dd, 
3
J (H,H) = 2.8, 8.9 Hz, H-3); 
13
C 
NMR (100 MHz, CDCl3, 25 °C) : δC 20.7-20.9 (4 × Ac CH3), 41.1 (CH2NH2), 62.4 (CH2-
6), 66.1 (CH-4), 67.4 (TEG CH2), 68.5 (CH-5), 69.1 (CH-3), 69.2 (CH-2), 69.9 (TEG CH2), 
70.2 (TEG CH2), 70.6 (TEG CH2), 70.7 (TEG CH2), 97.7 (CH-1), 169.7-170.7 (4 × Ac 
CO); MS (ES
+
) m/z 480.2 [M+H]
+
 (100 %); HRMS (ES
+
) m/z calculated for [C20H34NO12]
+
 
480.2081, found 480.2072; IR υ (cm-1) 1747, 2926, 3404. 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-methoxy)-decycloxy-N-
(2-(2-(2-α-D-(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethoxy)ethoxy)ethyl))-amide 
(50)  
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-methoxy)-decycloxy-N-(2-
(2-(2-α-D-(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethoxy)ethoxy)ethyl))-amide (50) 
was synthesized according to the general method for DCC/NHS coupling (general 
method 2) using 2.0 equivalents of 2,3,4,6-tetra-O-acetyl-1-(9-amino-triethylene 
glycol)-mannose (28) to yield a light yellow amorphous solid (32.1 mg, 49%); TLC Rf 
0.28 (19:1 CHCl3/MeOH), brown spot with ninhydrin followed by heat);
 1
H NMR (400 
MHz, CDCl3, 25 °C) : δH 1.98 (3H, s, Ac CH3), 2.03 (3H, s, Ac CH3), 2.09 (3H, s, Ac 
CH3), 2.15 (3H, s, Ac CH3), 3.52 (2H, t, 
3
J (H,H) = 5.6 Hz, CH2NH), 3.57-3.64 (9H, m, 
4 × TEG CH2 + TEG C(1)Ha), 3.79 (1H, dd, 
3
J (H,H) = 4.2, 8.9 Hz, TEG C(1)Hb), 3.98-
4.06 (5H, m, H-5, 2 × CH2CF2), 4.10 (1H, dd, 
3
J (H,H) = 1.9, 11.5 Hz, H-6a), 4.14 (2H, 
s, OCH2CONH), 4.28 (1H, dd, 
3
J (H,H) = 4.8, 12.1 Hz, H-6b), 4.86 (1H, d,
 3
J (H,H) = 
1.6 Hz, H-1), 5.26 (1H, dd, 
3
J (H,H) = 1.7, 3.3 Hz, H-2), 5.30 (1H, dd, 
3
J (H,H) = 9.9, 
10.2 Hz, H-4), 5.35 (1H, dd, 
3
J (H,H) = 3.3, 10.0 Hz, H-3), 5.41 (2H, s, Ar-CH2), 6.78 
(1H, t, 
3
J (H,H) = 5.3 Hz, NH), 8.00-8.37 (9H, m, 9 × Ar CH); 
13
C NMR (125 MHz, 
CDCl3, 25 °C) : δC 20.6-20.9 (4 × Ac CH3), 38.7 (CH2NH), 62.4 (CH2-6). 66.2 (CH-4), 
66.5 (t,
 2
J (C,F) = 26.1 Hz, CH2CF2), 67.4 (TEG CH2), 68.1 (t,
 2
J (C,F) = 25.4 Hz, 
CH2CF2), 68.5 (CH-5), 69.1 (CH-3), 69.6 (CH-2), 69.7 (TEG CH2), 70.0 (TEG CH2), 
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70.4 (TEG CH2), 70.6 (TEG CH2), 71.8 (CH2CONH), 73.1 (Ar-CH2), 97.7 (CH-1), 
123.0 (CH), 124.5 (CH), 124.6 (C), 125.0 (C), 125.5 (CH). 126.1 (CH), 127.3 (CH), 
127.4 (CH), 127.9 (CH), 128.2 (CH), 129.1 (CH), 129.6 (C), 130.8 (C), 131.2 (C), 
131.8 (C), 132.1 (C), 167.9 (CONH), 169.7-170.6 (4 × Ac CO); MS (ES
+
) m/z 1218.0 
[M+Na]
+ 
(10%), 1196.5 [M+H]
+ 
(16%), 1012.5 (8%), 624.0 (34%), 508.1 (23%), 480.4 
(12%), 331.1 (75%), 215.1 [pyreneCH2]
+
 (12%); HRMS (MALDI) m/z calculated for 
[C49H49F16NO15Na]
+
 1218.2739, found 1218.2720; IR υ (cm
-1
) 1050, 1081, 1137, 1223, 
1370, 1746, 2927, 3356. 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-methoxy)-decycloxy-N-
(2-(2-(2-α-D-mannopyranosyl-ethoxy)ethoxy)ethyl))-amide (51) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-methoxy)-decycloxy-N-(2-
(2-(2-α-D-(2,3,4,6-tetra-O-acetyl)-mannopyranosyl-ethoxy)ethoxy)ethyl))-amide (50, 
32.1 mg, 0.0269 mmol) was deprotected using the general method for deacetylation 
(general method 3) to yield a light yellow amorphous solid (24.7 mg, 90%); TLC Rf 
0.05 (9:1 chloroform/methanol/1 drop Et3N, brown spot with ninhydrin followed by 
heat); 
1
H NMR (400 MHz, acetone-d6, 25 °C) : δH 3.44-3.48 (2H, m, TEG CH2), 3.53 
(1H, t, 
3
J (H,H) = 6.2 Hz, TEG CHaHb), 3.59-3.72 (13H, m, 4 × TEG CH2, TEG CHaHb, 
OH-2,3,4,6), 3.80-4.10 (6H, m, CH-2,3,4,5,6a,6b), 4.22 (2H, s, OCH2CONH), 4.37 (2H, 
t, 
3
J (H,F) = 14.3 Hz, CH2CF2), 4.40 (2H, t, 
3
J (H,F) = 14.2 Hz, CH2CF2), 4.84 (1H, d, 
3
J (H,H) = 1.4 Hz, sugar H-1), 5.55 (2H, s, CH2Ar), 7.31 (1H, t, 
3
J (H,H) = 5.4 Hz, 
NH), 8.11-8.51 (9H, m, 9 × Ar CH); 
13
C NMR (100 MHz, acetone-d6, 25 °C) : δC 39.3 
(CH2NH), 63.2 (CH2-6), 67.2 (TEG CH2), 67.5 (t, 
2
J = 25.1, CH2CF2), 68.5 (t, 
2
J = 
25.0, CH2CF2), 69.1 (CH), 70.3 (CH), 70.9 (TEG CH2), 71.0 (TEG CH2), 71.3 (TEG 
CH2), 71.8 (TEG CH2), 72.2 (CH2CONH), 72.6 (CH), 73.3 (CH), 74.0 (Ar-CH2), 101.2 
(CH-1), 124.3 (CH), 125.4 (C), 125.5 (CH), 125.6 (C), 126.4 (2 × CH), 127.2 (CH), 
128.3 (2 × CH), 128.6 (CH), 128.7 (CH), 130.4 (C), 131.2 (C), 131.8 (C), 132.2 (C), 
132.6 (C), 168.8 (CONH); MS (ES
+
) m/z 1050.6 [M+Na]
+ 
(8%), 318.2 (45%), 268.2 
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(11%), 267.2 (64%), 215.0 [pyreneCH2]
+
 (62%); (MALDI) m/z calculated for 
C41H41F16NO11Na
+
 expected 1050.2316, found 1049.9567 (100%) [M+Na]
+
; HRMS 
(ES
+
) calculated for [C41H41F16NO11Na]
+
 1050.2322, found 1050.2297; IR υ (cm
-1
) 
1026, 1142, 1211, 1671, 2924, 3417. 
 
2,3,4,6-tetra-O-acetyl-1-(2-benzyloxycarbonylamino-ethoxy)-glucosamine (41) 
 
Glucosamine pentaacetate (40, 500 mg, 1.285 mmol) and N-Z-ethanolamine (500 mg, 
2.564 mmol, 2 eq.) were dissolved in dry acetonitrile (10 mL) under a nitrogen atmosphere. 
The reaction was cooled to 0 °C and Tin(IV) tetrachloride (1.54 mL of 1 M solution in 
CH2CL2) was added dropwise. The reaction was warmed to room temperature and heated at 
75 °C for 16 hours. The reaction mixture was allowed to cool to room temperature, water 
was added (20 mL) and the product extracted using ethyl acetate (3 × 20 mL), which was 
then dried over MgSO4. The product was purified via flash column chromatography (19:1 
chloroform/methanol on silica) followed by recrystallisation from 4:1 ethyl acetate/40-60 
°C petroleum ether (117 mg, 17 %); TLC Rf 0.2 (4:1 ethyl acetate/40-60 °C petroleum 
ether), Rf 0.45 (19:1 chloroform/methanol);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.85 
(3H, s, NHAc CH3), 1.98-1.99 (6H, m, 2 × Ac CH3), 2.01 (3H, s, Ac CH3), 3.27-3.32 (1H, 
m, OCH2CHaHb), 3.38-3.40 (1H, m, OCH2CHaHb), 3.62-5.68 (2H, m, CH2CH2NH), 3.82 
(1H, ddd, 
3
J (H,H) = 2.2, 5.0, 10.0 Hz, H-5), 3.88 (1H, ddd, 
3
J (H,H) = 8.5, 8.5, 10.1 Hz, H-
2), 4.09 (1H, dd, 
3
J (H,H) = 2.3, 12.3 Hz, H-6a), 4.20 (1H, dd, 
3
J (H,H) = 4.9, 12.3 Hz, H-
6b), 4.60 (1H, d, 
3
J (H,H) = 8.4 Hz, H-1), 5.01 (1H, dd, 
3
J (H,H) = 9.6, 9.6 Hz, H-4), 5.05 
(2H, s, Ar-CH2), 5.19 (1H, dd, 
3
J (H,H) = 9.6, 9.7 Hz, H-3), 5.42 (t, 
3
J (H,H) = 5.6 Hz, 
CH2NH), 6.13 (1H, d, 
3
J (H,H) = 8.6 Hz, NH-2), 7.28-7.32 (5H, m, 5 × Ar H);
 13
C NMR 
(100 MHz, CDCl3, 25 °C) : δH 20.8-20.9 (3 × OAc CH3), 23.4 (NHAc CH3), 40.9 
(CH2NH), 54.6 (CH-2), 62.3 (CH2-6), 66.9 (Ar-CH2), 68.7 (CH-4), 69.2 (CH2CH2NH), 
72.0 (CH-5), 72.6 (CH-3), 101.2 (CH-1), 128.3-128.8 (5 × Ar CH), 136.7 (Ar Cq), 156.8 
(Ar CO), 169.6-170.2 (5 × Ac CO); MS (ES
+
) m/z: 525.2 (61 %) [M+H]
+
, 547.2 (27 %) 
[M+Na]
+
; HRMS (ES
+
) m/z: calc. for [C24H33O11N2]
+
 525.2079, found 525.2097 [M+H]
+
; 
IR υ (cm-1) 1034, 1213, 1230, 1528, 1549 (CO), 1659 (CO), 1700 (CO), 1745 (CO), 2952, 
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3319 (NH); Anal. calc. for C24H32O11N2 C 54.96, H 6.15, N 5.34, found C 55.02, H 6.45, N 
5.45. 
 
2,3,4,6-tetra-O-acetyl-1-(2-amino-ethoxy)-glucosamine (27) 
 
2,3,4,6-tetra-O-acetyl-1-(2-benzyloxycarbonylamino-ethoxy)-glucosamine (41, 30 mg, 
0.0573 mmol) was deprotected using the general method for CBz removal to yield a clear 
oil (22 mg, 99 % yield); TLC Rf 0.0 (4:1 ethyl acetate/40-60 °C petroleum ether), Rf 0.05 
(9:1 chloroform/methanol on silica);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.96 (3H, s, 
NHAc-CH3), 2.02-2.03 (6H, m, 2 × Ac CH3), 2.08 (3H, s, Ac CH3), 2.83-2.97 (2H, m, 
OCH2CH2), 3.59-3.63 (1H, m, OCHaHbCH2), 3.68-3.73 (1H, m, OCHaHbCH2), 3.91-3.97 
(2H, m, H-2, H-5), 4.09 (1H, dd, 
3
J (H,H) = 1.6, 12.4 Hz, H-6a), 4.25 (1H, dd, 
3
J (H,H) = 
4.7, 12.3 Hz, H-6b), 4.67 (1H, d, 
3
J (H,H) = 8.4 Hz, H-1), 5.08 (1H, dd, 
3
J (H,H) = 9.6, 9.6 
Hz, H-4), 5.22 (1H, dd, , 
3
J (H,H) = 9.6, 9.9 Hz, H-3), 6.03 (1H, d, 
3
J (H,H) = 7.7 Hz, NH-
2); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δH 21.0-21.1 (3 × OAc CH3), 23.7 (NHAc CH3), 
41.6 (CH2NH), 54.7 (CH-2), 62.4 (CH2-6), 68.8 (CH-4), 71.5 (CH2CH2NH), 72.1 (CH-5), 
72.9 (CH-3), 101.6 (CH-1), 169.7-171.3 (4 × Ac-CO); MS (ES
+
) m/z: 391.2 (100 %) 
[M+H]
+
, 413.2 (6 %) [M+Na]
+
; HRMS (ES
+
) m/z: calc. for [C16H27O9N2]
+
 391.1711, found 
391.1727 [M+H]
+
, calc. for [C16H26O9N2Na]
+
 413.1531, found 413.1533 [M+Na]
+
; IR υ 
(cm
-1
) 1557 (CO), 1652 (CO), 1659 (CO), 1738 (CO), 3411 (v. broad NH). 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decloxy-N-(2-(2-N-
acetyl-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-ethyl)-acetamide (52) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decloxy-N-(2-(2-N-
acetyl-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-ethyl)-acetamide (52) was synthesized 
according to the general method for DCC/NHS coupling (general method 2) using 1.2 
equivalents of 2,3,4,6-tetra-O-acetyl-1-(2-amino-ethoxy)-glucosamine (27) to yield a white 
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solid (22.6 mg, 51 %); TLC Rf 0.1 (19:1 chloroform/methanol);
 1
H NMR (400 MHz, 
CDCl3, 25 °C) : δH 1.94 (3H, s, NHAc CH3), 2.03 (3H, s, Ac CH3), 2.04 (3H, s, Ac CH3), 
2.08 (3H, s, Ac CH3), 3.36-3.41 (1H, m, OCH2CHaHb), 3.65-3.72 (3H, m, OCH2CHaHb, 
OCH2CH2NH), 3.84-3.92 (2H, m, H-5, H-2), 4.03 (2H, t, 
3
J (H,F) = 14.0 Hz, CH2CF2), 
4.06 (2H, t, 
3
J (H,F) = 13.9 Hz, CH2CF2), 4.10-4.13 (1H, m, H-6a), 4.15 (2H, s, 
CH2CONH), 4.24 (1H, dd, 
3
J (H,H) = 4.9, 12.3 Hz, H-6b), 4.68 (1H, d, 
3
J (H,H) = 8.4 Hz, 
H-1), 5.07 (1H, dd, 
3
J (H,H) = 9.5, 9.8 Hz, H-4), 5.24 (1H, dd, 
3
J (H,H) = 9.4, 10.5 Hz, H-
3), 5.42 (2H, s, CH2-Ar), 5.68 (1H, d, 
3
J (H,H) = 8.6 Hz, NH-2), 6.80 (1H, t, 
3
J (H,H) = 6.0 
Hz, CONH), 8.00-8.36 (9H, m, 9 × Ar CH);
 13
C NMR (100 MHz, CDCl3, 25 °C) : δH 20.9-
21.0 (3 × OAc-CH3), 23.5 (NHAc-CH3), 38.5 (CH2NH), 54.6 (CH-2), 62.1 (CH2-6), 67.9 
(CH2CH2NH), 68.1 (t, 
2
J (C,F) = 24.8 Hz, CH2CF2), 68.5 (CH-4), 69.5 (t, 
2
J (C,F) = 24.4 
Hz, CH2CF2),  72.0 (CH2CONH), 72.1 (CH-5), 72.5 (CH-3), 73.2 (CH2-Ar), 100.4 (CH-1), 
123.4, (CH), 124.8 (CH), 124.9 (C), 125.3 (C), 125.9 (2 × CH), 126.5 (CH), 127.7 (2 × 
CH), 128.2 (CH), 128.5 (CH), 129.4 (C), 129.9 (C), 131.1 (C), 131.5 (C), 132.2 (C), 168.6 
(CONH), 169.7-171.3 (4 × Ac CO); MS (ES
+
) m/z: 1107.2 (8 %) [M+H]
+
, 1129.3 (10 %) 
[M+Na]
+
; IR υ (cm-1) 1022, 1095, 1169, 1260, 1465, 1668, 1732, 2853, 2923. 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decloxy-N-(2-(2-N-
acetyl-β-D-glucopyranosyl)-ethyl)-acetamide (53) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decloxy-N-(2-(2-N-
acetyl-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-ethyl)-acetamide (52, 18.3 mg, 0.0165 
mmol) was deprotected using the general method for deacetylation (general method 3) to 
yield a white solid (15.6 mg, 96%); TLC Rf 0.05 (9:1 chloroform/methanol, brown spot 
with ninhydrin followed by heat);
 1
H NMR (400 MHz, MeOD, 25 °C) : δH 1.88 (3H, s, 
NHAc CH3), 3.27-3.33 (2H, m, H-4, H-5), 3.41-3.46 (3H, m, CH2NH, H-3), 3.63-3.69 (3H, 
m, OCHaHbCH2, H-2, H-6a), 3.86-3.90 (2H, m, OCHaHbCH2, H-6b, 4.17 (2H, s, 
NHCOCH2), 4.20 (2H, t, 
3
J (H,F) = 13.9 Hz, CH2CF2), 4.23 (2H, t, 
3
J (H,F) = 14.2 Hz, 
CH2CF2), 4.40 (1H, d, 
3
J (H,H) = 8.4 Hz, H-1), 5.41 (2H, s, CH2-Ar), 8.02-8.40 (9H, m, 9 × 
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Ar CH); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δH 23.2 (NHAc CH3), 40.4 (CH2NH), 57.4 
(CH-2), 63.0 (CH2-6), 68.0 (t, 
2
J (C,F) = 24.7 Hz, CH2CF2), 68.9 (OCH2CH2), 69.3 (t, 
2
J 
(C,F) = 23.9 Hz, CH2CF2), 72.3 (CH-4), 72.8 (NHCOCH2), 74.0 (CH2-Ar), 76.3 (CH-3), 
78.2 (CH-5), 102.9 (CH-1), 124.5 (CH), 125.8 (H), 126.0 (C). 126.2 (C), 126.7 (2 × CH) 
127.4 ( CH), 128.6 (CH), 128.7 (CH), 129.0 (CH), 129.2 (CH), 131.1 (C), 131.3 (C), 132.4 
(C), 132.8 (C), 133.3 (C), 171.5 (CO), 174.1 (CO); MS (ES
+
) m/z: 981.3 (2 %) [M+H]
+
 
1003.3 (4 %) [M+Na]
+
; MS (MALDI) m/z: 1003.194 (100 %) [M+Na]
+
; HRMS (ES
+
) m/z: 
calc. for [C39H37F16N2O9]
+
 981.2238, found 981.2195 [M+H]
+
, calc. for 
[C39H36F16N2O9Na]
+
 1003.2058, found 1003.2013 [M+Na]
+
; IR υ (cm-1) 1147, 1204, 1655, 
2924, 3301-3369. 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-α-D-
glucopyranosyl bromide (43)
192
 
 
Lactose octaacetate (42, 1.3 g, 1.917 mmol) and acetic anhydride (0.2 mL) were 
dissolved in dry chloroform (6 mL). To the mixture was added HBr/AcOH (2.3 mL) and 
the mixture was stirred for 2 hours. The mixture was then diluted with chloroform (20 
mL) and washed with sodium bicarbonate (2 × 20 mL) followed by brine (20 mL). The 
organic layer was dried using anhydrous magnesium sulphate and the solvent was 
removed under vacuum. The product was recrystallised from 1:1 ethyl acetate/hexane to 
yield clear needle-like crystals (1.18 g, 89 %); TLC Rf 0.45 (1:1 ethyl acetate/40-60 °C 
petroleum ether);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.96 (3H, s, Ac CH3), 2.05-
2.06 (9H, m, 3 × Ac CH3), 2.09 (3H, s, Ac CH3), 2.13 (3H, s, Ac CH3), 2.16 (3H, s, Ac 
CH3), 3.83-3.86 (2H, m, H-4, H‟-5), 4.08-4.17 (4H, m, H-5, CH2‟-6, H-6a), 4.46-4.48 
(1H, m, H-6b), 4.50 (1H, d, 
3
J (H,H) = 7.9 Hz, H‟-1), 4.75 (1H, dd, 3J (H,H) = 4.1, 10.0 
Hz, H-2), 4.95 (1H, dd, 
3
J (H,H) = 3.5, 10.4 Hz, H‟-3), 5.12 (1H, dd, 3J (H,H) = 7.9, 
10.4 Hz, H‟-2), 5.35 (1H, dd, 3J (H,H) = 0.9, 3.4 Hz, H‟-4), 5.55 (1H, dd, 3J (H,H) =  
9.9, 10.0 Hz, H-3), 6.52 (1H, dd, 
3
J (H,H) = 4.0 Hz, H-1); 
13
C NMR (100 MHz, CDCl3, 
25 °C) : δH 20.8-21.1 (7 × Ac CH3), 61.2 (CH2‟-6), 61.4 (CH2), 67.0 (CH‟-4), 69.4 
(CH‟-2), 70.0 (CH-3), 71.1 (CH‟-5), 71.2 (CH-2), 71.4 (CH‟-3), 73.3 (CH-5), 75.3 (CH-
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4), 86.7 (CH-1), 101.2 (CH‟-1), 169.3-170.6 (7 × Ac CO); MS (ES+) m/z: 717.8 (38 %) 
[M+H3O]
+
; HRMS (ES
+
) m/z: calc. for [C26H35O17Br] 698.1058, found 659.1870 [M-
Br+Na+H2O]
+
; IR υ (cm-1) 1043, 1216, 1368, 1435, 1740, 2970-3016. 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl-1-benzyl N-(2-hydroxyethyl)carbamate (44)
192
 
 
Mercuric bromide (100 mg, 0.277 mmol, 1 eq.), mercuric cyanide (70 mg, 0.277 mmol, 
1 eq.) and N-Z-ethanolamine (139 mg, 0.701 mmol, 2.5 eq.) were dissolved in dry 
acetonitrile (1 mL) under nitrogen with 4 Å molecular sieves. 2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-α-D-glucopyranosyl bromide (43, 200 mg, 
0.286 mmol, 1 eq.) was dissolved in dry acetonitrile (1 mL) and added dropwise to the 
stirring solution. The reaction mixture was then stirred for 16 hours in the dark at room 
temperature. The mixture was then diluted with chloroform (10 mL) and washed with 
water (10 mL) followed by sodium iodide solution (1 M, 10 mL). The organic layer was 
dried using anhydrous magnesium sulphate and the solvent was removed under vacuum. 
The crude product was acetylated using 3:1 pyridine/acetic anhydride (4 mL) overnight. 
The crude product (1:1.7 α/β anomeric ratio) was then purified using flash column 
chromatography (3:2 40-60 °C petroleum ether/ethyl acetate on silica) to yield the pure 
β-anomer as a clear oil (67 mg, 29 % yield); TLC Rf 0.3 (1:1 ethyl acetate/40-60 °C 
petroleum ether);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.95 (3H, s, Ac CH3), 1.97 
(3H, s, Ac CH3), 2.02 (6H, s, 2 × Ac CH3), 2.04 (3H, s, Ac CH3), 2.06 (3H, s, Ac CH3), 
2.13 (3H, s, Ac CH3), 3.34-3.36 (2H, m, CH2NH), 3.56 (1H, ddd, 
3
J (H,H) = 1.9, 5.0, 
9.8 Hz, H-5), 3.65-3.67 (1H, m, CHaHbCH2), 3.75 (1H, dd, 
3
J (H,H) = 9.4, 9.8 Hz, H-4), 
3.77-3.79 (1H, m, CHaHbCH2), 3.85 (1H, dd, 
3
J (H,H) = 0.7, 7.0 Hz, H‟-5), 4.03-4.11 
(3H, m, CH2‟-6, H-6a), 4.42 (1H, d, 
3
J (H,H) = 8.0 Hz, H-1), 4.45 (1H, d, 
3
J (H,H) = 7.8 
Hz, H‟-1), 4.48 (1H, dd, 3J (H,H) = 1.5, 11.8 Hz, H-6b), 4.85 (1H, dd, 
3
J (H,H) = 8.0, 
9.6 Hz, H-2), 4.93 (1H, dd, 
3
J (H,H) = 3.4, 10.4 Hz, H‟-3), 5.07 (2H, s, CH2-Ar), 5.09 
(1H, dd, 
3
J (H,H) = 7.9, 10.4 Hz, H‟-2), 5.15 (1H, dd, 3J (H,H) = 9.4, 9.4 Hz, H-3), 5.20 
(1H, t, 
3
J (H,H) = 5.4 Hz, NH), 5.33 (1H, dd, 
3
J (H,H) = 0.7, 3.3 Hz, H‟-4), 7.28 (5H, 
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m, 5 × Ar H); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 20.8-21.1 (7 × Ac CH3), 41.3 
(CH2NH), 61.1 (CH2‟-6), 62.2 (CH2-6), 66.9 (CH‟-4), 67.0 (Ar-CH2), 69.4 (CH‟-2), 
69.8 (OCH2CH2NH), 71.0 (CH‟-5), 71.3 (CH‟-3), 71.9 (CH-2), 72.9 (CH-3) 73.0 (CH-
5), 76.5 (CH-4), 101.2 (CH-1), 101.4 (CH‟-1), 128.4-128.8 (5 × Ar CH), 136.8 (Ar Cq), 
156.6 (Ar CO), 169.4-170.6 (7 × OAc CO); MS (ES
+
) m/z: 813.9 (10 %) [M+H]
+
, 830.9 
(24 %) [M+H2O]; HRMS (ES
+
) m/z: calc. for [C36H47NO20Na]
+
 836.2584, found 
836.2584; IR 1429, 1521, 1753 (CO), 2945, 3386 (NH); Anal. Calc. for C36H47NO20 C 
53.13, H 5.82, N 1.72, found C 49.10, H 5.66, N 1.57. 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl-1-(2-hydroxyethyl)amine (26) 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl-1-
benzyl N-(2-hydroxyethyl)carbamate (44, 100 mg, 0.123 mmol) was deprotected using the 
general method for CBz removal to yield a clear oil (67 mg, 80 %); TLC Rf 0.0 (1:1 ethyl 
acetate/40-60 °C petroleum ether);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.93 (3H, s, Ac 
CH3), 2.01 (9H, s, 3 × Ac CH3), 2.03 (3H, s, Ac CH3), 2.09 (3H, s, Ac CH3), 2.12 (3H, s, 
Ac CH3), 2.28-2.33 (2H, m, NH2), 2.81-2.88 (2H, m, CH2NH2), 3.57-3.61 (2H, m, H-5, 
CHaHbCH2), 3.76 (1H, dd, 
3
J (H,H) = 9.2, 9.5 Hz, H-4), 3.79-3.85 (2H, m, CHaHbCH2, H‟-
5), 4.02-4.11 (3H, m, CH2‟-6, H-6a), 4.45 (1H, d, 
3
J (H,H) = 7.8 Hz, H‟-1), 4.47 (1H, d, 3J 
(H,H) = 7.8 Hz, H-1), 4.48-4.52 (1H, m, H-6b), 4.85 (1H, dd, 
3
J (H,H) = 7.8, 9.4 Hz, H-2), 
4.92 (1H, dd, 
3
J (H,H) = 3.1, 10.4 Hz, H‟-3), 5.08 (1H, dd, 3J (H,H) = 8.0, 10.2 Hz, H‟-2), 
5.16 (1H, dd, 
3
J (H,H) = 9.3, 9.3 Hz, H-3), 5.33 (1H, dd, 
3
J (H,H) = 0.7, 2.9 Hz, H‟-4); 13C 
NMR (100 MHz, CDCl3, 25 °C) : δC 20.8-21.2 (7 × Ac CH3), 41.8 (CH2NH2), 61.1 (CH2‟-
6), 62.2 (CH2-6), 66.9 (CH‟-4), 69.3 (CH‟-2), 70.9 (CH‟-5), 71.2 (CH‟-3), 71.9 (CH-2), 
72.4 (OCH2CH2NH), 73.0 (CH-3, CH-5), 76.5 (CH-4), 101.1 (CH-1), 101.3 (CH‟-1), 
169.4-170.6 (7 × Ac CO); MS (ES
+
) m/z: 680.3 (100 %) [M+H]
+
; HRMS (ES
+
) m/z: calc. 
for [C28H42NO11]
+
  680.2396, found 680.2399. 
 
7. Experimental Procedures 
 
195 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-2-(D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl) -ethyl)-acetamide (54) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-2-(D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl) -
ethyl)-acetamide (54) was synthesized according to the general method for DCC/NHS 
coupling (general method 2) using 1.5 equivalents of 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl-1-(2-hydroxyethyl)amine 
(26) to yield a light yellow oil (55 mg, 58%); TLC Rf 0.55 (19:1 chloroform/methanol);
 1
H 
NMR (400 MHz, CDCl3, 25 °C) : δH 1.96 (3H, s, Ac CH3), 2.02 (3H, s, Ac CH3), 2.03-2.04 
(9H, s, 3 × Ac CH3), 2.10 (3H, s, Ac CH3), 2.15 (3H, s, Ac CH3), 3.49-3.55 (2H, m, 
CH2NH2), 3.59 (1H, ddd, 
3
J (H,H) = 1.9, 3.6, 9.7 Hz, H-5), 3.63-3.69 (1H, m, CHaHbCH2), 
3.75 (1H, dd, 
3
J (H,H) = 9.2, 9.7 Hz, H-4), 3.82-3.87 (2H, m, CHaHbCH2, H‟-5), 4.02 (2H, 
t, 
3
J (H,F) = 13.7 Hz, CH2CF2), 4.04 (2H, t, 
3
J (H,F) = 14.3 Hz, CH2CF2), 4.05-4.12 (3H, 
m, CH2‟-6, H-6a), 4.13 (2H, s, CH2CONH), 4.46 (1H, d, 
3
J (H,H) = 7.7 Hz, H-1), 4.47 (1H, 
d, 
3
J (H,H) = 7.7 Hz, H‟-1), 4.50 (1H, dd, 3J (H,H) = 1.7, 11.7 Hz, H-6b), 4.87 (1H, dd, 
3
J 
(H,H) = 8.0, 9.3 Hz, H-2), 4.95 (1H, dd, 
3
J (H,H) = 3.3, 10.4 Hz, H‟-3), 5.10 (1H, dd, 3J 
(H,H) = 7.9, 10.4 Hz, H‟-2), 5.19 (1H, dd, 3J (H,H) = 9.2, 9.3 Hz, H-3), 5.33 (1H, dd, 3J 
(H,H) = 0.7, 3.0 Hz, H‟-4), 5.40 (2H, s, Ar-CH2), 6.72 (1H, t, 
3
J (H,H) = 5.6 Hz, CONH), 
7.99-8.36 (9H, m, 9 × Ar CH); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 20.6-20.9 (7 × Ac 
CH3), 38.9 (CH2NH), 60.9 (CH2‟-6), 62.0 (CH2-6), 66.6 (t, 
2
J (C,F) = 24.7 Hz, CH2CF2), 
66.7 (CH‟-4), 68.2 (t, 2J (C,F) = 24.4 Hz, CH2CF2), 68.5 (OCH2CH2NH), 69.3 (CH‟-2), 
70.9 (CH‟-5), 71.1 (CH‟-3), 71.7 (CH-2), 72.0 (CH2CONH), 72.9 (CH-3) 73.0 (CH-5), 
73.2 (CH2-Ar), 76.4 (CH-4), 100.6 (CH-1), 101.2 (CH‟-1), 123.2 (CH), 124.6 (CH), 124.7 
(C), 125.1 (C), 125.6 (2 × CH), 126.3 (CH), 127.4 (2 × CH), 128.0 (CH), 128.3 (CH), 129.3 
(C), 129.7 (C), 130.9 (C), 131.3 (C), 132.0 (C), 168.2 (CONH), 169.2-170.3 (7 × Ac CO); 
IR υ (cm-1) 1020, 1263, 1577, 1610, 2933. 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-2-(D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl) -ethyl)-acetamide (55)  
 
The deprotection of 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-
decyloxy-N-(2-D-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl -ethyl)-acetamide (54, 20 mg) was deprotected using the general method 
for deacetylation (general method 3) to yield a light yellow solid (8.3 mg, 53%); TLC Rf 
0.0 (19:1 chloroform/methanol);
 1
H NMR (400 MHz, DMF-d7, 25 °C) : δH 3.18 (1H, ddd, 
3
J (H,H) = 4.0, 8.2, 8.2 Hz, H-2), 3.41-3.58 (7H, m, CH2NH, H‟-2, 4 × sugar CH), 3.61-
3.92 (10H, m, CH2CH2NH, CH2-6, CH2‟-6, 2 × sugar CH, OH-6, OH‟-6), 4.24 (2H, s, 
CH2CONH), 4.35 (1H, d, 
3
J (H,H) = 7.8 Hz, H-1), 4.37 (1H, d, 
3
J (H,H) = 7.6 Hz, H-1), 
4.43 (2H, t, 
3
J (H,F) = 13.9 Hz, CH2CF2), 4.50 (2H, t, 
3
J (H,F) = 14.6 Hz, CH2CF2), 4.70-
4.77 (3H, m, OH-3, OH‟-3, OH‟-4), 5.29 (1H, d, 3J (H,H) = 4.1 Hz, OH-2), 5.36 (1H, d, 3J 
(H,H) = 4.4 Hz, OH‟-2), 5.54 (2H, s, Ar-CH2), 7.97 (1H, t, 
3
J (H,H) = 5.8 Hz, CONH), 
8.11-8.50 (9H, m, 9 × Ar CH); 
13
C NMR (100 MHz, DMF-d7, 25 °C) : δC 39.1 (CH2NH), 
61.5 (CH2), 61.7 (CH2), 66.7 (t, 
2
J = 25.2 Hz, CH2CF2), 68.0 (t, 
2
J = 25.8 Hz, CH2CF2), 
68.5 (OCH2CH2NH), 69.2 (CH), 71.6 (CH2CONH), 71.7 (CH), 72.6 (CH2-Ar), 74.2 (CH), 
74.4 (CH), 75.8 (2 × CH), 76.5 (CH), 81.5 (CH), 103.8 (CH-1), 104.9 (CH‟-1), 123.8 (CH), 
124.6 (C), 124.9 (C), 125.1 (CH), 125.9 (2 × CH), 126.7 (CH), 127.8 (CH), 127.9 (CH), 
128.1 (CH), 128.3 (CH), 129.7 (C), 130.9 (C), 131.1 (C), 131.6 (C), 131.9 (C), 168.9 
(CONH); MS (MALDI) m/z: 1124.463 (100 %) [M+Na]
+
; IR υ (cm-1) 1020, 1266, 1624, 
2921, 3340. 
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2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl (9-azido)-triethylene glycol (45)
192
 
 
Mercuric bromide (100 mg, 0.277 mmol, 1 eq.), mercuric cyanide (70 mg, 0.277 mmol, 1 
eq.) and monoazido triethylene glycol (50 mg, 0.286 mmol, 1 eq.) were dissolved in dry 
acetonitrile (1 mL) under nitrogen with 4 Å molecular sieves. 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-α-D-glucopyranosyl bromide (43, 200 mg, 0.286 
mmol, 1 eq.) was dissolved in dry acetonitrile (1 mL) and added dropwise to the stirring 
solution. The reaction mixture was then stirred for 12 hours in the dark at room 
temperature. The mixture was then diluted with chloroform (10 mL) and washed with water 
(10 mL) followed by sodium iodide solution (1 M, 10 mL). The organic layer was dried 
using anhydrous magnesium sulphate and the solvent was removed under vacuum. The 
crude product was acetylated using 3:1 pyridine/acetic anhydride (4 mL) overnight. The 
product was then purified using flash column chromatography (3:2 40-60 °C petroleum 
ether/ethyl acetate on silica) to yield a clear oil (44 mg, 20 % yield); TLC Rf 0.2 (1:1 ethyl 
acetate/40-60 °C petroleum ether);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.95 (3H, s, Ac 
CH3), 2.02-2.03 (9H, m, 3 × Ac CH3), 2.04 (3H, s, Ac CH3), 2.10 (3H, s, Ac CH3), 2.13 
(3H, s, Ac CH3), 3.38 (2H, t, 
3
J (H,H) = 5.2 Hz, TEG CH2N3), 3.57-3.59 (1H, m, H-5), 
3.61-3.67 (9H, m, 4 × TEG CH2, TEG C(1)HaHb), 3.77 (1H, dd, 
3
J (H,H) = 9.3, 9.3 Hz, H-
4), 3.83-3.91 (2H, m, H‟-5, TEG C(1)HaHb), 4.04-4.13 (3H, m, CH2‟-6, H-6a), 4.46 (1H, d, 
3
J (H,H) = 7.9 Hz, H‟-1), 4.47 (1H, dd, 3J (H,H) = 1.9, 12.4 Hz, H-6b), 4.55 (1H, d, 
3
J 
(H,H) = 7.9 Hz, H-1), 4.88 (1H, dd, 
3
J (H,H) = 8.0, 9.6 Hz, H-2), 4.93 (1H, dd, 
3
J (H,H) = 
3.4, 10.4 Hz, H‟-3), 5.09 (1H, dd, 3J (H,H) = 7.9, 10.4 Hz, H‟-2), 5.18 (1H, dd, 3J (H,H) = 
9.3, 9.5 Hz, H-3), 5.33 (1H, dd, 
3
J (H,H) = 0.9, 3.4 Hz, H‟-4); 13C NMR (100 MHz, CDCl3, 
25 °C) : δC 20.8-21.2 (7 × Ac CH3), 51.0 (CH2N3), 61.1 (CH2‟-6), 62.3 (CH2-6), 66.9 (CH‟-
4), 69.3 (TEG C(1)H2CH2), 69.4 (CH‟-2), 70.4 (TEG CH2), 70.7 (TEG CH2), 70.9-71.0 
(CH‟-5, 2 × TEG CH2), 71.3 (CH‟-3), 72.0 (CH-2), 72.9 (CH-5), 73.1 (CH-3), 76.6 (CH-4), 
100.9 (CH-1), 101.4 (CH‟-1), 169.4-170.7 (7 × Ac CO); MS (ES+) m/z: 810.9 (100 %) 
[M+H2O]; HRMS (ES
+
) m/z: calc. for [C32H47N3O13Na]
+
 816.2645, found 816.2670; IR υ 
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(cm
-1
) 1058, 1229, 1370, 1437, 1584, 1753 (sharp, CO), 2111 (sharp, N3), 2876, 2938, 
3339. 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl (9-amino)-triethylene glycol (29)
200
 
 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl (9-
azido)-triethylene glycol (45, 44 mg, 0.0555 mmol) was dissolved in ethanol (2 mL) and 10 
% palladium on charcoal (5 mg) was added. The mixture was put under a nitrogen 
atmosphere and then subjected to a H2 atmosphere. The reaction mixture was stirred for 60 
minutes, filtered through Celite and then the solvent was removed under reduced pressure 
to yield a clear oil (37 mg, 87 %); TLC Rf 0.0 (1:1 ethyl acetate/40-60 °C petroleum ether);
 
1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.93 (3H, s, Ac CH3), 2.01 (9H, s, 3 × Ac CH3), 
2.03 (3H, s, Ac CH3), 2.09 (3H, s, Ac CH3), 2.12 (3H, s, Ac CH3), 2.41-2.44 (2H, m, NH2), 
2.85-2.87 (2H, m, TEG CH2NH2), 3.49 (2H, t, 
3
J (H,H) = 6.5 Hz, TEG CH2CH2NH2), 3.57-
3.63 (7H, m, 3 × TEG CH2, H-5), 3.64-3.66 (1H, m, TEG C(1)HaHb), 3.77 (1H, dd, 
3
J = 9.2, 
9.7 Hz, H-4), 3.83-3.92 (2H, m, H‟-5, TEG C(1)HaHb), 4.02-4.13 (3H, m, CH2‟-6, H-6a), 
4.45-4.48 (2H, m, H‟-1, H-6b), 4.55 (1H, d, 
3
J (H,H) = 7.8 Hz, H-1), 4.86 (1H, dd, 
3
J (H,H) 
= 8.2, 9.3 Hz, H-2), 4.92 (1H, dd, 
3
J (H,H) = 3.4, 10.4 Hz, H‟-3), 5.08 (1H, dd, 3J (H,H) = 
7.9, 10.4 Hz, H‟-2), 5.16 (1H, dd, 3J (H,H) = 9.2, 9.3 Hz, H-3), 5.31 (1H, dd, 3J (H,H) = 
0.8, 3.0 Hz, H‟-4); 13C NMR (100 MHz, CDCl3, 25 °C) : δC 20.7-21.2 (7 × Ac CH3), 41.8 
(CH2NH2), 61.1 (CH2‟-6), 62.3 (CH2-6), 66.9 (CH‟-4), 69.3 (TEG C(1)H2CH2), 69.4 (CH‟-
2), 70.5 (TEG CH2), 70.6 (TEG CH2), 70.9 (TEG CH2), 71.0 (CH‟-5), 71.3 (CH‟-3), 72.0 
(CH-2), 73.0 (CH-5), 73.1 (CH-3, CH2CH2NH2), 76.5 (CH-4), 100.9 (CH-1), 101.4 (CH‟-
1), 169.3-170.6 (7 × Ac CO); MS (ES
+
) m/z: 768.3 (100 %) [M+H]
+
; HRMS (ES
+
) m/z: 
calc. for [C32H50NO13]
+
 768.2921, found 768.2948; IR υ (cm-1) 1058, 1224, 1432, 1752 
(sharp, CO), 2864-2945 (broad, NH). 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-2-(D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl-(2-(2-ethoxy)ethoxy)ethyl)-acetamide (56) 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-(2-α-D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl-
(2-(2-ethoxy)ethoxy)ethyl)-acetamide (56) was synthesized according to the general 
method for DCC/NHS coupling (general method 2) using 1.2 equivalents of 2,3,4,6-tetra-
O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl (9-amino)-
triethylene glycol (29) to yield a light yellow clear oil (26 mg, 44%); TLC Rf 0.46 (19:1 
chloroform/methanol);
 1
H NMR (400 MHz, CDCl3, 25 °C) : δH 1.97 (3H, s, Ac CH3), 2.03 
(3 H, s, Ac CH3), 2.04-2.06 (9H, m, 3 × Ac CH3), 2.11 (3H, s, Ac CH3), 2.15 (3H, s, Ac 
CH3), 3.49-3.55 (2H, m, CH2NH), 3.56-3.62 (9H, m, 4 × TEG CH2, H-5), 3.66-3.72 (1H, 
m, TEG C(1)HaHbCH2), 3.78 (1H, dd, 
3
J (H,H) = 9.4, 9.4 Hz, H-4), 3.85-3.92 (2H, m, TEG 
C(1)HaHbCH2, H‟-5), 4.00-4.12 (7H, m, 2 × CH2CF2, CH2‟-6, H-6a), 4.14 (2H, s, 
CH2CONH), 4.46 (1H, d, 
3
J (H,H) = 7.8 Hz, H‟-1), 4.49 (1H, dd, 3J (H,H) = 1.9, 11.8 Hz, 
H-6b), 4.54 (1H, d, 
3
J (H,H) = 8.0 Hz, H-1), 4.89 (1H, dd, 
3
J (H,H) = 8.0, 9.6 Hz, H-2), 
4.95 (1H, dd, 
3
J (H,H) = 3.4, 10.4 Hz, H‟-3), 5.11 (1H, dd, 3J (H,H) = 8.0, 10.4 Hz, H‟-2), 
5.19 (1H, dd, 
3
J (H,H) = 9.3, 9.3 Hz, H-3), 5.35 (1H, dd, 
3
J (H,H) = 0.8, 3.0 Hz, H‟-4), 5.42 
(2H, s, Ar-CH2), 6.85 (1H, t, 
3
J (H,H) = 5.6 Hz, CONH), 8.00-8.38 (9H, m, 9 × Ar CH); 
13
C NMR (100 MHz, CDCl3, 25 °C) : δC 20.6-20.9 (7 × Ac-CH3), 38.8 (CH2NH), 60.9 
(CH2‟-6), 62.1 (CH2-6), 66.7 (t, 
2
J (C,F) = 25.4 Hz, CH2CF2), 66.8 (CH‟-4), 68.2 (t, 
2
J 
(C,F) = 25.4 Hz, CH2CF2), 69.2 (CH‟-2 + CH2), 69.7 (CH2), 70.4 (CH2), 70.5 (CH2), 70.7 
(CH2), 70.8 (CH‟-5), 71.1 (CH‟-3), 71.7 (CH-2), 71.9 (CH2), 72.7 (CH-3), 72.9 (CH-5), 
73.2 (Ar-CH2), 77.4 (CH-4), 100.8 (CH-1), 101.2 (CH‟-1), 123.2 (CH), 124.6 (CH), 124.7 
(C), 125.1 (C), 125.7 (2 × CH), 126.3 (CH), 127.5 (2 × CH), 128.0 (CH), 128.3 (CH), 129.2 
(C), 129.7 (C), 130.9 (C), 131.3 (C), 132.0 (C), 168.0 (CONH), 169.2-170.5 (7 × Ac CO); 
MS (MALDI) m/z: 1507.212 (100 %) [M+Na]
+
; IR υ (cm-1) 1062, 1227, 1427, 1755, 3345 
(NH). 
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2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-decyloxy-N-2-(D-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-D-
glucopyranosyl-(2-(2-ethoxy)ethoxy)ethyl)-acetamide (57) 
 
The deprotection of 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-Hexadecafluoro-10-(pyren-1-ethoxy)-
decyloxy-N-(2-α-D-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1-4)-2,3,6-tri-O-acetyl-β-
D-glucopyranosyl-(2-(2-ethoxy)ethoxy)ethyl)-acetamide (56, 26 mg) was deprotected using 
the general method for deacetylation (general method 3) to yield a light yellow solid (17.8 
mg, 86%); TLC Rf 0.0 (19:1 chloroform/methanol); 
 1
H NMR (400 MHz, MeOD, 25 °C) : 
δH 3.31 (1H, t, 
3
J (H,H) = 8.6 Hz, TEG-CHaHb), 3.43 (1H, ddd, 
3
J (H,H) = 1.8, 3.7, 9.8 Hz, 
H-5), 3.47-3.50 (2H, m, TEG CH2), 3.52-3.54 (1H, m, TEG-CHaHb), 3.56-3.88 (17H, m, H-
2, H-3, H-4, H‟-2, H‟-3, H‟-4, H‟-5, sugar CH2, 4 × TEG CH2), 3.90-4.03 (2H, m, sugar 
CH2), 4.20 (2H, s, CH2CONH), 4.24 (2H, t, 
3
J (H,F) = 14.0 Hz, CH2CF2), 4.26 (2H, t, 
3
J 
(H,F) = 14.2 Hz, CH2CF2), 4.36 (1H, d, 
3
J (H,H) = 7.8 Hz, H-1), 4.39 (1H, d, 
3
J (H,H) = 
7.6 Hz, H-1), 5.44 (2H, s, Ar-CH2), 8.05-8.42 (9H, m, 9 × Ar CH); 
13
C NMR (100 MHz, 
MeOD, 25 °C) : δC 39.9 (CH2NH), 61.9 (CH2-6), 62.5 (CH2-6), 67.8 (t, 
2
J (C,F) = 26.2 Hz, 
CH2CF2), 69.0 (t, 
2
J (C,F) = 26.2 Hz, CH2CF2), 69.7 (TEG CH2), 70.3 (CH), 70.4 (TEG 
CH2), 71.2 (TEG CH2), 71.4 (TEG CH2), 71.5 (TEG CH2), 72.4 (CH2-Ar), 72.5 (CH), 73.8 
(TEG CH2), 74.7 (CH), 74.8 (CH), 76.3 (CH), 76.5 (CH), 77.1 (CH), 80.6 (CH), 104.3 
(CH), 105.1 (CH), 124.3 (CH), 125.5 (CH), 125.7 (C), 126.0 (C), 126.5 (2 × CH), 127.2 
(CH), 128.4 (CH), 128.5 (CH), 128.8 (CH), 128.9 (CH), 130.8 (C), 131.1 (C), 132.2 (C), 
132.6 (C), 133.1 (C), 171.1 (CONH); MS (MALDI) m/z: 1212.384 (100 %) [M+Na]
+
; IR υ 
(cm
-1
) 1082, 1220, 1435, 1761, 2948 (broad), 3343. 
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7.3 Analytical procedures 
 
7.3.1 General procedures for fluorescence spectroscopy 
 
For fluorescence spectroscopy pyrene species were excited at 346 nm and emission was 
measured at the point of highest intensity (379 or 395 nm for monomer fluorescence and 
470 nm for excimer fluorescence). MUM was excited at 317 nm and emission read at 375 
nm. CF was excited at 483 nm and emission read at 520 nm. Fluorescein was excited at 492 
nm and emission read at 517 nm. Rh-DHPE was excited at 560 nm and emission read at 
588 nm. Fluorescence spectra were measured at a scan speed of 300 nm/min and the 
excitation/emission slit widths were varied as appropriate (typically 10 nm widths). 
 
7.3.2 Dynamic light scattering (DLS) 
 
Lipid 49 or 51 (0.2 μmol) was dissolved in ethanol-free spectrophotometric grade 
chloroform and a thin film of lipid made by rotary evaporation of the solvent. Lipid 49 or 
51 was then suspended in buffer (1 mL, 20 mM MOPS, 100 mM NaCl, pH 7.4) by 
sonication for 5 minutes to give a 200 µM dispersion of lipid. 0.2 mL was transferred to a 
DLS cuvette and 10 × 10 second acquisitions at 25 °C were performed for each lipid. This 
was repeated 3 times using a laser power of 30%. Results were analysed using Wyatt 
Dynamics software (version 6.7.7.9). 
 
7.3.3 Critical aggregation concentration (CAC) 
 
Buffer (1 mL, 20 mM MOPS, 100 mM NaCl, pH 7.4) was added to a thin film of 
glyclipid and was vortex mixed and sonicated for 5 minutes to give a lipid dispersion 
(200 µM lipid). The fluorescence spectrum was recorded, then the solution diluted 10-
fold using buffer and fluorescence spectrum re-recorded. This procedure was repeated 
until the fluorescence was too weak to measure (2 nM). The excimer to monomer 
fluorescence ratio (E/M) was plotted vs. log[lipid]; the point at which excimer emission 
is no longer significant corresponded to the the CAC. 
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7.3.4 Solution-phase binding of ConA to mannosyl-lipids – MUM method 
 
Determination of K for 4-methylumbelliferyl-α-D-mannopyranoside (MUM) binding to 
ConA: Concanavalin A/MUM solution (1.57 mM ConA, 2 µM MUM, 20 mM MOPS, 
100 mM NaCl, pH 7.4, 15 × 10 µL titres) was added to a buffered solution of MUM (2 
mL, 2 µM MUM, 20 mM MOPS, 100 mM NaCl, pH 7.4). Fluorescence spectra were 
recorded (ex. at 317 nm) 60 s after each addition. The quenching of emission at 375 nm 
was fitted to a Stern-Volmer plot, which gave K = 3.37 ± 0.09 × 10
4
 M
-1
 (Kstat = K). 
 
Determination of K for 49 and 51 binding to ConA in solution (Competition experiment 
with MUM): 15 × 10 µL titres of ConA/MUM solution with 49 or 51 (1.57 mM ConA, 
20 µM 49 or 51, 2 µM MUM, 20 mM MOPS, 100 mM NaCl, pH 7.4) were added to a 
solution of MUM with 49 or 51 (2 µM MUM, 20 µM 49 or 51, 2 mL, 20 mM MOPS, 
100 mM NaCl, pH 7.4). Fluorescence spectra were recorded (ex. at 317 nm) 60 s after 
each addition. The emission of MUM (375 nm) and pyrene monomer (379 and 395 nm) 
overlaps when excited at 317 nm, while that of the pyrene excimer was clear. Therefore 
analogous titrations in the absence of MUM were carried to give E/M ratios that 
allowed the determination of the contribution of pyene monomer and thus MUM to the 
fluorescence at 375 nm. In a modification of the procedure of Landschoot et al,
201
 a 
Scatchard plot was employed to determine K. Equations 7.1 and 7.2 were used to 
resolve values for the response (amount of bound ligand, r) and amount of unbound 
pyrene lipid [P]f ([49]f or [51]f) at each titre point.   
 
    
 
   
     
 
        
     (7.1) 
 
                   
 
        
     (7.2) 
 
Where [C], [U] and [P] are the total concentrations of ConA, MUM and pyrene lipid 
respectively. Kcu is the association constant of MUM with ConA and B = 1 – Fu(0)/Fu 
(Fu(0) is the initial MUM fluorescence at 375 nm). Plotting r/[P] f vs. r gave a linear plot 
with a gradient of –K, which gave K = 5.4 ± 0.5 × 103 M-1 for 49 and K was 6.9 ± 1.1 × 
10
3
 M
-1
 for 51. 
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7.3.5 Solution-phase binding of ConA to lipid 51 – ITC 
 
24 × 12 µL titres of a 2 mM suspension of 51 (20 mM MOPS, 1 mM MnCl2, 1 mM CaCl2, 
100 mM NaCl, pH 7.4, 5% v/v DMSO) were injected into the cell containing 200 µM 
ConA (20 mM MOPS, 1 mM MnCl2, 1 mM CaCl2, 100 mM NaCl, pH 7.4, 5% v/v 
DMSO), at 25 ºC, using a reference power of 12 and stirring at 310 rpm. Lipid 51 was also 
titrated into neat buffer to obtain heats of dilution. The heats of dilution were subtracted 
from the titration with ConA and curve-fitted using a single-site binding model with 
Origin-ITC (version 5). 
 
7.3.6 Preparation of large unilamellar vesicles (LUVs) 
 
800 nm unilamellar vesicles were prepared by dissolving the required molar ratio of 
DMPC, DSPC, DPPC cholesterol and synthetic lipid in ethanol-free spectroscopic grade 
chloroform (total lipid = 20 µmol) followed by removal of the solvent to give a thin 
film of lipid. The appropriate buffer (for ConA studies, 1 mL, 20 mM MOPS, 100 mM 
NaCl, pH 7.4 at room temperature; for β4GalT1 studies, 1 mL, 50 mM MES, pH 7 at 37 
°C; for TcTS studies, 1mL, 100 mM phosphate buffer, pH 7.4 at 37 °C) was added to 
the flask, and the thin film detached by vortex mixing. Extrusion (19 ×) through a single 
800 nm polycarbonate membrane using an Avestin Liposofast extrusion apparatus 
above the lipid Tm gave unilamellar vesicles. For 1% mol/mol loading the final 
concentration of phospholipid was 20 mM and that of the synthetic lipid 200 μM. For 
vesicles containing 2, 5 or 10% mol/mol synthetic lipid, the synthetic lipid 
concentration remained constant but the amount of phospholipid was reduced to 9.8 
µmol, 3.8 µmol 1.8 µmol respectively. This gave final total lipid concentrations of 10 
mM, 4 mM and 2 mM respectively whilst that of the synthetic lipid remained 200 μM. 
All vesicle suspensions were freshly extruded and incubated at the required assay 
temperature overnight prior to fluorescence or UV studies. 
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7.3.7 Preparation of giant unilamellar vesicles (GUVs) 
 
GUVs composed of DMPC, DPPC and DMPC/chol doped with 10% mol/mol 1 were made 
by slight modification of  literature protocols.
19
 The desired phospholipid in chloroform (18 
μL, 10 mM) and glycolipid (20 μL, 1 mM) were mixed and spotted onto an indium tin 
oxide (ITO) glass slide. The chloroform was evaporated to leave a thin lipid film. The 
electroformation chamber was assembled, glucose solution (30 μL, 300 mM) was added 
and the chamber sealed. Vesicles were electroformed above their respective transition 
temperatures (30 °C for DMPC, 65 °C for DPPC and DMPC/chol) in a glucose solution 
(300 mM). After electroformation GUVs (30 μL) were mixed with a sucrose solution (30 
μL, 300 mM) in a custom glass chamber and visualised using epifluorescence microscopy. 
 
7.3.8 Determination of lipid insertion into vesicles - GPC 
 
Dispersions of synthetic glycolipids (2.5 mL, 20 µM glycolipid) in buffer or suspensions of 
DMPC vesicles with 1, 2 or 5 % mol/mol glycolipid (2.5 mL) were loaded onto GPC 
columns. The samples were eluted with buffer and fluorescence spectra recorded for each 1 
mL of eluent. For each sample the fluorescence emission at 379 and 460 nm was plotted 
against elution volume. Very little free glycolipid eluted from the GPC columns within the 
first 10 mL, whereas almost all (~99 %) vesicle-bound glycolipid in DMPC irrespective of 
membrane loading of glycolipid. 
 
7.3.9 Determination of lipid insertion into vesicles – UV-vis method 
 
Glycolipid was added at 1, 5 or 10 % mol/mol to the appropriate lipid mixture in buffer and 
vortex mixed to give a lamellar suspension. The UV-visible spectra of the resulting 
suspensions were taken. 800 nm vesicles were formed using the extrusion protocol and UV-
vis spectra of each mixture were measured again. The suspensions were each passed down 
PD-10 GPC columns, eluting with the appropriate buffer. The amount of glycolipid 
incorporated was determined by calculating the difference in peak height (using the 
maximal UV absorption at 346 nm) of glycolipid before and after extrusion. 
7. Experimental Procedures 
 
205 
 
7.3.10 Insertion of synthetic glycolipids into phospholipid vesicles – ‘flip-flop’ 
 
A solution of glycolipid in methanol (4 nmol in 20 μL) was added to a suspension of 
blank vesicles formed by the extrusion method (0.4 μmol, 80 μL, 5 mM) to give 1% 
mol/mol loading of glycolipid. Immediately after addition, the mixture was vortexed at 
high speed for 300 s. The suspension was diluted with MOPS buffer (1.9 mL) and the 
fluorescence (ex. at 346 nm) of the resulting suspension of vesicles (2 mL, 200 μM total 
lipids, 2 μM glycolipid) measured. The fluorescence spectra of the sample was 
measured at 30 minute intervals for 24 hours.  
 
7.3.11 Quenching of vesicle-bound pyrenyl-lipids by ConA - titration 
 
Freshly extruded vesicle suspension (200 µL) containing the desired synthetic lipid (1% 
mol/mol non-ConA-binding 23 or 47 or mannosyl-lipids 49 or 51) were diluted to 2 mL 
with buffer (2 mM total lipid, 20 mM MOPS, 100 mM NaCl, pH 7.4) and the 
fluorescence spectrum measured. For 2% or 5% mol/mol loading the total lipid 
concentration was 1 mM and 400 μM respectively. Using a constant analyte 
concentration method, 20 × 10 µL titres of ConA solution (62.4 mg/mL, 2.4 mM 
(binding sites), 2 mM vesicles in 20 mM MOPS buffer, 100 mM NaCl, pH 7.4) were 
added and the fluorescence spectrum recorded 60 s after each addition. These 
fluorescence data were corrected for dilution of ConA and fitted to a Stern-Volmer plot. 
Control experiments using synthetic lipid 23 or 47 possessing no binding groups for 
ConA gave the dynamic quenching constants (Kdyn). The association constants (Kstat) for 
49 or 51 to ConA binding were determined by subtracting the observed Kdyn values for 
titrations with 23 from the linear fit of the initial slopes in the Stern-Volmer plots for 49 
or 51.  
 
7.3.12 ConA binding fluorescence timecourse eperiment  
 
Freshly extruded vesicle suspension (200 µL) containing the desired synthetic lipid (1% 
mol/mol 23, 49 or 51) were diluted to 2 mL with buffer (2 mM total lipid, 20 mM 
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MOPS, 100 mM NaCl, pH 7.4) and the fluorescence spectrum measured. ConA (2.08 
mg, 4 eq. binding sites) was added and fluorescence spectra recorded every 60 s for 10 
minutes, then every 600 s for two hours and finally once every 2 hours until 24 hours 
had passed. The E/M ratios were determined and normalised to the highest value 
observed. 
 
7.3.13 Determination of vesicle aggregation by ConA - titration 
 
Freshly extruded vesicle suspension (200 µL) containing the desired synthetic lipid (1% 
mol/mol 49 or 51) were diluted to 2 mL with buffer (2 mM total lipid, 20 mM MOPS, 
100 mM NaCl, pH 7.4) and the absorption spectrum measured. Using a constant analyte 
concentration method, 20 × 10 µL titres of a concanavalin A so lution (40.8 mg/mL, 
1.57 mM ConA, 2 mM vesicles) were added and the absorption spectrum recorded 1 
min after each addition. The absorption at 700 nm was used as the UV indicator of 
turbidity.  
 
7.3.14 Determination of vesicle aggregation by ConA – timecourse 
 
Freshly extruded vesicle suspension (200 µL) containing the desired synthetic lipid (1% 
mol/mol 23, 47, 49 or 51) were diluted to 2 mL with buffer (2 mM total lipid, 20 mM 
MOPS, 100 mM NaCl, pH 7.4) and the absorption spectrum measured. ConA (2.08 mg, 
4 eq. binding sites) was added and absorption spectra recorded every 60 s for 10 
minutes, then every 600 s for 2 hours and finally once every 2 hours until 24 hours had 
passed 
 
7.3.15 Determination of vesicle aggregation by lectins – fluorescence microscopy 
 
ConA: Vesicle suspension (200 µL) containing the desired synthetic lipid (1% mol/mol 23, 
47, 49 or 51) were diluted to 2 mL with buffer (2 mM total lipid, 20 mM MOPS, 100 mM 
NaCl, pH 7.4). Unlabelled ConA or FITC-ConA (2.08 mg, 4 eq. binding sites) was added 
and the mixture left for 5 minutes. The mixture (2 μL) was then spotted onto a microscopy 
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glass slide and covered with a glass cover slip. Fluorescence micrographs were taken at 0 
min and at 30 minute intervals after the initial mixing using the DAPI filter to detect pyrene 
fluorescence or the FITC filter for observing FITC fluorescence.  
 
WGA: Vesicle suspension (10 µL, 20 mM total lipid, 50 mM MES, pH 7 at 37 °C) 
containing the desired synthetic lipid (1% mol/mol 53 or 68 (after β4GalT1 treatment of 
vesicles containing 53)) were mixed with FITC-WGA solution (10 μL, 1 mg/mL, 111 μM 
binding sites, 20 mM Tris buffer, pH 7.4) to give a ~2:1 glycolipid/WGA binding sites ratio 
(100 μM 53 or 68, 55.5 μM WGA binding sites). The mixture was left for 5 minutes, 
spotted onto a microscopy glass slide (2 μL) and covered with a glass cover slip. 
Fluorescence micrographs were taken at 0 min and at 30 minute intervals after the initial 
mixing using the DAPI filter to detect pyrene fluorescence or the FITC filter for observing 
FITC fluorescence. The concentration of WGA was calculated using a molecular weight of 
36,000 g/mol with 4 binding sites.
202
 
 
ECL: Vesicle suspension (10 µL, 20 mM total lipid, 50 mM MES, pH 7 at 37 °C) 
containing the desired synthetic lipid (1% mol/mol 53 or 68 (after β4GalT1 treatment of 
vesicles containing 53)) were mixed with FITC-ECL solution (30 μL, 1 mg/mL, 37 μM 
binding sites, 20 mM Tris buffer, pH 7.4) to give a ~2:1 glycolipid/ECL binding sites ratio 
(50 μM 53 or 68, 27.8 μM ECL binding sites). The mixture was left for 5 minutes, spotted 
onto a microscopy glass slide (2 μL) and covered with a glass cover slip. Fluorescence 
micrographs were taken at 0 min and at 30 minute intervals after the initial mixing using 
the DAPI filter to detect pyrene fluorescence or the FITC filter for observing FITC 
fluorescence. The concentration of ECL was calculated using a molecular weight of 56,800 
g/mol with 2 binding sites.
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7.3.16 Triton X-100 (TX-100)-induced lysis of vesicles 
 
Following the method descrbed by Liu et al,
163
 vesicles composed of DPPC with 10% 
mol/mol lipid 53 (2 mM total lipid, 200 μM 53) were made using the extrusion method in a 
CF solution (10 mM CF, 50 mM MES, pH 7 at 37 °C) to encapsulate CF. The vesicles (1 
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mL) were then diluted to 2.5 mL and eluted through a GPC column with buffer (3.5 mL, 50 
mM MES, pH 7 at 37 °C) to remove any unencapsulated CF. This gave a 3.5 mL vesicular 
solution of 0.571 mM total lipid, 57.1 μM 53. TX-100 solution (8 × 1 μL, 0.5% v/v TX-
100, 50 mM MES, pH 7 at 37 °C) was then titrated into the vesicular solution (200 μL) and 
the fluorescence spectra were recorded after each titre (exciting at 346 nm for pyrene and 
491 nm for CF). Any remaining vesicles were then lysed with 25% v/v TX-100 in buffer 
(10 μL, 50 mM MES, pH 7 at 37 °C) to determine the maximal CF release value. %CF 
release was then determined and plotted against log[TX-100]. The E/M pyrene ratio was 
also plotted against log[TX-100]. The two plots were used to gauge a TX-100 concentration 
in the β4GalT1 buffer that would not cause vesicle membrane rupture or full lysis. 
 
7.3.17 β4GalT1 buffer exchange protocol 
 
Throughout the procedure the β4GalT1 solution was kept on ice where possible to help 
reduce denaturation. A GE Healthcare HiTrap™ column (1 mL size) was rinsed by eluting 
water (5 mL) and activated with Ni
2+
 solution (1 mL, 0.1 M NiSO4 hexahydrate in H2O). 
The column was then rinsed with water (5 mL) followed by buffer (5 mL, 50 mM MES, pH 
7 at 37 °C). β4GalT1 solution (150 μL, 1% v/v TX-100, 50 mM MES, pH 7 at 37 °C) was 
then eluted onto the column. The β4GalT1 expressed contained a hexa-His tag for chelation 
to Ni
2+
-affinity columns. The TX-100 concentration was then reduced by eluting buffer (5 
mL, 0.05% v/v TX-100, 50 mM MES, pH 7 at 37 °C) through the column. β4GalT1 was 
recovered by eluting with an imidazole buffer (4 mL, 0.5 M imidazole, 0.05% v/v TX-100, 
50 mM MES, pH 7 at 37 °C). The imidazole was then removed using a Vivaspin 500 
ultrafiltration vial from Sartorius Stedin Biotech (30,000 MWCO, 200 uL volume) by 
spinning in a mini centrifuge at 13,000 rpm (5 mins per 100 μL). When the volume of the 
β4GalT1 solution reached 100 μL, imidazole-free buffer (100 μL, 0.05% v/v TX-100, 50 
mM MES, pH 7 at 37 °C) was added and the solution spun again in a mini centrifuge 
(13,000 rpm) until the solution again reached 100 μL. This was repeated 3 times to ensure 
the complete removal of imidazole. The β4GalT1 solution (100 μL) was then collected and 
the UV-vis spectrum measured to estimate protein concentration. Glycerol (10 μL) was 
added to the β4GalT1 solution as anti-freeze. The β4GalT1 solution was stored in a -20 °C 
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freezer when not used. The HiTrap column was rinsed with water (5 mL) and stored in the 
fridge. For subsequent purifications using the same HiTrap column, the column was 
regenerated by washing with EDTA solution (2 mL, 0.1 M), water (5 mL), NiSO4 solution 
(1 mL, 0.1 M in H2O), water (5 mL) then finally buffer (5 mL). 
 
7.3.18 β4GalT1 enzymatic reaction protocols and analysis 
 
General reaction procedure: Vesicle suspension containing 53 at 1, 2 or 10% mol/mol 
loading (100 μL, 200 μM 53 in 50 mM MES buffer, pH 7 at 37 °C) or PNP-GlcNAc (100 
μL, 200 μM in 50 mM MES buffer, pH 7 at 37 °C), β4GalT1 solution (30 μL, estimated 
11.645 μM, in MES 50 mM, 0.05% v/v TX-100, 10% v/v glycerol, pH 7 at 37 °C), UDP-
Gal solution (30 μL, 10 mM in H2O) and MnCl2 solution (1 μL, 1 M in H2O) were mixed in 
a 200 μL Eppendorf tube or small volume mass spec. vial and incubated at 37 °C.  
 
MALDI-ToF analysis: Samples were spotted (1 μL) onto a polished steel MTP 384 plate. 
Sinapinic acid matrix (1 μL, 10 mg/mL in 5:3:2 MeOH/H2O/ CH3CN) was spotted into the 
sample, mixed and allowed to dry. The plate was mounted on a transponder target frame 
and measurements made using a reflector positive mode. The mass prodicts obtained were 
calibrated to the molecular weights of DMPC + Na
+
 (700.4888 g/mol) and dimer of 2 × 
DMPC + Na
+
 (1377.9883 g/mol) or DPPC + Na
+
 (756.5514 g/mol) and dimer of 2 × DPPC 
+ Na
+
 (1490.1135). 
 
Reaction rate determination – vesicle HPLC method: Enzymatic reactions were performed 
as outlined in the general β4GalT1 reaction procedure and analyzed using HPLC: 5 μL 
injects (with a 10 μL CH3CN needle wash) were performed on a 30 minute gradient of 
50:50 THF (+ 0.1% TFA)/H2O (+ 0.1% TFA) to 100% THF (+ 0.1% TFA) on a 
Phenomenex Luna C18 column (250 × 4.6 mm, 5 μm) fitted with a guard column, with a 
flow rate of 0.5 mL/min. The HPLC DAD module was set to detect the pyrene UV-vis 
absorption at 346 nm. This was repeated every half hour for 8 hours and at 24 hours. 
Percent conversions were determined using the ratio of product peak area to the combined 
product and starting material area.  
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Reaction rate determination – LC/MS method: Enzymatic reactions were performed as 
outlined in the general β4GalT1 reaction procedure and analyzed using LC/MS: 5 μL 
injects (with a 10 μL H2O needle wash) were performed on a 30 minute gradient of 50:50 
CH3CN (+ 0.1% FA)/H2O (+ 0.1% FA) to 100% CH3CN (+ 0.1% FA) on a Phenomenex 
Luna C18 column (150 × 4.6 mm, 5 μm) fitted with a guard column, with a flow rate of 0.5 
mL/min. The HPLC DAD module was set to detect the pyrene UV-vis absorption at 346 
nm and the MS detector set to detect m/z 1003 (53 + Na
+
) and 1165 (68 + Na
+
). This was 
repeated every half hour for 8 hours and at 24 hours. Co-elution of the product 68 mass and 
UV-vis peak at around 14.5 minutes and peaks for 53 at around 16.5 minutes was observed. 
 
Reaction rate determination – PNP-GlcNAc HPLC method: Enzymatic reactions were 
performed as outlined in the general β4GalT1 reaction procedure and analyzed using 
HPLC: 5 μL injects (with a 10 μL H2O needle wash) were performed on a 30 minute 
isocratic method of 20:80 CH3CN (+ 0.1% TFA)/H2O (+ 0.1% TFA) on a Macherey-Nagel 
Nucleosil 100-5 C18 column (250 × 4.6 mm, 5 μm) fitted with a guard column, with a flow 
rate of 0.8 mL/min. The HPLC DAD module was set to detect the maximal PNP UV-vis 
absorption at 300 nm. 
 
‘Mixed raft’ β4GalT1 reactions: Enzymatic reactions were performed as outlined in the 
general β4GalT1 reaction procedure and analyzed using HPLC: 5 μL injects (with a 10 μL 
H2O needle wash) were performed on a 30 minute gradient of 50:50 CH3CN (+ 0.1% 
FA)/H2O (+ 0.1% FA) to 100% CH3CN (+ 0.1% FA) on a Phenomenex Luna C18 column 
(150 × 4.6 mm, 5 μm) fitted with a guard column, with a flow rate of 0.5 mL/min. The 
HPLC DAD module was set to detect the pyrene UV-vis absorption at 346 nm. 
 
Km, Vmax and kcat determination – modification of [53]: β4GalT1-catalysed reactions were 
performed with varying concentrations of 53 in vesicles (stock solution = 1% mol/mol 53, 
30 – 250 μM 53, corresponding to 3 – 25 mM total lipid). Vesicle solution (16.7 μL in 50 
mM MES buffer, pH 7 at 37 °C) was mixed with UDP-Gal solution (5 μL, 10 mM in H2O) 
and MnCl2 solution (0.17 μL, 1 M in H2O) and β4GalT1 solution (5 μL, estimated 11.645 
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μM, in MES 50 mM, 0.05% v/v TX-100, 10% v/v glycerol, pH 7 at 37 °C) in a small 
volume mass spec. vial and incubated at 37 °C for 30 minutes. HPLC analysis was 
performed on an aliquot (5 μL) of the samples every 30 minutes using the method 
described above. The concentration of product 68 formed was determined by calculating 
the ratio of product peak area to the combined product and starting material area, then 
multiplying it by the total concentration of glycolipid in the sample (18.6 – 155 μM 53 + 
68). The rate of product formation (V) was the determined by plotting the concentration of 
product 68 formed against time (in s), to give a linear slope with a gradient in M/s. The 
values of V for each concentration were averaged and plotted against concentration of 53 to 
give a Michaelis-Menten plot. Apparent Km and Vmax values were determined using Origin 
software to curve-fit the Michaelis-Menten plot using a single-site (n = 1) non-linear Hill 
fit. kcat was calculated by dividing the apparent Vmax by the concentration of  β4GalT1. 
 
7.3.19 Removal of β4GalT1 and UDP-Gal from vesicular reaction solutions 
 
β4GalT1 and UDP-Gal was removed from the vesicle mixtures by successive iterations of 
centrifugation at 13,000 rpm. β4GalT1-transformed vesicles (100 μL) were diluted to 1 mL 
with buffer (50 mM MES, pH 7 at 37 °C). The mixtures were then spun in a mini 
centrifuge at 13,000 rpm for 5 minutes and the supernatant solution (950 μL) removed. The 
vesicular mixture was resuspended with MES buffer (950 μL, 50 mM, pH 7 at 37 °C) 
followed by vortex mixing. Each supernatant solution removed was analysed via UV-vis 
spectroscopy (peak at 280 nm) to determine the amount of enzyme present. The procedure 
was repeated 8 times, by which time very little absorbance at 280 remained in the 
supernatant solution. 
 
7.3.20 NHS-Fluorescein labelling of β4GalT1 
 
Labelling procedure: β4GalT1 was freshly buffer exchanged according to the protocol 
described in section 7.3.17. NHS-fluorescein (1 mg) was dissolved in DMSO (100 μL). 
NHS-fluorescein solution (10 μL) was added to β4GalT1 solution (100 μL, MES 50 mM, 
0.05% v/v TX-100, pH 7 at 37 °C) in a mini Eppendorf tube and the mixture left for 2 
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hours over ice. The fluorescein-labelled β4GalT1 was then purified using HiTrap 
methodology as described in section 7.3.17. The concentration of the fluorescein-β4GalT1 
solution was estimated at 11.3 μM based on the UV-vis absorption at 279 nm.161, 162 The 
extent of NHS-labelling was estimated at 3-fluorescein molecules per protein; the 
concentration of fluorescein was determined as 35.37 μM using the absorbance at 494 nm, 
giving a ratio of ~1:3 β4GalT1/fluorescein concentration. The activity of the fluorescein-
labelled β4GalT1 was confirmed by test reactions with vesicles composed of DPPC (1% 
and 10% mol/mol 53) and 50/50 DMPC/chol (10% mol/mol 53) using the general reaction 
protocol in section 7.3.18, which revealed comparable % conversions to the unlabelled 
enzyme after 8 hour reactions, with HPLC and MALDI analysis. 
 
FRET between rhodamine-labelled vesicles and fluorescein-labelled β4GalT1: DPPC 
vesicles containing 0.1% mol/mol Rh-DHPE (20 μM Rh-DHPE, 20 mM total lipid, 50 mM 
MES, pH 7 at 37 °C) were made using the extrusion technique and fluorescence spectra 
taken at 37 °C (exciting at 496 nm for fluorescein and 560 nm for rhodamine). The Rh-
DHPE-labelled vesicles (100 μL) were then mixed with fluorescein-labelled β4GalT1 (30 
μL, 11.3 μM, MES 50 mM, 0.05% v/v TX-100, pH 7 at 37 °C), UDP-Gal (30 μL, 10 mM 
in H2O) and MnCl2 (1 μL, 1 M in H2O). Fluorescence spectra were then recorded at 37 °C 
(exciting at 496 nm for fluorescein and 560 nm for rhodamine).  
 
FRET between vesicles with GlcNAc-lipid 53 and fluorescein-labelled β4GalT1: DPPC 
vesicles containing 1% or 10% mol/mol 53 (200 μM 53, 20 or 2 mM total lipid, 50 mM 
MES, pH 7 at 37 °C) were made using the extrusion technique and fluorescence spectra 
were taken at 37 °C (exciting at 346 nm for pyrene and 496 nm for fluorescein). The 
vesicles (100 μL) were then mixed with fluorescein-labelled β4GalT1 (30 μL, 11.3 μM, 
MES 50 mM, 0.05% v/v TX-100, pH 7 at 37 °C), UDP-Gal (30 μL, 10 mM in H2O) and 
MnCl2 (1 μL, 1 M in H2O). Fluorescence spectra were then recorded at 37 °C (exciting at 
346 nm for pyrene and 496 nm for fluorescein).  
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7.3.21 Trypanosoma cruzi trans-sialidase (TcTS)-catalysed sialylation  
 
General reaction procedure: Vesicle suspension containing 55 at 1 or 10% mol/mol 
loading (100 μL, 200 μM 55 in 100 mM phosphate buffer, pH 7.4 at 37 °C), TcTS solution 
(1 or 5 μL, 3.91 μM, 100 mM phosphate buffer, pH 7.4 at 37 °C) and fetuin (1 or 5 mg, 
equivalent to 1.25 mM and 6 mM sialic acid respectively)
182
 were mixed in a 200 μL 
Eppendorf tube or small volume mass spec. vial and incubated overnight at 37 °C. The 
amount of enzyme/donor added was either 1 μL and 1 mg or 5 μL and 5 mg of TcTS and 
fetuin respectively. The enzyme concentration was estimated using its UV absorption at 
280 nm;
204
 the molar extinction coefficient was estimated at ε = 147,250 from the 
tryptophan and tyrosine residues in the protein amino acid sequence.
205
 
 
MALDI-ToF analysis: Samples were prepared in the same manner as for β4GalT1 analysis 
(section 7.3.18), but MALDI-ToF spectra were taken in both reflector-positive and linear-
positive modes. 
 
MALDI-ToF analysis methylation: Vesicle reaction mixtures were treated with MeI 
according to the method described by Powel and Harvey.
183
 MeI (5 μL) was added to the 
vesicle mixtures after sialylation (100 μL) in a small glass vial and vortex mixed for 1 
minute. After 2 hours the MeI was evaporated by warming (45 °C) the mixtures on a stirrer 
hotplate in a fume hood for 2 hours. The resulting solution was analysed using MALDI-
ToF in reflector positive and negative modes. 
 
Reaction rate determination – vesicle HPLC method: Enzymatic reactions were performed 
as outlined in the general TcTS reaction procedure and were analyzed using the HPLC 
procedure as for β4GalT1 analysis (section 7.3.18). Analysis was performed after overnight 
incubation with TcTS. Percent conversions were determined using the ratio of product peak 
area to the combined product and starting material area.  
 
Reaction rate determination – LC/MS method: Enzymatic reactions were performed as 
outlined in the general TcTS reaction procedure and analyzed using the same LC/MS 
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procedure as for β4GalT1 analysis (section 7.3.18). The HPLC DAD module was set to 
detect the pyrene UV-vis absorption at 346 nm and the MS detector set to detect m/z 1126 
(55 + Na
+
) and 1437 (sialylated product – H+ + 2Na+). Correlation of the HPLC peak for 
Lac-lipid 55 and mass of 1126 m/z was observed, however, no product mass was observed 
in the mass spec. trace. 
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